US20140315817A1 - Variant serum albumin with improved half-life and other properties - Google Patents
Variant serum albumin with improved half-life and other properties Download PDFInfo
- Publication number
- US20140315817A1 US20140315817A1 US14/358,857 US201214358857A US2014315817A1 US 20140315817 A1 US20140315817 A1 US 20140315817A1 US 201214358857 A US201214358857 A US 201214358857A US 2014315817 A1 US2014315817 A1 US 2014315817A1
- Authority
- US
- United States
- Prior art keywords
- vsa
- protein
- sequence
- agent
- serum albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000007562 Serum Albumin Human genes 0.000 title claims abstract description 122
- 108010071390 Serum Albumin Proteins 0.000 title claims abstract description 122
- 230000001976 improved effect Effects 0.000 title abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 168
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 158
- 239000003814 drug Substances 0.000 claims abstract description 77
- 238000000034 method Methods 0.000 claims abstract description 77
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 66
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 63
- 239000012634 fragment Substances 0.000 claims abstract description 48
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 42
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 42
- 239000000032 diagnostic agent Substances 0.000 claims abstract description 28
- 229940039227 diagnostic agent Drugs 0.000 claims abstract description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 157
- 235000018102 proteins Nutrition 0.000 claims description 154
- 235000001014 amino acid Nutrition 0.000 claims description 145
- 229940024606 amino acid Drugs 0.000 claims description 143
- 150000001413 amino acids Chemical class 0.000 claims description 133
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 95
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 95
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 89
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 80
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 80
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 65
- 229920001184 polypeptide Polymers 0.000 claims description 62
- 230000027455 binding Effects 0.000 claims description 60
- 102000009027 Albumins Human genes 0.000 claims description 49
- 108010088751 Albumins Proteins 0.000 claims description 49
- 230000002829 reductive effect Effects 0.000 claims description 47
- 108010002350 Interleukin-2 Proteins 0.000 claims description 36
- 102000000588 Interleukin-2 Human genes 0.000 claims description 35
- 238000006467 substitution reaction Methods 0.000 claims description 29
- 230000035772 mutation Effects 0.000 claims description 26
- 108010068617 neonatal Fc receptor Proteins 0.000 claims description 24
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 23
- 108010092464 Urate Oxidase Proteins 0.000 claims description 19
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 18
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 18
- 102000004127 Cytokines Human genes 0.000 claims description 16
- 108090000695 Cytokines Proteins 0.000 claims description 16
- 239000004277 Ferrous carbonate Substances 0.000 claims description 16
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 14
- 229940005267 urate oxidase Drugs 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 9
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 8
- 230000015271 coagulation Effects 0.000 claims description 8
- 238000005345 coagulation Methods 0.000 claims description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- 235000004279 alanine Nutrition 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 229940088598 enzyme Drugs 0.000 claims description 5
- 201000005569 Gout Diseases 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 3
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 238000010322 bone marrow transplantation Methods 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 34
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 33
- 239000000463 material Substances 0.000 abstract description 13
- 210000004027 cell Anatomy 0.000 description 82
- 125000005647 linker group Chemical group 0.000 description 47
- 230000008901 benefit Effects 0.000 description 44
- 230000000875 corresponding effect Effects 0.000 description 41
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 35
- 108010023321 Factor VII Proteins 0.000 description 34
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 32
- 102100023804 Coagulation factor VII Human genes 0.000 description 31
- 229940012413 factor vii Drugs 0.000 description 31
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 29
- 102100040918 Pro-glucagon Human genes 0.000 description 29
- 210000002381 plasma Anatomy 0.000 description 27
- 230000004927 fusion Effects 0.000 description 26
- 108020004705 Codon Proteins 0.000 description 24
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 24
- 238000011282 treatment Methods 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 20
- 102000004877 Insulin Human genes 0.000 description 19
- 108090001061 Insulin Proteins 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 108060003558 hepcidin Proteins 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 18
- 108010076504 Protein Sorting Signals Proteins 0.000 description 18
- 229940125396 insulin Drugs 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 102100022641 Coagulation factor IX Human genes 0.000 description 17
- 102000001690 Factor VIII Human genes 0.000 description 17
- 108010054218 Factor VIII Proteins 0.000 description 17
- 102000018511 hepcidin Human genes 0.000 description 17
- 229940066919 hepcidin Drugs 0.000 description 17
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- 239000008103 glucose Substances 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
- 108090000172 Interleukin-15 Proteins 0.000 description 15
- 229940098773 bovine serum albumin Drugs 0.000 description 15
- 229960000301 factor viii Drugs 0.000 description 15
- 102000003812 Interleukin-15 Human genes 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 108010076282 Factor IX Proteins 0.000 description 13
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 102000004042 Fibroblast Growth Factor-23 Human genes 0.000 description 12
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 12
- 102000014150 Interferons Human genes 0.000 description 12
- 108010050904 Interferons Proteins 0.000 description 12
- 229960004222 factor ix Drugs 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 229910052742 iron Inorganic materials 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 101710153349 Fibroblast growth factor 19 Proteins 0.000 description 11
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 11
- -1 e.g. Proteins 0.000 description 11
- 229940079322 interferon Drugs 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 241000282693 Cercopithecidae Species 0.000 description 10
- 102000003951 Erythropoietin Human genes 0.000 description 10
- 108090000394 Erythropoietin Proteins 0.000 description 10
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 10
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 229940105423 erythropoietin Drugs 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 10
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 9
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 108010013773 recombinant FVIIa Proteins 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 102000014914 Carrier Proteins Human genes 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 108010054265 Factor VIIa Proteins 0.000 description 6
- 208000009292 Hemophilia A Diseases 0.000 description 6
- 206010065973 Iron Overload Diseases 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 6
- 108010000499 Thromboplastin Proteins 0.000 description 6
- 102000002262 Thromboplastin Human genes 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 108091008324 binding proteins Proteins 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 102000057593 human F8 Human genes 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 5
- 201000003542 Factor VIII deficiency Diseases 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
- 208000003623 Hypoalbuminemia Diseases 0.000 description 5
- 102000008070 Interferon-gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 235000009697 arginine Nutrition 0.000 description 5
- 150000005829 chemical entities Chemical class 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000430 cytokine receptor antagonist Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229940012414 factor viia Drugs 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 208000009429 hemophilia B Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 241000701447 unidentified baculovirus Species 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 101800000060 C-type natriuretic peptide Proteins 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 4
- 102000003996 Interferon-beta Human genes 0.000 description 4
- 108090000467 Interferon-beta Proteins 0.000 description 4
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 4
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 4
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 102100020880 Kit ligand Human genes 0.000 description 4
- 229930126263 Maytansine Natural products 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 108010039445 Stem Cell Factor Proteins 0.000 description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 229940044627 gamma-interferon Drugs 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000004190 glucose uptake Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- YQNQTEBHHUSESQ-UHFFFAOYSA-N lithium aluminate Chemical compound [Li+].[O-][Al]=O YQNQTEBHHUSESQ-UHFFFAOYSA-N 0.000 description 4
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000692 natriuretic peptide Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- 229960001134 von willebrand factor Drugs 0.000 description 4
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- 102000016519 Coagulation factor VII Human genes 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 3
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 3
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 3
- 101000749809 Homo sapiens 2',3'-cyclic-nucleotide 3'-phosphodiesterase Proteins 0.000 description 3
- 101000796277 Homo sapiens C-type natriuretic peptide Proteins 0.000 description 3
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 3
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 3
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 description 3
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 description 3
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 3
- 101001021253 Homo sapiens Hepcidin Proteins 0.000 description 3
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 3
- 108010000521 Human Growth Hormone Proteins 0.000 description 3
- 102000002265 Human Growth Hormone Human genes 0.000 description 3
- 239000000854 Human Growth Hormone Substances 0.000 description 3
- 206010021137 Hypovolaemia Diseases 0.000 description 3
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 3
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 108020001621 Natriuretic Peptide Proteins 0.000 description 3
- 102000004571 Natriuretic peptide Human genes 0.000 description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 description 3
- 102000003982 Parathyroid hormone Human genes 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- 108091006976 SLC40A1 Proteins 0.000 description 3
- 241000256251 Spodoptera frugiperda Species 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 108700005078 Synthetic Genes Proteins 0.000 description 3
- 108010022394 Threonine synthase Proteins 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229930195731 calicheamicin Natural products 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229940105772 coagulation factor vii Drugs 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 208000001031 fetal erythroblastosis Diseases 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 102000047974 human CNP Human genes 0.000 description 3
- 102000044890 human EPO Human genes 0.000 description 3
- 102000047000 human FGF19 Human genes 0.000 description 3
- 102000056003 human IL15 Human genes 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 208000009928 nephrosis Diseases 0.000 description 3
- 231100001027 nephrosis Toxicity 0.000 description 3
- 229940005483 opioid analgesics Drugs 0.000 description 3
- 239000000199 parathyroid hormone Substances 0.000 description 3
- 229960001319 parathyroid hormone Drugs 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 3
- 238000011809 primate model Methods 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 229940068953 recombinant fviia Drugs 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 2
- URJOZSLMTIRWFW-QGZVFWFLSA-N (4r)-4-(1,3-benzodioxol-5-yl)-5,6-dimethoxy-4,9-dihydro-1h-benzo[f][2]benzofuran-3-one Chemical compound C1=C2OCOC2=CC([C@H]2C3=C(COC3=O)CC3=CC=C(C(=C32)OC)OC)=C1 URJOZSLMTIRWFW-QGZVFWFLSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 2
- 241000228197 Aspergillus flavus Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 108010075254 C-Peptide Proteins 0.000 description 2
- 101800000433 CNP-53 Proteins 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102000003712 Complement factor B Human genes 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000012545 EGF-like domains Human genes 0.000 description 2
- 108050002150 EGF-like domains Proteins 0.000 description 2
- 102400001047 Endostatin Human genes 0.000 description 2
- 108010079505 Endostatins Proteins 0.000 description 2
- 108091006010 FLAG-tagged proteins Proteins 0.000 description 2
- 108010048049 Factor IXa Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 108700012941 GNRH1 Proteins 0.000 description 2
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 2
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 2
- 102400000320 Glicentin Human genes 0.000 description 2
- 101800002945 Glicentin Proteins 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 2
- 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 description 2
- 101001123834 Homo sapiens Neprilysin Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108010005716 Interferon beta-1a Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 description 2
- 108050000588 Neurogenic differentiation factor 1 Proteins 0.000 description 2
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 description 2
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 2
- 241001504519 Papio ursinus Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100038246 Retinol-binding protein 4 Human genes 0.000 description 2
- 101710137011 Retinol-binding protein 4 Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 201000003674 autosomal dominant hypophosphatemic rickets Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000003491 cAMP production Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229940105778 coagulation factor viii Drugs 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 231100000409 cytocidal Toxicity 0.000 description 2
- 230000000445 cytocidal effect Effects 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000010030 glucose lowering effect Effects 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 102000045598 human DPP4 Human genes 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 108010093470 monomethyl auristatin E Proteins 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229940112216 novoseven Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 102220126190 rs556840308 Human genes 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- KSDDQEGWVBODMD-OULINLAESA-N (2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-4-carboxybutanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CS)CC1=CC=CC=C1 KSDDQEGWVBODMD-OULINLAESA-N 0.000 description 1
- KUHSEZKIEJYEHN-BXRBKJIMSA-N (2s)-2-amino-3-hydroxypropanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.OC[C@H](N)C(O)=O KUHSEZKIEJYEHN-BXRBKJIMSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- IEUUDEWWMRQUDS-UHFFFAOYSA-N (6-azaniumylidene-1,6-dimethoxyhexylidene)azanium;dichloride Chemical compound Cl.Cl.COC(=N)CCCCC(=N)OC IEUUDEWWMRQUDS-UHFFFAOYSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
- YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- PMMURAAUARKVCB-CERMHHMHSA-N 2-deoxy-D-glucopyranose Chemical compound OC[C@H]1OC(O)C[C@@H](O)[C@@H]1O PMMURAAUARKVCB-CERMHHMHSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- LTQYPAVLAYVKTK-YFKPBYRVSA-N 5-Hydroxyisourate Natural products O=C1[C@]2(O)NC(O)=NC2=NC(=O)N1 LTQYPAVLAYVKTK-YFKPBYRVSA-N 0.000 description 1
- LTQYPAVLAYVKTK-UHFFFAOYSA-N 5-hydroxyisouric acid Chemical compound N1C(=O)NC2(O)C1=NC(=O)NC2=O LTQYPAVLAYVKTK-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102400000069 Activation peptide Human genes 0.000 description 1
- 101800001401 Activation peptide Proteins 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102100030805 Adropin Human genes 0.000 description 1
- 101710161788 Adropin Proteins 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000589156 Agrobacterium rhizogenes Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102100022977 Antithrombin-III Human genes 0.000 description 1
- 102400000059 Arg-vasopressin Human genes 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- 108010082340 Arginine deiminase Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010089996 B-domain-deleted factor VIII Proteins 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 1
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 101800000457 CNP-22 Proteins 0.000 description 1
- 101800000459 CNP-29 Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102100024155 Cadherin-11 Human genes 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 102100038518 Calcitonin Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 102000006397 Ephrin-B1 Human genes 0.000 description 1
- 108010044099 Ephrin-B1 Proteins 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 206010016077 Factor IX deficiency Diseases 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 108010080805 Factor XIa Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 201000000361 Hemochromatosis type 2 Diseases 0.000 description 1
- 102100022816 Hemojuvelin Human genes 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000788682 Homo sapiens GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 101000756823 Homo sapiens Hemojuvelin Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 229940079288 Insulin receptor agonist Drugs 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102100039897 Interleukin-5 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102100021592 Interleukin-7 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 101150009057 JAK2 gene Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000016261 Long-Acting Insulin Human genes 0.000 description 1
- 108010092217 Long-Acting Insulin Proteins 0.000 description 1
- 229940100066 Long-acting insulin Drugs 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102100034028 Membrane-bound transcription factor site-1 protease Human genes 0.000 description 1
- 101710193467 Membrane-bound transcription factor site-1 protease Proteins 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 108010056902 Mononine Proteins 0.000 description 1
- 101000930477 Mus musculus Albumin Proteins 0.000 description 1
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 1
- 101100288142 Mus musculus Klkb1 gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- WTBIAPVQQBCLFP-UHFFFAOYSA-N N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O WTBIAPVQQBCLFP-UHFFFAOYSA-N 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 241001452677 Ogataea methanolica Species 0.000 description 1
- 208000005072 Oncogenic osteomalacia Diseases 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101100081884 Oryza sativa subsp. japonica OSA15 gene Proteins 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102400000319 Oxyntomodulin Human genes 0.000 description 1
- 101800001388 Oxyntomodulin Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 101150082245 PSAG gene Proteins 0.000 description 1
- 108700020479 Pancreatic hormone Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010068701 Pegloticase Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 108010088847 Peptide YY Proteins 0.000 description 1
- 102100029909 Peptide YY Human genes 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 239000000381 Placental Lactogen Substances 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102000035554 Proglucagon Human genes 0.000 description 1
- 108010058003 Proglucagon Proteins 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 241000277289 Salmo salar Species 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000026552 Severe hemophilia A Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- DMWVGXGXHPOEPT-UHFFFAOYSA-N Src Inhibitor-1 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC(C=C1)=CC=C1OC1=CC=CC=C1 DMWVGXGXHPOEPT-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108091000182 THR-184 Proteins 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- 108010020828 Thrombofax Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 240000001866 Vernicia fordii Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 229940099550 actimmune Drugs 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229940031675 advate Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 108010001818 alpha-sarcin Proteins 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000003024 amidolytic effect Effects 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000868 anti-mullerian hormone Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 229940082620 antifibrinolytics Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000006493 arterial relaxation Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 108010014210 axokine Proteins 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 229940031422 benefix Drugs 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 208000016532 chronic granulomatous disease Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 238000007820 coagulation assay Methods 0.000 description 1
- 229940105774 coagulation factor ix Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229930191339 dianthin Natural products 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical class CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- 229960000533 dornase alfa Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 108010002601 epoetin beta Proteins 0.000 description 1
- 229940089118 epogen Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 229940065186 gila monster venom Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000000386 hemochromatosis type 2A Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000047279 human B2M Human genes 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000017730 intein-mediated protein splicing Effects 0.000 description 1
- 108010042414 interferon gamma-1b Proteins 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229940054136 kineret Drugs 0.000 description 1
- 229940047434 kogenate Drugs 0.000 description 1
- 229940120535 krystexxa Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 108010010621 modeccin Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 description 1
- 229940090053 mononine Drugs 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
- UHSBKBYWHCBDCJ-DYGWFTAGSA-N natriuretic peptide, c-type Chemical compound N1C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CN)CSSC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H]1CC1=CC=CC=C1 UHSBKBYWHCBDCJ-DYGWFTAGSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- 108010000953 osteoblast cadherin Proteins 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 229960002404 palifermin Drugs 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000027317 positive regulation of immune response Effects 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 108010087851 prorelaxin Proteins 0.000 description 1
- 108010076038 prosaptide Proteins 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 229960000424 rasburicase Drugs 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 108010025139 recombinant factor VIII SQ Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003979 response to food Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 108700031632 somatrem Proteins 0.000 description 1
- 229960003259 somatrem Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001300 stimulation of adenylate cyclase Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940054870 urso Drugs 0.000 description 1
- 230000002883 vasorelaxation effect Effects 0.000 description 1
- 230000002551 venodilator Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940018782 wilate Drugs 0.000 description 1
- 229940036647 xyntha Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Definitions
- the present invention relates to the area of therapeutic and diagnostic proteins, materials for producing such proteins, and methods for their production and use.
- Serum albumin is an abundant plasma protein that that is essential for maintaining oncotic pressure and is useful in regulating the volume of circulating blood. Serum albumin has therapeutic uses and is indicated, for example, to treat hypovolemia and hypoalbuminemia (e.g., hypoalbuminemia associated with inadequate production, excessive catabolism, hemorrhage, excessive renal excretion, redistribution within the body e.g., due to surgery or inflammatory conditions, burns, adult respiratory distress syndrome, nephrosis), and may be used prior to or during cardiopulmonary bypass surgery or to treat hemolytic disease of the newborn. Serum albumin can also be used in association with other agents.
- hypovolemia and hypoalbuminemia e.g., hypoalbuminemia associated with inadequate production, excessive catabolism, hemorrhage, excessive renal excretion, redistribution within the body e.g., due to surgery or inflammatory conditions, burns, adult respiratory distress syndrome, nephrosis
- Serum albumin can also be used in association with other agents.
- variant sequences of serum albumin can be used, e.g., to prepare or provide a protein product (e.g., a therapeutic or diagnostic protein product).
- the protein product has improved properties (e.g., higher recycling fraction via an FcRn mechanism and/or improved pharmacokinetic properties, e.g., increased half-life and/or reduced clearance), e.g., as compared with a protein product that is prepared using a corresponding native (e.g., wild type) serum albumin sequence (e.g., a mammalian serum albumin, e.g., human serum albumin or bovine serum albumin).
- a native serum albumin sequence e.g., a mammalian serum albumin, e.g., human serum albumin or bovine serum albumin.
- a “corresponding native serum albumin” refers to a corresponding full length native serum albumin sequence, or fragment thereof, of which the variant serum albumin polypeptide (VSA) is a variant.
- VSA variant serum albumin polypeptide
- the disclosure provided herein includes disclosure of proteins that comprise variant serum albumin sequences and methods of using such proteins.
- the disclosure provides a variant serum albumin polypeptide (VSA).
- the variant is a variant of a full-length serum albumin polypeptide sequence (e.g., a human serum albumin polypeptide sequence, or a serum albumin polypeptide sequence from another species, e.g., a bovine serum albumin polypeptide sequence).
- the variant is a variant of a fragment of a serum albumin polypeptide sequence (e.g., a fragment of the human serum albumin polypeptide sequence, or a fragment of a serum albumin polypeptide sequence from another species, e.g., a fragment of the bovine serum albumin polypeptide sequence).
- the fragment comprises a domain III of a serum albumin polypeptide sequence (e.g., domain III of the human serum albumin polypeptide sequence).
- the VSA has or comprises a mutation at one or more of the positions corresponding to V418, T420, V424, E505 and V547 of serum albumin.
- the VSA can bind to an FcRn (e.g., human FcRn) at a pH in the range of 5.5 to 6.0 (e.g., at a pH of 5.5, 5.6, 5.7, 5.8, 5.9, or 6.0).
- the VSA binds to an FcRn (e.g., human FcRn) with higher affinity than does a corresponding native serum albumin.
- the higher affinity binding occurs at a specified pH (e.g., at a pH of 5.5, 5.6, 5.7, 5.8, 5.9, 6.0) or in a specified pH range, e.g., at a pH in the range of 5.5-6.0 or 6.0-6.5.
- the ratio of the binding affinity of the VSA, or of the recombinant protein comprising the VSA, at a pH of 5.5 to 6.0 to the binding affinity at a pH of 7.0 to 7.4 is greater than or equal to the ratio for a corresponding native serum albumin (e.g., a corresponding native human serum albumin).
- the ratio of the binding affinity of the VSA, or of the recombinant protein comprising the VSA, at a pH of 5.5 to 6.0 to that at a pH of 7.0 to 7.4 is 5; 10; 50; 100; 1000; 10,000; 100,000; or 1 million times that of a corresponding native human albumin.
- the VSA or the recombinant protein comprising the VSA, binds to FcRn at a pH in the range of 7.0 to 7.4 with an affinity not greater than a corresponding native human albumin.
- the disclosure provides an isolated, recombinant protein comprising a VSA that has altered binding properties for an FcRn (e.g., a human FcRn) relative to a corresponding native serum albumin sequence (e.g., the wild-type human serum albumin sequence).
- the protein can include a heterologous sequence as described herein.
- the recombinant protein comprising aVSA binds to FcRn with an affinity that is altered compared to a recombinant protein comprising a wild type albumin (e.g., a wild type human albumin) and the heterologous sequence.
- the VSA or recombinant protein comprising the VSA binds to FcRn with a dissociation constant (K D ) of less than 50 nM at pH 5.5.
- the VSA or recombinant protein has an affinity for FcRn at pH 7.4 that is less than or equal to its affinity for FcRn of a wild type albumin at pH 7.4.
- the VSA has a K D that is below 100 nM. In some embodiments, the VSA has a K D that is below 75 nM, below 50 nM, below 40 nM, below 30 nM, below 25 nM, below 20 nM, below 15 nM, below 10 nM, below 9 nM, below 8 nM, below 7 nM, below 6 nM, below 5 nM, or below 4 nM. In some embodiments, the protein has a K D that is 3 nM or less.
- the VSA comprises a substitution of V418 with another amino acid, for example, with a methionine.
- the VSA comprises a substitution of T420 with another amino acid, for example, an uncharged amino acid, such as alanine.
- the VSA comprises a substitution of V424 with another amino acid, for example, an uncharged amino acid, such as isoleucine.
- the VSA comprises a substitution of E505 with another amino acid, for example, an uncharged amino acid, such as glycine, or a positively charged amino acid, such as lysine or arginine.
- the VSA comprises a substitution of V547 with another amino acid, for example, an uncharged amino acid, such as alanine.
- the VSA comprises substitutions at two or more (e.g., at two, three, four, or five) of the positions corresponding to V418, T420, V424, E505 and V547.
- the VSA can comprise two, three, four, or five substitutions selected from V418M, T420A, V424I, E505(R/K/G) and V547A.
- the VSA comprises the substitutions V418M, T420A and E505R.
- the VSA comprises the substitutions V418M, T420A, E505G and V547A.
- the VSA comprises one or more additional substitutions at positions selected from N429, M446, A449, T467, and A552.
- the substitutions are selected from N429D, M446V, A449V, T467M, and A552T.
- a protein provided herein includes a VSA that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, but less than 100% identical to domain III of a naturally occurring serum albumin, e.g., a human serum albumin.
- the protein includes a VSA that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, but less than 100% identical to domain III of human serum albumin.
- a protein provided herein includes a VSA that differs by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 residues from a corresponding native serum albumin, e.g., a corresponding human serum albumin sequence. In some embodiments, a protein provided herein includes a VSA that differs by at least 1, but no more than 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 residues from a corresponding native serum albumin e.g., a corresponding human serum albumin sequence. In embodiments the differences are in domain III, e.g., in domain III of human serum albumin.
- the disclosure provides an agent in association with a VSA, e.g., a VSA as described herein.
- the agent is a therapeutic or diagnostic agent, e.g., an agent as described herein.
- the agent is fused to the VSA or to a protein that comprises the VSA, e.g., in the form of a fusion protein.
- a VSA can be fused to a heterologous sequence using recombinant genetic techniques.
- a heterologous sequence can comprise, e.g., the agent, a protein that comprises the agent, or a sequence to which the agent is attached or can be attached.
- the disclosure provides an isolated, recombinant protein that comprises a VSA as described herein and a heterologous sequence, e.g., a heterologous sequence as described herein (e.g., the heterologous sequence can be a cytokine, immunoglobulin, cell surface receptor, coagulation protein, or functional fragment of any of these).
- a heterologous sequence as described herein (e.g., the heterologous sequence can be a cytokine, immunoglobulin, cell surface receptor, coagulation protein, or functional fragment of any of these).
- the protein can also include more than one heterologous sequence.
- the VSA is a variant of domain III of a naturally-occurring serum albumin.
- the recombinant protein is a fusion protein.
- the heterologous sequence comprises a cytokine domain, for example, an amino acid sequence originating or derived from an interleukin-2.
- the heterologous sequence comprises an immunoglobulin single-chain variable domain, e.g., an scFv.
- the heterologous domain is a scaffold, e.g., an anti-calin, a DARPin, a SurrobodyTM AdnectinTM, a Domain antibody, Affibody, or fragment of any of the foregoing.
- the heterologous sequence comprises a soluble fragment of a cell surface receptor.
- the heterologous sequence comprises an enzyme.
- the heterologous sequence comprises a component of a coagulation protein, such as an amino acid sequence originating or derived from coagulation factor VII (FVII) or coagulation factor VIII (FVIII). In some embodiments, the heterologous sequence comprises two or more of the foregoing.
- the protein comprises a first and a second heterologous sequence.
- the first and the second heterologous sequence are identical.
- the first and second heterologous sequence are in tandem.
- the first heterologous sequence is located N-terminal to the variant sequence and the second heterologous sequence is located C-terminal to the variant sequence.
- the present disclosure provides an isolated recombinant DNA molecule and/or nucleotide sequence that encodes a polypeptide, peptide, protein or recombinant protein disclosed herein.
- the recombinant DNA molecule and/or nucleotide sequence comprises a variant nucleotide sequence that encodes a VSA.
- the VSA includes at least a variant of domain III of a naturally-occurring serum albumin.
- the present disclosure provides a recombinant host cell (e.g., a recombinant CHO cell, or a Saccharomyces cerevisiae cell) that has been transformed with a recombinant DNA molecule or nucleotide sequence that encodes a polypeptide, peptide, protein or recombinant protein as disclosed herein.
- a recombinant host cell e.g., a recombinant CHO cell, or a Saccharomyces cerevisiae cell
- protein includes polypeptides and peptides.
- the disclosure provides a method of treatment or diagnosis, the method comprising administering to a subject (e.g., a human or non-human animal) a VSA (e.g., a VSA as described herein), or a pharmaceutical composition comprising a VSA, e.g., a VSA as described herein.
- a subject e.g., a human or non-human animal
- a VSA e.g., a VSA as described herein
- a pharmaceutical composition comprising a VSA, e.g., a VSA as described herein.
- the subject is suffering from a disease or condition in which albumin is indicated.
- the disease or condition is selected from hypovolemia, hypoalbuminemia, a burn, adult respiratory distress syndrome, nephrosis, and hemolytic disease of the newborn.
- the disclosure provides a method of treatment and/or a method of diagnosis, wherein the method comprises administering to a subject an agent (e.g., a therapeutic or diagnostic agent) in association with a VSA (e.g., a VSA as described herein).
- the method is a method of treatment that comprises administering to a subject a therapeutic agent in association with a VSA, e.g., a VSA as described herein.
- the method is a method of diagnosis that comprises administering to a subject a diagnostic agent in association with a VSA, e.g., a VSA as described herein.
- the agent can be any biologically or pharmaceutically active moiety (e.g., a biologic, such as a peptide or nucleotide sequence or a chemical entity such as a small molecule).
- a biologic such as a peptide or nucleotide sequence or a chemical entity such as a small molecule.
- the agent is administered in an effective amount and at an effective frequency, e.g., in an amount and frequency that is effective for the desired therapeutic or diagnostic purpose.
- the agent is a known therapeutic or diagnostic agent.
- the agent comprises an entire known protein, nucleotide sequence or chemical entity.
- the agent comprises a fragment or variant of a known protein, nucleotide sequence or chemical entity.
- the fragment or variant can have the same or similar activity as does the known protein, nucleotide sequence or chemical entity, or the fragment or variant can have altered activity, e.g., an increased desirable activity or a reduced undesirable activity compared with the known protein, nucleotide sequence or chemical entity.
- administering the agent in association with the VSA results in an improved function of the agent.
- the improved function is an improved pharmacokinetic property (e.g., increased half-life and/or reduced clearance) of the agent.
- the improved function is a reduced effective dosage and/or a reduced effective frequency of administration of the agent compared with the agent when it is administered without the association with VSA.
- the improved function is a more desirable delivery level of the agent (e.g., a higher, more consistent, and/or less variable level of delivery).
- An improved function of the agent can be established, e.g., by comparing the function of the agent when it is administered in association with the VSA with the same function of the agent when it is administered without the association with the VSA (e.g., when the agent is administered alone or when it is administered in association with a corresponding native serum albumin sequence).
- the agent e.g., therapeutic or diagnostic agent
- the agent is fused to the VSA.
- the agent is fused to the VSA via a covalent bond.
- the agent is fused to the VSA via a peptide bond.
- the agent is fused to the VSA via a non-peptide bond.
- the agent is fused to the VSA via a linker, e.g., a linker as described herein.
- the agent is fused to the VSA using recombinant genetic methods.
- the agent is fused to the VSA using chemical methods.
- the agent e.g., therapeutic or diagnostic agent
- the agent is not fused to the VSA.
- the agent is not fused to the VSA and is stably associated with the VSA.
- “Stably associated” means that the VSA and the agent can be or remain physically associated at a pH at which they are intended to function, e.g., at an endosomal pH. Typically, the agent and VSA also can be or remain physically associated at a neutral pH.
- the agent can be associated with the VSA by any means known in the art.
- the agent can be conjugated to a moiety that is capable of binding the VSA.
- the moiety is an albumin binding protein.
- the moiety is a fatty acid.
- the agent is non-covalently bound to the VSA.
- the agent can be administered before, after, or concurrently with the VSA.
- the agent is administered concurrently with the VSA.
- the agent is administered at the same frequency as is the VSA.
- the agent is administered more or less frequently than the VSA.
- the disclosure provides a method of treating a subject, the method comprising administering to the subject an effective amount of a therapeutic agent in association with a VSA (e.g., a VSA as described herein), such that the dosage and/or frequency of administration at which the agent produces a therapeutic effect is reduced relative to the dosage and/or frequency of administration at which the agent produces a therapeutic effect when it is not in association with the albumin protein.
- a VSA e.g., a VSA as described herein
- the agent comprises a polypeptide component that is fused to the VSA or to a protein comprising the VSA.
- the polypeptide component and the VSA or protein that comprises the VSA are separated by a linker sequence.
- the polypeptide component and the VSA or protein that comprises the VSA are covalently linked by a non-peptide bond. In some embodiments, the polypeptide component and the VSA or protein that comprises the VSA are non-covalently and stably associated.
- the present disclosure provides a method of engineering a VSA associated therapeutic agent or a VSA associated diagnostic agent.
- the method comprises providing a biologically or pharmaceutically active agent (e.g., an agent as described herein) and associating the agent with a VSA as described herein to provide a VSA associated agent; i.e., a VSA associated therapeutic agent or a VSA associated diagnostic agent.
- a biologically or pharmaceutically active agent e.g., an agent as described herein
- associateating the agent with the VSA can be done by any means known in the art or any means described herein, e.g., by fusing the agent to the VSA using recombinant genetic and/or chemical means, by conjugating the agent to a moiety that is capable of binding the VSA, or by non-covalent methods.
- the method further comprises formulating the albumin modified agent, or providing a formulation or pharmaceutical composition, for administration to a subject, such as a human subject.
- the method may further comprise administering the albumin modified diagnostic agent to a subject and detecting the albumin modified diagnostic agent, for example, a method wherein the subject is imaged.
- the formulation is in a storage or delivery device, e.g., a syringe.
- the present disclosure provides a formulation that comprises a biologically or pharmaceutically active agent (e.g., an agent as described herein) in association with VSA.
- a biologically or pharmaceutically active agent e.g., an agent as described herein
- amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”.
- the percent identity between the two sequences is a function of the number of identical positions shared by the sequences.
- a position is considered to be identical if it is identical to at least one amino acid at a corresponding position in any one or more of the group of reference sequences.
- identity can be calculated collectively for all members of such list to arrive an overall percentage identity.
- sequences that are at least 60, 65, 70, 75, 80, 82, 85, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to sequences disclosed herein.
- FIG. 1 is a set of graphs depicting the results of SPR experiments determining the binding of the variant serum albumin polypeptides (VSAs) HSA-5, HSA-11, HSA-7, and HSA-13 to human FcRn at pH 5.5, pH 6.0, pH 6.5, and pH 7.4.
- VSAs variant serum albumin polypeptides
- FIG. 2 is a table depicting the K D s as determined by ELISA of variant serum albumin polypeptides (VSAs) at pH 5.5.
- FIG. 3 is a set of graphs depicting the results of ELISA that determining the binding of VSAs and wild type HSA to human FcRn at pH 5.5, 6.0, and 7.4.
- FIG. 4 is s set of graphs depicting the pharmacokinetics of VSAs (HSA-5, HSA-11, and HSA-13) and wild type human serum albumin (wt-HSA) in wild type mice.
- the left panel shows plasma concentration over time.
- the right upper panel shows half-life, and the right lower panel shows clearance.
- FIG. 5 is s set of graphs that depicting the pharmacokinetics of VSAs (HSA-5, HSA-11, and HSA-13) and wild type HSA in human FcRn transgenic mice.
- the left panel shows plasma concentration over time.
- the right upper panel shows half-life, and the right lower panel shows clearance.
- FIG. 6 is a table depicting the PK parameters of a wild type HSA (HSA-wt) and a VSA (HSA-7) in a primate.
- FIG. 7 is a graph and a table depicting the pharmacokinetics of IL-2 fused to wild type HSA and to a VSA (HSA-13) in C57Bl/6J mice.
- One limitation of certain agents can be their suboptimal pharmacokinetics (PK), particularly when administered systemically.
- PK suboptimal pharmacokinetics
- Relatively short PKs can mean, for example, that a therapeutic must be administered at a relatively high frequency.
- the present disclosure provides VSAs that have improved functional properties, e.g., improved pharmacokinetics (e.g., increased half-life, reduced clearance, and/or reduced beta phase clearance).
- the VSAs can be useful themselves, e.g., for therapeutic or diagnostic uses.
- the VSAs can be used to improve the functional properties, e.g., the pharmacokinetics, of other agents.
- a variant serum albumin polypeptide can refer to a variant of a full length native serum albumin or to a variant of a fragment of a native serum albumin (e.g., a variant of a functional fragment of a native serum albumin).
- a VSA that is a variant of a fragment of a native serum albumin has a minimal length that provides functionality (e.g., an ability to bind FcRnat endosomal pH).
- the variant comprises or consists of a sequence that is a variant of the domain III sequence of a native serum albumin.
- the variant comprises a sequence that is a variant of the domain III sequence of a native human serum albumin sequence.
- the affinity of a VSA for an FcRn is increased at an endosomal pH (e.g., pH 5.5 or 6.0) compared to the affinity of wild type albumin corresponding to the VSA.
- the affinity of a VSA for an FcRn is increased at an endosomal pH (e.g., pH 5.5 or 6.0) compared to the affinity of wild type albumin corresponding to the VSA and the affinity of the VSA for FcRn at a neutral pH (e.g., pH 7.0 or 7.4) is the same or less than the affinity of a corresponding wild type albumin for an FcRn.
- an endosomal pH e.g., pH 5.5 or 6.0
- a neutral pH e.g., pH 7.0 or 7.4
- Applicants have found that in selecting a VSA that is useful, e.g., as a therapeutic, it is necessary to evaluate the affinity for FcRn at both endosomal and neutral pH, noting that a VSA with the greatest affinity for FcRn at endosomal pH may be unsuitable for use because it also has an increased affinity at a neutral pH.
- a VSA comprises an amino acid substitution or deletion at one or more (e.g., 1, 2, 3, 4, 5, or more) positions disclosed herein, e.g., at the positions that were mutated in the experiments disclosed in the Examples and Figures.
- a VSA comprises a substitution described herein, e.g., one or more substitutions of a specific amino acid at a specific position as described herein, e.g., as disclosed in the Examples and Figures.
- a VSA has one or more of the following mutations (amino acid residue numbers defined in accordance with the mature human amino acid sequence of SEQ ID NO:2): V418M; T420A; V424I; N429D; M446V; A449V; T467M; E505(R/K/G); V547A; and A552T, wherein “(X/Z)” means that the amino acid sequence may alternatively comprise amino acid X or amino acid Z at that residue.
- the VSA can include one or more of the following mutations: V418M; T420A; V424I; E505(R/K/G); and V547A.
- a VSA comprises a mutation that is present in a VSA disclosed herein, e.g., a VSA selected from one or more of the following variants described herein: HSA-15, HSA-13, HSA-12, HSA-7, HSA-21, HSA-11, HSA-14, HSA-5, HSA-10, HSA-6, HSA-9, and HSA-18.
- a VSA includes each of the mutations that are present in a variant described herein, e.g., a variant selected from HSA-15, HSA-13, HSA-12, HSA-7, HSA-21, HSA-11, HSA-2, HSA-14, HSA-5, HSA-10, HSA-6, HSA-9, and HSA-18.
- a VSA has the sequence of HSA-15, HSA-13, HSA-12, HSA-7, HSA-21, HSA-11, HSA-14, HSA-5, HSA-10, HSA-6, HSA-9, or HSA-18.
- the VSAs provided herein have improved functional properties (e.g., higher affinity for FcRn at endosomal pH and/or extended pharmacokinetics, e.g., increased half-life and/or reduced clearance) compared with a corresponding native serum albumin sequence.
- Such VSAs can be useful for therapeutic or diagnostic applications.
- VSAs can be useful for treating, or for producing formulations that are useful for treating, conditions for which serum albumin is indicated.
- a VSA that has improved properties compared with a corresponding native serum albumin sequence has therapeutic advantages.
- a VSA that has extended PK compared with a corresponding native serum albumin polypeptide can have therapeutic advantages, such as less frequent and/or reduced dosing and/or more consistent delivery levels.
- a VSA can also be less expensive to administer because fewer doses are required.
- Native human serum albumin binds to human FcRn at pH 6.0 with an affinity of about 1-10 micromolar, and about 400 micromolar affinity at pH 7.4.
- the VSAs described herein can have improved binding to FcRn at endosomal pH, e.g., at pH 6.0 compared with a native serum albumin (e.g., a corresponding native serum albumin, e.g., the corresponding full length native serum albumin or fragment thereof of which the VSA is a variant).
- the VSA binds to FcRn with a K D that is less than a value selected from 2 micromolor, 1.5 micromolar, 1 micromolar, and 0.5 micromolar. In some embodiments, the VSA binds to FcRn with a K D that is less than a value selected from 100 nM, 95 nM, 90 nM, 85 nM, 80 nM, 75 nM, 70 nM, 65 nM, 60 nM, 55 nM, 50 nM, 45 nM, 40 nM, 35 nM, 30 nM, 25 nM, 20 nM, 15 nM, 10 nM, and 5 nM.
- the K D can be determined as described herein or using any method known in the art.
- the K D is pH dependent.
- the VSA exhibits improved binding to FcRn at a specified pH, e.g., at pH 5.0, 5.2, 5.5, 5.6, 5.7, 5.8, 5.9, 6.2, 6.0, or 6.2.
- the VSA exhibits improved binding to FcRn at an endosomal pH, for example at pH 5.0-6.2, pH 5.0-6.2, pH 5.0-6.0, or pH 5.5-6.0.
- the VSA exhibits improved binding to FcRn at pH 5.5 or 6.0.
- the VSA binds to FcRn at an endosomal pH, e.g., at pH 5.5 or pH 6.0, with a K D that is less than a value selected from 2 micromolar, 1.5 micromolar, 1 micromolar, and 0.5 micromolar.
- the VSA binds to FcRn at an endosomal pH, e.g., at pH 5.5 or pH 6.0 with a K D that is less than a value selected from 100 nM, 95 nM, 90 nM, 85 nM, 80 nM, 75 nM, 70 nM, 65 nM, 60 nM, 55 nM, 50 nM, 45 nM, 40 nM, 35 nM, 30 nM, 25 nM, 20 nM, 15 nM, 10 nM, and 5 nM.
- the serum albumin variants have a K D for FcRn at pH 5.5 that is less than 23 nM. In some embodiments, the serum albumin variants have a K D for FcRn at pH 5.5 that is less or equal to 75 nM, 50 nM, 25 nM, 15 nM, 10 nM, 5 nM, or 3 nM.
- the VSA binds to FcRn at an endosomal pH, e.g., pH 5.5 or pH 6.0, but does not bind to FcRn at pH 7.4. In some embodiments, the VSA binds to FcRn at an endosomal pH, e.g., pH 5.5 or pH 6.0, and shows reduced binding to FcRn at pH 7.4 compared with its binding to FcRn at pH 5.5 (e.g., the binding to FcRn at pH 7.4 is less than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 60% of the level observed at pH 5.5).
- the VSA binds to FcRn at pH 5.5 and shows reduced binding to FcRn at pH 7.4 compared with its binding to FcRn at an endosomal pH, e.g., pH 5.5 or pH 6.0 (e.g., the binding to FcRn at pH 7.4 is less than 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 60% of the level observed at pH 5.5), and the VSA has improved pharmacokinetics (e.g., increased plasma half-life and/or reduced clearance, e.g., reduced beta phase clearance) compared with a corresponding native serum albumin.
- endosomal pH e.g., pH 5.5 or pH 6.0
- the binding to FcRn at pH 7.4 is less than 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or
- the VSA has a decreased K D for FcRn at an endosomal pH, e.g. pH5.5 or pH 6.0, compared to the K D of a wild type albumin (e.g., an HSA) at endosomal pH, and has the same or increased K D for FcRn at a neutral pH, e.g., pH 7.0 or pH 7.4.
- an endosomal pH e.g. pH5.5 or pH 6.0
- a wild type albumin e.g., an HSA
- the ratio of the K D s of wild type HSA to FcRn at pH 7.4 and 5.5 is 40-400, depending on the report. In some embodiments, the ratio of K D s of the VSA to FcRn at pH 7.4 and 5.5 is greater than for wild type HSA (e.g., a ratio of 500; 1000; 5000; 10,000; 100,000; or 1 million). In some embodiments, the binding of VSA to FcRn is assessed using SPR. In some embodiments, the binding of VSA to FcRn is assessed using ELISA.
- the half life (T1 ⁇ 2) of the VSA is greater than the T1 ⁇ 2 of a corresponding native serum albumin. In some embodiments, the T1 ⁇ 2 of the VSA is increased by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared with the T1 ⁇ 2 of a corresponding native serum albumin.
- the T1 ⁇ 2 of the VSA is at least two times, three times, or four times as long as the T1 ⁇ 2 of a corresponding native serum albumin. In some embodiments, the T1 ⁇ 2 of the VSA is at least twice as long as the T1 ⁇ 2 of a corresponding native serum albumin.
- Wild type HSA has a half-life (T1 ⁇ 2) in plasma of about 15-20 days in humans.
- a variant serum albumin described herein can have a longer serum half-life than a corresponding albumin, e.g., T1 ⁇ 2 at least about 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days.
- the VSA has a longer serum T1 ⁇ 2 in an animal compared to the corresponding wild type VSA, e.g., a VSA has a longer serum T1 ⁇ 2 in a monkey than the T1 ⁇ 2 of a human wild type albumin in a monkey.
- Wild type HSA (UniProt DB Accession No. P02768; SEQ ID NO:1 below) is a 609 amino acid protein, comprising an 18 amino acid signal peptide; a 6 amino acid propeptide, extending from amino acid 19 to 24; Domain 1, extending from amino acid 25 to 210; Domain 2, extending from amino acid 211 to 403; and Domain 3, extending from amino acid 404 to 601 or amino acid 404 to 609 of Sequence ID No. 1.
- An exemplary sequence of a human serum albumin (including its leader sequence) is as follows:
- HSA human serum albumin
- SEQ ID NO:2 An exemplary sequence of a human serum albumin (HSA) (in its mature form) is a 585 amino acid polypeptide as follows in SEQ ID NO:2.
- the VSAs as described herein comprise variant domain III regions. Typically, such variant domain III regions retain the three-dimensional fold of domain III of serum albumin.
- Exemplary variant domain III regions are at least 80% identical to domain III of a naturally occurring serum albumin, e.g., at least 90% identical to the domain III of a human serum albumin (e.g., amino acids 404 to 609 of SEQ ID NO:1 or amino acids 380 to 585 of SEQ ID NO:2 below).
- a variant serum albumin polypeptide can have one or more (e.g., 1, 2, 3, 4, 5, or more) substitutions, insertions, or deletions relative to a corresponding native serum albumin.
- the variant polypeptide can include a domain III with at least one, two, three, four or five substitutions relative to a domain III of HSA.
- a VSA is a polypeptide that has a three-dimensional fold that is similar or identical to that of a native serum albumin, e.g., as described in PDB files 1A06 (Sugio et al. (1999) Protein Eng. Jun; 12(6):439-46); or 1E78 (Bhattacharya et al., (2000) J. Biol. Chem., 275:38731)); or 1E7H (Bhattacharya et al., (2000) J. Mol. Biol., 303:721).
- variant serum albumin polypeptides are at least 70% identical to a naturally occurring serum albumin, e.g., at least 75%, 80%, 85%, 90%, or 95% identical to a human serum albumin (e.g., SEQ ID NO:1 above).
- a variant serum albumin polypeptide can have one or more substitutions, insertions, or deletions.
- the variant polypeptide can have at least one, two, three, four, or five substitutions relative to HSA.
- sequences of serum albumins from other species, particularly mammalian species are also known.
- Exemplary sequences include albumin sequences from Bos taurus (CAA76847, P02769, CAA41735, 229552, AAF28806, AAF28805, AAF28804, AAA51411); Sus scrofa (P08835, CAA30970, AAA30988); Equus caballus (AAG40944, P35747, CAA52194); Ovis aries (P14639, CAA34903); Salmo salar (CAA36643, CAA43187); Gallus gallus (P19121, CAA43098); Felis catus (P49064, 557632, CAA59279, JC4660); Canis familiaris (P49822, 529749, CAB64867).
- Bos taurus CAA76847, P02769, CAA41735, 229552, AAF28806, AAF28805, AAF28804, AAA5
- Variations e.g., substitutions described herein in HSA, can also be introduced at corresponding positions into serum albumins from other species, e.g., into mammalian serum albumins, including, e.g., bovine serum albumin.
- Serum albumin can be divided into at least three domains, termed Domain I, Domain II, and Domain III.
- a serum albumin protein useful in the present invention typically includes at least a domain III, and can also include domain I and domain II.
- Exemplary domains I, II, and III can have at least 60, 65, 70, 75, 80, 85, 90, 95% identity to respective domains from a mammalian serum albumin.
- the variant serum albumin polypeptide of the present invention comprises domain III of human HSA, that is, amino acids 404 to 601 or 404 to 609 of SEQ ID NO:1, or amino acids 380 to 585 of SEQ ID NO:2, into which at least one, two, three, four, or five substitutions have been engineered relative to domain III of HSA.
- a residue that is within less than 7 angstroms of position H464 is substituted with another amino acid.
- the residue is amino acid 415, 418, 458, 459, 460, 461, 462, 463, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, or 477.
- a residue that is within less than 7 angstroms of position H510 is substituted with another amino acid.
- the residue is amino acid 508, 509, 511, 512, 513, 514, 554, 555, 559, 564, 565, 568, or 569.
- a residue that is within less than 7 angstroms of position H535 is substituted with another amino acid.
- the residue is amino acid 412, 497, 498, 499, 500, 501, 502, 503, 507, 529, 530, 531, 532, 533, 534, 536, 537, 538, 580, or 583.
- residue V418 is altered, e.g., to a residue other than valine, e.g., to an hydrophobic residue such as methionine.
- a residue that is within less than 7 angstroms of position V418 is substituted with another amino acid.
- the residue is amino acid 411, 412, 415, 416, 417, 419, 420, 421, 422, 423, 424, 426, 460, 464, 469, 470, 473, 497, 530, or 534.
- residue T420 is altered, e.g., to a residue other than threonine, e.g., to an uncharged residue, e.g., a small uncharged residue such as alanine or glycine.
- a residue that is within less than 7 angstroms of position T420 is substituted with another amino acid.
- the residue is amino acid 408, 412, 416, 417, 418, 419, 421, 422, 423, 424, 425, 500, 526, 527, 528, 529, 530, 531, or 534.
- residue V424 is altered, e.g., to a residue other than valine, e.g., to an uncharged residue, e.g., to isoleucine.
- a residue that is within less than 7 angstroms of position V424 is substituted with another amino acid.
- the residue is amino acid 404, 408, 412, 418, 419, 420, 421, 422, 423, 425, 426, 427, 428, 429, 430, 522, 523, 524, 526, 527, 528, or 530.
- residue E505 is altered, e.g., to a residue other than glutamic acid, e.g., to an uncharged residue, e.g., a small uncharged residue such as alanine or glycine, or to a positively charged residue, e.g. lysine or arginine.
- a residue that is within less than 7 angstroms of position E505 is substituted with another amino acid.
- the residue is amino acid 502, 503, 504, 506, 507, 508, or 509.
- residue V547 is altered, e.g., to a residue other than valine, e.g., to an uncharged residue, e.g., a small uncharged residue such as alanine or glycine.
- a residue that is within less than 7 angstroms of position V547 is substituted with another amino acid.
- the residue is amino acid 529, 532, 542, 543, 544, 545, 546, 548, 549, 550, 551, or 552.
- Variant serum albumin polypeptides can be incorporated into a fusion protein, with the N- or C-terminus thereof fused to the N- or C-terminus of a diagnostic or therapeutic protein, or variant thereof.
- the variant serum albumin polypeptide and the diagnostic or therapeutic protein are joined through a linker moiety, such as a peptide linker Linkers useful in the present invention are described in greater detail further herein.
- a VSA can be used as a therapeutic, e.g., in uses for which albumin such as human albumin is typically used.
- a VSA as described herein can have the advantage of extended PK, which can enable less frequent and/or reduced dosing for albumin replacement or supplementation.
- Such uses include, for example, hypovolemia, hypoalbuminemia, burns, adult respiratory distress syndrome, nephrosis, and hemolytic disease of the newborn.
- Hypoalbuminemia can result from, for example, inadequate production of albumin (e.g., due to malnutrition, burns, major injury, or infection), excessive catabolism of albumin (e.g., due to burn, major injury such as cardio-pulmonary bypass surgery, or pancreatitis), loss through bodily fluids (e.g., hemorrhage, excessive renal excretion, or burn exudates), deleterious distribution of albumin within the body (e.g., after or during surgery or in certain inflammatory conditions).
- a VSA for such uses is administered by injection or iv in a solution that is from 5%-50% VSA (w/v), for example, 10%-40%, 15%-30%, 20%-25%, 20%, or 25%.
- administration is sufficient to produce a total albumin plus VSA concentration in a treated subject's serum that is 3.4-5.4 grams per deciliter (g/dL).
- Methods of assaying albumin concentration are well known in the art and can generally be used to assay total albumin plus VSA concentration.
- VSA a VSA
- a pharmaceutical composition comprising a VSA for use in therapy.
- a VSA or a pharmaceutical composition comprising a VSA, for use in the treatment of a disease, e.g., a disease or condition for which albumin is indicated.
- Other embodiments include the use of a VSA, or a pharmaceutical composition comprising aVSA, for the manufacture of a medicament for the treatment of a disease.
- VSAs can also be used in association with other agents, e.g., therapeutic or diagnostic agents, to confer functional advantages, e.g., advantages of VSAs as described herein.
- the agent can be, e.g., any agent that is useful in the diagnosis or therapy of a disease or disorder, e.g., a disease or disorder that affects a human or a non-human animal.
- VSAs include, e.g., lack of Fc effector function, high solubility, potential for high expression, low immunogenicity, and ability to be fused to another moiety at both termini to generate bivalent, bispecific, or bifunctional molecules.
- VSAs with improved binding to an FcRn at endosomal pH, thereby potentiating the ability of the VSA and an agent associated with that VSA to have improved PK.
- a VSA that has an extended PK can be associated with an agent (e.g., a therapeutic or diagnostic agent) to extend the PK of the agent.
- the extended PK can have advantages; for example, the agent can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the agent can be achieved.
- associating a VSA with an agent improves the functional properties of the agent.
- the dosage and/or frequency at which the agent is effective for producing a particular effect is reduced when the agent is used in association with the VSA.
- associating a VSA with an agent improves the pharmacokinetic properties of the agent (e.g., increases its half-life and/or reduces its clearance). Any relevant pharmacokinetic parameters that are known in the art can be used to assess pharmacokinetic properties.
- the pharmacokinetics of a VSA or a VSA associated with an agent can be measured in any relevant biological sample, e.g., in blood, plasma, or serum.
- associating a VSA with an agent improves the half life (T1 ⁇ 2) of the agent.
- the T1 ⁇ 2 of the agent is increased by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%.
- the T1 ⁇ 2 is at least two times, three times, or four times as long as the T1 ⁇ 2 of the agent when it is not associated with the VSA.
- the T1 ⁇ 2 of the VSA is at least twice as long as the T1 ⁇ 2 of the agent when it is not associated with the VSA.
- the dose at which the agent is effective for producing a particular effect is reduced when the agent is associated with the VSA.
- the effective dose is reduced to 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10% of the dose that is required when the agent is not associated with the VSA.
- the frequency of dosing of the agent that is effective for producing a particular effect is reduced when the agent is associated with the VSA.
- the frequency of dosing at which the agent is effective when it is associated with the VSA is decreased by 10%, 20%, 30%, 40%, 50%, or more compared with the frequency at which the agent is effective when it is not associated with the VSA.
- the frequency of dosing at which the agent is effective when it is associated with the VSA is decreased by at least 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 2 weeks, 3 weeks, or 4 weeks compared with the frequency at which the agent is effective when it is not associated with the VSA.
- the improvement in the properties of the agent can be assessed relative to any appropriate control.
- the improvement in the properties of an agent that is associated with a VSA can be assessed by comparing the properties of the agent that is associated with the VSA with the properties of the agent when it is not in an association with the VSA.
- the improvement in the properties of an agent that is associated with a VSA can be assessed by comparing the properties of the agent that is associated with the VSA with the properties of the agent when it is in an association with a corresponding native serum albumin polypeptide.
- VSA a VSA in association with another agent
- a pharmaceutical composition comprising a VSA or a pharmaceutical composition comprising a VSA in association with another agent, for use in therapy or for use in the treatment of a disease, e.g., a disease or condition described herein or described in U.S. Pat. No. 5,766,883, U.S. Pat. No. 5,875,969, U.S. Patent Publication No. US 2002/0151011, or International Publication No. WO 2011/103076, the entire contents of each of which are hereby incorporated herein by reference.
- VSA or a pharmaceutical composition comprising aVSA, a VSA in association with another agent, a pharmaceutical composition comprising a VSA, or a pharmaceutical composition comprising a VSA in association with another agent, for the manufacture of a medicament for the treatment of a disease.
- the agent can be another protein, e.g., a heterologous protein.
- the agent is a diagnostic agent.
- the agent is a therapeutic agent.
- a protein that comprises a VSA can be used to extend the PK of a systemically administered therapeutic agent.
- the heterologous protein can be, for example, a therapeutic protein or a diagnostic protein.
- the serum albumin polypeptide with altered FcRn binding properties or a domain thereof e.g., domain III
- the variant serum albumin or a domain thereof can be in the same polypeptide chain as is at least a component of the therapeutic protein.
- a variant serum albumin can be associated with another agent, e.g., a therapeutic agent or a diagnostic agent.
- the other agent e.g., therapeutic agent
- the activity of the agent can be evaluated in an appropriate in vitro or in vivo assay for the agent's activity.
- the activity of the agent fused to a VSA is not reduced, for example, by more than 50%, by more than 40%, by more than 30%, by more than 20%, by more than 10%, by more than 5%, or by more than 1% compared with the activity of the agent when it is not in association with the agent. Examples of methods for assessing the activity of certain agents are provided herein.
- the VSA is attached to the agent by one or more covalent bonds to form a variant serum albumin fusion molecule.
- Any agent that can be linked to a VSA described herein can be used as the agent in a variant serum albumin fusion molecule.
- the agent can be a therapeutic or diagnostic agent.
- the agent can be any polypeptide or drug known to one of skill in the art.
- an agent e.g., therapeutic or diagnostic agent
- the agent can be associated with the VSA by any means known in the art.
- the agent can be conjugated to a moiety that is capable of binding the VSA.
- the moiety is an albumin binding protein.
- the moiety is a fatty acid.
- the agent is non-covalently bound to the VSA, generally via the affinity of the VSA for small lipophilic moieties.
- the agent can be administered before, after, or concurrently with the VSA.
- the agent is administered concurrently with the VSA.
- the agent is administered at the same frequency as is the VSA. In some embodiments, the agent is administered more or less frequently than the VSA.
- the agent is a polypeptide consisting of at least 5, for example, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 or at least 100 amino acid residues.
- the agent can be derived from any protein for which an improved property is desired, e.g., an increase in serum levels and/or serum half-life of the agent; or a modified tissue distribution and/or tissue-targeting of the agent.
- the agent is a cytokine or a variant thereof.
- a cytokine is a protein released by one cell population that acts on another cell as an intercellular mediator.
- cytokines include lymphokines, monokines, and traditional polypeptide hormones.
- interleukins such as IL-1 (IL-1 ⁇ and IL1 ⁇ ), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12; IL-15, IL-18, and IL-37; a tumor necrosis factor such as TNF-alpha or TNF-beta; growth hormone such as human growth hormone (HGH); somatotropin; somatrem; N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; insulin-like growth factors, such as insulin-like growth factors-1, -2, and -3 (IGF-1; IGF-2; IGF-3); proglucagon; glucagon and glucagon-like peptides, such as glucagon-like peptide-1 and -2 (GLP-1 and GLP-2); exendins, such as exendin-4; gas
- the agent is BMP peptide analogue (e.g., THR-184, Thrasos Therapeutics, Inc.).
- the agent is GLP-2.
- the therapeutic protein is a monomeric protein (such as a monomeric cytokine, e.g., an IL-1Ra, or an scFv).
- a monomeric cytokine e.g., an IL-1Ra, or an scFv
- Albumin fusion proteins are known in the art; the variant serum albumin polypeptides with altered FcRn binding properties, described herein, can be used in place of serum albumin and linked to a therapeutic agent to form fusion proteins with improved properties, such as increased half-life.
- polypeptides useful as the active agent include, but are not limited to, various types of antibodies, antibody fragments, such as antigen binding domains (e.g., scFv, Fv, Fab, F(ab) 2 , domain antibodies, and the like); Surrobodies, AdnectinsTM, anti-calin, affibody, or fragments of the foregoing.
- receptor antagonists such as IL-1Ra (e.g., anakinra), cell adhesion molecules (e.g., cadherins, such as cadherin-11, CTLA4, CD2, and CD28); anti-angiogenic factors such as endostatin; receptors, as well as soluble fragments of tissue-bound receptors.
- the agent e.g., therapeutic moiety included in a fusion protein as described herein, can also be a therapeutic moiety such as a cytotoxin (e.g., a cytostatic or cytocidal agent), a non-peptide therapeutic agent or a radioactive element (e.g., alpha-emitters, gamma-emitters, etc.).
- a cytotoxin e.g., a cytostatic or cytocidal agent
- a non-peptide therapeutic agent e.g., a radioactive element
- a radioactive element e.g., alpha-emitters, gamma-emitters, etc.
- cytostatic or cytocidal agents include, but are not limited to, paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof.
- Non-peptide therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cisdichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC), and anti-mitotic agents (e.
- the present invention also encompasses fusing the variant serum albumin (VSA) moiety to an active agent that is a diagnostic agent.
- VSA-diagnostic molecule of the invention can be used diagnostically to, for example, monitor the development or progression of a disease, disorder or infection as part of a clinical testing procedure to, e.g., determine the efficacy of a given 5 treatment regimen. Detection can be facilitated by coupling the pharmacologic enhancing molecule to a detectable substance. Examples of detectable substances include enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals, and nonradioactive paramagnetic metal ions.
- the detectable substance can be coupled or conjugated either directly to the antibody or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Pat. No. 4,741,900 for metal ions that can be conjugated to antibodies for use as a diagnostic according to the methods and compositions described herein.
- suitable enzymes include, e.g., horseradish peroxidase, alkaline phosphatase, O-galactosidase, or acetylcholinesterase
- suitable prosthetic groups include, e.g., complexes including, e.g.
- Suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include, e.g., 125 I, 131 I, 111 In or 99 mTc. See, for example, Plumridge et al., WO2011/051489; Lubman et al.; WO2010/141329.
- nucleotide and amino acid sequences and structures for the above molecules that are useful as, or in preparing the active moiety to be fused to the variant serum albumin moiety in the present invention are known, and all of the publications and websites described as providing such information, such as Genbank, the protein database and Uniprot (www.ncbi.nlm.nih.gov/genbank; www.pdb.org; and www.uniprot.org, respectively), are incorporated herein by reference for this purpose.
- Non-limiting examples of therapeutic proteins that can be used in preparing some of the embodiments of the present invention are described in further detail below.
- Glucagon-Like Peptide 1 (GLP-1).
- the therapeutic agent includes a GLP-1 or a biologically active variant or fragment thereof.
- GLP-1 is a 37 amino acid peptide that is formed from cleavage of glucagon, secreted by the L-cells of the intestine in response to food ingestion (Uniprot accession number: P01275). GLP-1 can stimulate insulin secretion, causing glucose uptake by cells and decreased serum glucose levels (e.g., Mojsov, Int. J. Peptide Protein Research, 40:333-343 (1992)). GLP-1 can be cleaved to produce a biologically active peptide GLP-1 (7-37)0H.
- GLP-1 analogs and derivatives include, e.g., exendins which are peptides found in Gila monster venom. Exendins have sequence homology to native GLP-1 and can bind the GLP-1 receptor and initiate the signal transduction cascade of GLP-1 (7-37)OH. GLP-1 compounds can have one or more of the following biological properties: ability to stimulate insulin release, lower glucagon secretion, inhibit gastric emptying, and enhance glucose utilization. (e.g., Nauck et al., Diabetologia 36:741-744 (1993); Gutniak et al., New England J. of Med. 326:1316-1322 (1992); Nauck et al., J. Clin.
- a therapeutic agent including GLP-1, GLP-1 (7-37)0H, an exendin, or biologically active variants or fragments thereof can be used for treating a diabetic disorder, e.g., non-insulin dependent diabetes mellitus (NIDDM).
- NIDDM non-insulin dependent diabetes mellitus
- the amino acid sequence of human GLP-1 is as follows:
- Advantages of using a VSA in association with a GLP-1 include, e.g., extending the PK of the GLP-1.
- the extended PK can have advantages; for example, the GLP-1 can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the GLP-1 can be achieved.
- the therapeutic agent is an insulin.
- the insulin can be a full length insulin polypeptide or a biologically active variant or fragment thereof.
- the insulin can be a glucose sensitive molecule that includes an insulin receptor agonist.
- An exemplary insulin polypeptide (110 amino acids) has the sequence:
- the B-chain (1-30 or
- Therapeutic proteins as disclosed herein can include the B-chain and A-chain of insulin, linked by the C-peptide of insulin or another natural or artificial sequence, such as a peptide linker
- a number of adipose and muscle related cell lines can be used to test for glucose uptake/transport activity in the absence or presence of a combination of any one or more of the therapeutic drugs listed for the treatment of diabetes mellitus.
- the 3T3-L1 murine fibroblast cells and the L6 murine skeletal muscle cells can be differentiated into 3T3-L1 adipocytes and into myotubes, respectively, to serve as appropriate in vitro models for the [3 H ]-2-deoxyglucose uptake assay (Urso et al., J Biol Chem, 274:30864-73 (1999); Wang et al., J Mol Endocrinol, 19:241-8 (1997); Haspel et al., J Membr Biol, 169:45-53 (1999); Tsakiridis et al., Endocrinology, 136:4315-22 (1995)).
- Female NOD (non-obese diabetic) mice are characterized by displaying IDDM with a course which is similar to that found in humans, although the disease is more pronounced in female than male NOD mice.
- Advantages of using a VSA in association with an insulin include, e.g., extending the PK of the insulin.
- the extended PK can have advantages; for example, the insulin can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the insulin can be achieved.
- Fibroblast Growth Factor 19 FGF-19.
- the therapeutic agent is an FGF-19 (e.g., human FGF-19) or a biologically active variant or fragment thereof.
- Human FGF-19 is a 216 amino acid protein, including a 24 amino acid N-terminal signal peptide.
- An exemplary FGF-19 peptide sequence is the sequence of human FGF-19 (Uniprot accession number: O95750):
- FGF-19 is active in the suppression of bile acid biosynthesis and stimulates glucose uptake in adipocytes. Holt et al., Genes Dev. 17:1581-91 (2003). FGF-19 can be used for treatment of dietary and leptin-deficient diabetes. Fu et al., Endocrinology, 145:2594-603 (2004).
- Advantages of using a VSA in association with FGF-19 include, e.g., extending the PK of the FGF-19.
- the extended PK can have advantages; for example, the FGF-19 can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the FGF-19 can be achieved.
- Fibroblast Growth Factor 21 FGF-21.
- the therapeutic agent is an FGF-21 (e.g., human FGF-21) or a biologically active variant or fragment thereof.
- Human FGF-21 is a 209 amino acid protein, including a 28 amino acid N-terminal signal peptide.
- An exemplary FGF-21 peptide sequence is the sequence of human FGF-21 (Uniprot accession number: Q9NSA1):
- FGF-21 stimulates glucose uptake in differentiated adipocytes via the induction of the insulin-independent glucose transporter GLUT1.
- FGF-21 has been demonstrated to have durable glucose control and triglyceride lowering effects with minimal adverse side effects.
- Advantages of using a VSA in association with FGF-21 include, e.g., extending the PK of the FGF-21.
- the extended PK can have advantages; for example, the FGF-21 can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the FGF-21 can be achieved.
- Fibroblast Growth Factor 23 (FGF-23).
- the therapeutic agent is an FGF-23 (e.g., human FGF-23) or a biologically active variant or fragment thereof.
- Human FGF-23 is a 251 amino acid protein, including a 24 amino acid N-terminal signal peptide. FGF-23 is cleaved by protein convertases into an N-terminal peptide of approximately 155 amino acids (amino acid 25-179); and a C-terminal peptide of approximately 72 amino acids (amino acids 180-251).
- An exemplary FGF-23 peptide sequence is the sequence of human FGF-23 (Uniprot accession number: Q9GZV9):
- FGF-23 is involved in regulating phosphate homeostasis.
- FGF-23 has been shown to inhibit renal tubule phosphate transport (Bowe et al., Biochem. Biophys. Res. Commun., 284:977-81 (2001)); to regulate vitamin D metabolism (Shimada et al., J. Bone Miner. Res., 19:429-35 (2004)); and to negatively regulate osteoblast differentiation and matrix mineralization (Wang et al., J. Bone Miner. Res., 23:939-48 (2008)).
- FGF-23 can be used in treatment of autosomal dominant hypophosphatemic rickets (ADHR) and tumor-induced osteomalacia (Riminucci et al., J. Clin. Invest., 112:683-92 (2003)).
- ADHR autosomal dominant hypophosphatemic rickets
- tumor-induced osteomalacia Rost al., J. Clin. Invest., 112:683-92 (2003).
- Advantages of using a VSA in association with FGF-23 include, e.g., extending the PK of the FGF-23.
- the extended PK can have advantages; for example, the FGF-23 can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the FGF-23 can be achieved.
- Interleukin-2 (IL-2).
- the therapeutic agent is an IL-2 (e.g., human IL-2) or a biologically active variant or fragment thereof.
- Human IL-2 is a 153 amino acid protein, including a 20 amino acid N-terminal signal peptide.
- An exemplary IL-2 peptide sequence is the sequence of human IL-2 (Uniprot accession number: P60568):
- IL-2 can induce proliferation of antigen-activated T cells and stimulates natural killer (NK) cells, as well as stimulates proliferation of regulatory T cells (Tregs).
- the biological activity of IL-2 is mediated through a multi-subunit IL-2 receptor complex (IL-2R) of three polypeptide subunits that span the cell membrane: p55 (IL-2R ⁇ , the alpha subunit, also known as CD25 in humans), p75 (IL-2R ⁇ , the beta subunit, also known as CD122 in humans) and p64 (IL-2R ⁇ , the gamma subunit, also known as CD132 in humans).
- IL-2-derived polypeptides can be used in cancer immunotherapies and to deliver therapeutic agents to CD25-positive cells in vivo or in cell culture.
- Proleukin® is an approved biologic that contains IL-2.
- Exemplary agonists are described by Rao et al., Protein Engineering 16:1081-1087 (2003) and Rao et al., Biochemistry 44:10696-701 (2005), and in US Patent Application Publication 2005/0142106; see also U.S. Pat. Nos. 7,569,215 and 7,951,360.
- the therapeutic agent can also further include an IL-2 binding fragment of CD25, e.g., the sushi domain of IL-2R ⁇ .
- the IL-2 binding fragment of CD25 can be covalently linked to the biologically active portion of IL-2 or can be non-covalently linked.
- Exemplary IL-2 antagonists that bind CD25 but do not activate the IL-2 receptor are described in US 2011/0091412.
- the IL-2 antagonists can be used to specifically target T regulatory cells and/or specifically inhibit T regulatory cell function.
- the ability of low-dose IL-2 to reduce inflammation and/or immune response may be particularly surprising in light of previous publications advocating low doses of IL-2 for stimulation of immune response. See, U.S. Pat. No. 6,509,313.
- Low-dose IL-2 can be used to specifically induce Treg proliferation and promote an anti-inflammatory state.
- low-dose IL-2 can be administered subcutaneously, for example using a self-administered pen or cartridge device, such as is used with other self-administered peptide biotherapeutic drugs, such as long-acting insulin.
- a self-administered pen or cartridge device such as is used with other self-administered peptide biotherapeutic drugs, such as long-acting insulin.
- peptide biotherapeutic drugs such as long-acting insulin.
- Particular indications for which low-dose IL-2 can be appropriate include, for example, graft-vs-host-disease; for example, in connection with bone marrow transplantation.
- Administration of low-dose IL-2 can be advantageous in reducing the need for pre-graft conditioning and/or post-graft treatment with immunosuppressant drugs. Ferrara et al., Biology of Blood and Marrow Transplantation, 5:347-56 (1999). Additional advantages can include avoiding the adverse effects of short-term, high dose IL-2.
- Advantages of using a VSA in association with IL-2 include, e.g., extending the PK of the IL-2.
- the extended PK can have advantages; for example, the IL-2 can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the IL-2 can be achieved.
- Interleukin-15 (IL-15).
- the therapeutic agent is an IL-15 (e.g., human IL-15) or a biologically active variant or fragment thereof.
- Human IL-15 is a 162 amino acid protein, including a 29 amino acid N-terminal signal peptide.
- An exemplary IL-15 peptide sequence is the sequence of human IL-15 (Uniurot accession number: P409331:
- IL-15 can induce proliferation of antigen-activated T cells and stimulate natural killer (NK) cells.
- the biological activity of IL-15 is mediated through a multi-subunit receptor complex (IL-15R) which shares the beta (CD122) and gamma (CD132) subunits of the IL-2 receptor complex, but has a unique alpha subunit (IL-15Ra, also known as CD215 in humans).
- IL-15 derived polypeptides can be used in cancer immunotherapies.
- the therapeutic agent can also further include an IL-15 binding fragment of the IL-15Ra receptor, e.g., the sushi domain of IL-2R ⁇ .
- the IL-15 binding fragment of IL-15Ra can be covalently linked to the biologically active portion of IL-15 or can be non-covalently linked.
- Advantages of using a VSA in association with IL-15 include, e.g., extending the PK of the IL-15.
- the extended PK can have advantages; for example, the IL-15 can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the IL-15 can be achieved.
- the therapeutic agent is a hepcidin (e.g., human hepcidin), or a biologically active variant of hepcidin.
- Human hepcidin is an 84 amino acid protein (Uniprot Accession number P81172), including a 24 amino acid N-terminal signal peptide, a thirty amino acid propeptide, and a 25 amino acid mature peptide (amino acids 60 to 84); hepcidin can be alternately cleaved to form a 20 amino acid mature peptide (amino acids 65 to 84).
- Hepcidin is known to be involved in iron homeostasis (e.g., Laftah et al., Blood, 103:3940-44 (2004); U.S. Pat. No. 7,169,758). Accordingly, hepcidin can be used an agent for regulation of iron absorption and homeostasis. It can be used to treat abnormal iron absorption, e.g., in individuals with ⁇ -thalassemia and related disorders.
- the therapeutic agent can comprise a hepcidin peptide, or a variant of such peptide containing one or more amino acid variations from the mature hepcidin peptide.
- two mature hepcidin peptides are fused or joined to each end of an albumin moiety, such as a VSA, such that the hepcidin molecules are able to interact with the natural binding partner for hepcidin, ferroportin.
- Ferroportin is known to exist in dimers, and both monomers must be capable of binding hepcidin for Jak2 to bind to ferroportin.
- Advantages of using a VSA in association with a hepcidin include, e.g., extending the PK of the hepcidin.
- the extended PK can have advantages; for example, the hepcidin can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the hepcidin can be achieved.
- the therapeutic agent is an FVII (e.g., a human FVII) or a biologically active variant or fragment thereof.
- Human FVII is a 466 amino acid protein, including a 20 amino acid N-terminal signal peptide and a 40 amino acid propeptide, a 152 amino acid light chain and a 254 amino acid heavy chain. Thim et al., Biochemistry, 27:7785-93 (1998); Hagen et al., PNAS USA 83:2412-16 (1986); O'Hara et al., PNAS USA 84:5158-62 (1987) and Sabater-Lleal et al., Hum Genet.
- FVII Coagulation Factor VII
- the mature FVII is a single chain glycoprotein (mol. wt. 50,000) of 406 amino acids that is secreted into the blood where it circulates in a zymogen form.
- FVII comprises a 45 amino acid Gla domain (amino acids 61 through 105); a potentially calcium-binding 37 amino acid EGF-like domain (amino acids 106 through 142); a 42 amino acid EGF-like domain (amino acids 147 through 188) and a 240 amino acid serine peptidase domain (amino acids 213 through 452).
- FVII can be proteolytically cleaved to form activated FVII, or FVIIa, by the action of activated coagulation factors Factor X (FXa), Factor IX (FIXa), Factor XII (FXIIa) or Factor II (FIIa).
- FVIIa does not promote coagulation by itself, but can complex with tissue factor (TF) exposed at the site of injury.
- TF tissue factor
- the FVIIa/TF complex can convert FX to FXa, and FIX to FIXa, thereby inducing local hemostasis at the site of injury.
- FVII to FVIIa involves proteolytic cleavage at a single peptide bond between Arg-152 and Ile-153, resulting in a two-chain molecule consisting of a light chain of 152 amino acid residues and a heavy chain of 254 amino acid residues held together by a single disulfide bond.
- Persons with hemophilia may have normal levels of FVII. However, they suffer from a relative deficiency in FVIIa and other activated clotting factors.
- NovoSeven® is a 406 amino acid glycoprotein that is structurally similar to plasma-derived FVIIa.
- recombinant FVIIa is expensive to manufacture.
- Another critical problem is the short half-life (2 hours) of recombinant FVIIa. Therefore, recombinant FVIIa therapy requires an intravenous infusion of high doses of the protein every 2 hours.
- sequences useful as the therapeutic agent in the present invention include sequences encoding FVII and FVIIa.
- the agent used herein can be a Factor VII or Factor VIIa peptide.
- the Factor VII peptide can contain one or more mutations to provide an enzymatic cleavage site, such as an enzymatic cleavage site susceptible to cleavage by SKI-1 or furin (e.g., U.S. Pat. No. 7,615,537).
- Advantages of using a VSA in association with a FVII include, e.g., extending the PK of the FVII.
- the extended PK can have advantages; for example, the FVII can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the FVII can be achieved.
- the therapeutic agent is an FVIII (e.g., human FVIII) or a biologically active variant or fragment thereof.
- FVIII e.g., human FVIII
- Toole, U.S. Pat. No. 4,757,006 discloses the amino acid sequence of the full-length wild-type human FVIII
- Toole, U.S. Pat. No. 4,868,112 discloses the amino acid sequence of human FVIII, wherein the B-domain has been deleted.
- FVIII also commonly referred to as antihemophilic factor (AHF) is a large, 2351 amino acid protein that is processed into multiple chains in a complex manner, including a 19 amino acid signal peptide (amino acids 1 to 19); a 1313 amino acid (amino acids 20 through 1332) or 740 amino acid (amino acids 20 through 759) light chain; a 573 amino acid B chain (amino acids 760 through 1332); and a 684 amino acid light chain (amino acids 1668 through 2351). Wood et al., Nature 312:330-37 (1984); Toole et al., Nature, 312:342-47 (1984); UniProt Accession No. P00451.
- AHF molecules have been approved as therapeutic treatments for subjects with hemophilia A (Recombinate®, Baxter Healthcare/Wyeth BioPharma; Advate®, Baxter Healthcare; Kogenate®, Bayer Healthcare; Xyntha® Wyeth Pharmaceuticals; Monoclate-P®, CSL Behring LLC). It has been found that the B-domain is not essential to activity, Pittman et al., Blood, 81:2925-35 (1993), and therefore, B-domain-deleted Factor VIII molecules have also been approved as a therapeutic treatment for hemophilia A (ReFacto®; Genetics Institute/Wyeth Pharmaceuticals). See, also, U.S. Pat. No. 7,572,619. Accordingly, sequences useful as the therapeutic agent in the present invention include sequences encoding FVIII and B-domain deleted FVIII.
- FVIII and B-domain-deleted FVIII may be expressed and/or administered in conjunction with von Willebrand's Factor (VWF).
- VWF von Willebrand's Factor
- VWF is a large (2,813 amino acid) protein comprising multiple repetitive domains which form multimers and acts as a chaperone protein for FVIII. Accession number P04275. VWF/FVIII complex has been approved as a therapeutic treatment for spontaneous or trauma-induced bleeding episodes in patients with moderate or severe von Willebrand Disease (Wilate®, Octapharma).
- Advantages of using a VSA in association with a FVIII include, e.g., extending the PK of the FVIII.
- the extended PK can have advantages; for example, the FVIII can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the FVIII can be achieved.
- the therapeutic agent is an FIX (e.g., a human FIX) or a biologically active variant or fragment thereof.
- Human FIX is a 461 amino acid secreted protein, including a 28 amino acid N-terminal signal peptide and an 18 amino acid propeptide.
- the protein comprises a 415 amino acid chain [amino acids 47 through 461]; or can be processed by human Factor XIa to form a 145 amino acid Factor IXa light chain [amino acids 47 through 191]; a 35 amino acid propeptide/activation peptide [amino acids 192 through 226]; and a 235 amino acid Factor IXa heavy chain [amino acids 227 through 461].
- Coagulation Factor 1 ⁇ therapy has been approved as therapeutic treatment for subjects suffering from hemophilia B, including BeneFIX® (Wyeth); Mononine (Behring); and Alphanine (Grifols Biologics). Accordingly, sequences useful as the therapeutic agent in the present invention include sequences encoding FIX (below) and FIXa.
- Advantages of using a VSA in association with a FIX include, e.g., extending the PK of the FIX.
- the extended PK can have advantages; for example, the FIX can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the FIX can be achieved.
- EPO Erythropoietin
- the therapeutic agent is an EPO (e.g., a human EPO) or a biologically active variant or fragment thereof.
- Human EPO is a 193 amino acid protein, including a 27 amino acid N-terminal signal peptide. (Uniprot Accession Number: P01588).
- the therapeutic agent can have the ability to increase red blood cell production.
- EPO is an approved therapeutic for treatment of anemia, and is marketed as Epogen® (Amgen, Thousand Oaks, Calif.); Recormon® (Roche, South San Francisco, Calif.) and under a number of other marketed names.
- An exemplary amino acid sequence encoding human EPO is:
- Advantages of using a VSA in association with an EPO include, e.g., extending the PK of the EPO.
- the extended PK can have advantages; for example, the EPO can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the EPO can be achieved.
- G-CSF Granulocyte Colony Stimulating Factor
- the therapeutic agent is a G-CSF (e.g., human G-CSF) or a biologically active variant or fragment thereof.
- Human G-CSF is a 207 amino acid protein, including a 29 amino acid N-terminal signal peptide. (Uniprot Accession No. P09919).
- the therapeutic agent can have the ability to increase the level of neutrophils in the blood.
- G-CSF is an approved therapeutic for the treatment of neutropenia, that is low neutrophil levels, and is marketed as Neupogen® (Amgen); and as Granocyte® (Chugai, Turnham Green, UK).
- An exemplary amino acid sequence encoding human G-CSF is:
- Advantages of using a VSA in association with an G-CSF include, e.g., extending the PK of the G-CSF.
- the extended PK can have advantages; for example, the G-CSF can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the G-CSF can be achieved.
- the therapeutic agent is an interferon (e.g., a human interferon) or a biologically active variant or fragment thereof.
- the interferon is a human alpha interferon, beta interferon or gamma interferon.
- the therapeutic can have antiviral, antibacterial or anticancer activities, and important immunoregulatory activity, such as activation of macrophages.
- Alpha interferons are a family of closely related proteins.
- Alpha interferon-2 is a 188 amino acid protein, including a 23 amino acid N-terminal signal peptide. (Uniprot Accession No. P01563).
- Alpha interferon-2 is an approved therapeutic for the treatment of various cancers, and is marketed as Roferon-A® (Roche); and Intron-A® (Schering-Plough).
- An exemplary amino acid sequence of human alpha interferon-2 is:
- Beta interferon is a 187 amino acid protein, including a 21 N-terminal amino acid signal peptide. (Uniprot Accession No. P01574). Beta interferon is an approved therapeutic for the treatment of multiple sclerosis, and is marketed as Avonex® (Biogen Idec, Cambridge, Mass.); Betaseron® (Berlex) and Rebif® (Ares-Serono). See also, Houghton et al., Nucleic Acids Res., 8:2885-94 (1980). An exemplary amino acid sequence of human beta interferon is:
- Gamma interferon is a 166 amino acid protein, including a 23 amino acid N-terminal signal peptide, and a 5 amino acid propeptide [residues 162-166]. (Uniprot Accession No. P01579). Gamma interferon is an approved therapeutic for the treatment of serious infections, such as those associated with chronic granulomatous disease, and is marketed as Actimmune® (Genentech). See also, Rinderknecht et al., J. Biol. Chem., 259:6790-97 (1984). An exemplary amino acid sequence of human gamma interferon is:
- Advantages of using a VSA in association with an interferon include, e.g., extending the PK of the interferon.
- the extended PK can have advantages; for example, the interferon can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the interferon can be achieved.
- the therapeutic agent is an antagonist of cytokine signaling, e.g., an antagonist of interleukin or interferon signaling.
- the therapeutic agent is an IL-1 receptor antagonist (IL-1ra) such as Kineret® (Amgen) or a variant thereof (see, e.g., U.S. Pat. No. 6,599,873).
- IL-1ra IL-1 receptor antagonist
- Human IL-1Ra is a 177 amino acid protein, including a 25 amino acid N-terminal signal peptide (Uniprot Accession No. P018510).
- IL1-Ra is an approved therapeutic for rheumatoid arthritis.
- An exemplary IL-1 receptor antagonist (IL-1ra) includes the following human amino acid sequence:
- the antagonist is a variant cytokine can be a cytokine with altered function, e.g., a dominant negative cytokine.
- exemplary variant cytokines include IL-17 molecules described in WO2011/044563 and IL-23 molecules described in WO2011/011797.
- Advantages of using a VSA in association with a cytokine antagonist include, e.g., extending the PK of the cytokine antagonist.
- the extended PK can have advantages; for example, the cytokine antagonist can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the cytokine antagonist can be achieved.
- the therapeutic agent is a urate oxidase, also known as uricase, or a biologically active variant or fragment thereof.
- a urate oxidase sequence is the sequence from Aspergillus flavus :
- Urate oxidase catalyzes the oxidation or uric acid to 5-hydroxyisourate, leading to increased solubility and renal excretion, which can prevent symptoms of gout.
- Urate oxidase is an approved therapeutic for the treatment of hyperuricaemia, and is marketed as Rasburicase® (recombinant uricase from aspergillus flavus produced in saccharomyces cerevisiae ; Sanofi-Aventis) or Krystexxa® (recombinant pegylated chimeric uricase, sequence from pig/baboon, produced in saccharomyces cerevisiae , Sagent Pharmaceuticals, Inc.).
- Rasburicase® recombinant uricase from aspergillus flavus produced in saccharomyces cerevisiae ; Sanofi-Aventis
- Krystexxa® recombinant pegylated chimeric uricase, sequence from pig/baboon,
- VSA can serve to prevent or impede the native immune system from readily accessing the biologically active uricase moiety, and thereby can reduce or prevent the formation of antibodies to the biologically active uricase moiety after administration.
- Advantages of using a VSA in association with a urate oxidase include, e.g., extending the PK of the urate oxidase.
- the extended PK can have advantages; for example, the urate oxidase can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the urate oxidase can be achieved.
- CNP C-Natriuretic Peptide
- the therapeutic agent is a CNP (e.g., human CNP) or a biologically active variant or fragment thereof.
- Human CNP is a 126 amino acid protein, including a 23 amino acid N-terminal signal peptide; a 50 amino acid propeptide (amino acids 24-73); and a 53 amino acid CNP-53 peptide (amino acids 74-126).
- the 53 amino acid CNP-53 peptide may be further processed to a 29 amino acid CNP-29 peptide (amino acids 98-126) or a 22 amino acid CNP-22 peptide (amino acids 105-126) (Uniprot Accession No. P23582).
- An exemplary amino acid sequence encoding human CNP is:
- CNP has been implicated in a number of physiological processes, including vasorelaxant with powerful venodilator effects, exhibiting the ability to reduce mean arterial pressure, atrial pressure and cardiac output in mammals; dose-dependent relaxant effects on bronchial smooth muscle and pulmonary arterial relaxation; and can also have involvement in neurotransmission. See, Barr et al., Peptides 17:1243-51 (1996).
- Advantages of using a VSA in association with a CNP include, e.g., extending the PK of the CNP.
- the extended PK can have advantages; for example, the CNP can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the CNP can be achieved.
- nucleic acid constructs encoding a protein that includes a serum albumin or a domain thereof.
- the nucleic acid sequences can be any sequences that code for the VSA of interest.
- a nucleic acid sequence can be based on a known sequence that enclodes a corresponding native (e.g., wild type) serum albumin.
- a sequence that encodes a wild type albumin can be that corresponding to UniProt DB Accession No. P02768, e.g., ENI database sequence V00494.1 (www.ebi.ac.uk/ena/data/viewN00494).
- the coding sequence can include, e.g., a sequence encoding a protein described herein, a variant of such sequence, or a sequence that hybridizes to such sequences.
- An exemplary coding sequence for mammalian expression can further include an intron.
- Coding sequences can be obtained, e.g., by a variety of methods including direct cloning, PCR, and the construction of synthetic genes. Various methods are available to construct useful synthetic genes, see, e.g., the GeneArt® GeneOptimizer® from Life Technologies, Inc. (Carlsbad, Calif.), Sandhu et. al. (2008) In Silico Biology 8: 0016; Gao et al. (2004) Biotechnol Prog, 20: 443-8; Cai et al. (2010) J Bioinformatics Sequence Analysis 2: 25-29; and Graf et al (2000), J Virol 74: 10822-10826.
- the coding sequence generally employs one or more codons according to the codon tables for eukaryotic or prokaryotic expression.
- a coding sequence can be generated with specific codons (e.g., preferred codons) and/or one or more degenerate codons.
- specific codons e.g., preferred codons
- degenerate codons A possible set of degenerate codons is set forth in the table below.
- the degenerate codon can be representative of all possible codons encoding each amino acid, but may not always be unambiguous.
- the degenerate codon for serine can, in some circumstances, encode arginine (AGR), and the degenerate codon for arginine (MGN) can, in some circumstances, encode serine (AGY).
- WSN can, in some circumstances, encode arginine
- MGN can, in some circumstances, encode serine
- some polynucleotides encompassed by the degenerate sequence may encode variant amino acid sequences, but one of ordinary skill in the art can easily identify such variant sequences by reference to the amino acid sequences disclosed herein. Variant sequences can be readily tested for functionality as described herein.
- the coding sequence includes one or more preferred codons for the cell in which it is to be expressed.
- preferred codons are those that are translated most efficiently and can include the codons that are most frequently used by cells of the species in question. Each species can exhibit its own codon preferences. See, e.g. Gustafsson et al. (2004) Trends in Biotechnol. 22:346-353; Grantham et al. (1980) Nuc. Acids Res. 8:1893 912; Haas et al. (1996) Curr. Biol. 6:315 24; Wain-Hobson et al.
- Thr amino acid threonine
- ACA ACA
- ACC is the most commonly used Thr codon
- Thr codons may be preferred in other species.
- Preferred codons for a particular species can be introduced into coding sequences by a variety of methods, including direct cloning, PCR mutagenesis, and the construction of synthetic genes.
- codon sequences can increase translational efficiency.
- at least 10, 20, 30, 50, 60, 70, or 80% of the codons in a coding sequence are preferred codons.
- Sequences containing preferred codons can be constructed, and tested for expression in various species.
- a protein described herein such as a protein containing a serum albumin domain described herein, can be expressed in bacterial, yeast, plant, insect, or mammalian cells.
- Exemplary mammalian host cells for recombinant expression include Chinese Hamster Ovary (CHO cells) (including dhfr-CHO cells, described in Urlaub and Chasin (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220, used with a DHFR selectable marker, e.g., as described in Kaufman and Sharp (1982) Mol. Biol. 159:601-621), lymphocytic cell lines, e.g., NS0 myeloma cells and SP2 cells, COS cells, K562, and a cell from a transgenic animal, e.g., a transgenic mammal.
- the cell can be a mammary epithelial cell.
- Coding nucleic acid sequences can be maintained in recombinant expression vectors that include additional nucleic acid sequences, such as a sequence that regulate replications of the vector in host cells (e.g., origins of replication) and a selectable marker gene.
- the selectable marker gene facilitates selection of host cells into which the vector has been introduced.
- Exemplary selectable marker genes appropriate for mammalian cells include the dihydrofolate reductase (DHFR) gene (for use in dhfr host cells with methotrexate selection/amplification) and the neo gene (for G418 selection).
- DHFR dihydrofolate reductase
- the coding nucleic acid sequences can be operatively linked to transcriptional control sequences (e.g., enhancer/promoter regulatory elements) to drive high levels of transcription of the genes.
- transcriptional control sequences include the metallothionein gene promoter, promoters and enhancers derived from eukaryotic viruses, such as SV40, CMV, adenovirus and the like. Specific examples include sequences including a CMV enhancer/AdMLP promoter regulatory element or an SV40 enhancer/AdMLP promoter regulatory element.
- An exemplary recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection/amplification.
- the selected transformant host cells are cultured to allow for expression of the protein.
- An adenovirus system can also be used for protein production.
- the cells By culturing adenovirus-infected non-293 cells under conditions where the cells are not rapidly dividing, the cells can produce proteins for extended periods of time. For instance, BHK cells are grown to confluence in cell factories, and exposed to the adenoviral vector encoding the secreted protein of interest. The cells are then grown under serum-free conditions, which allows infected cells to survive for several weeks without significant cell division.
- adenovirus vector-infected 293 cells can be grown as adherent cells or in suspension culture at relatively high cell density to produce significant amounts of protein (See Garnier et al., (1994) Cytotechnol.
- the expressed, secreted heterologous protein can be repeatedly isolated from the cell culture supernatant, lysate, or membrane fractions depending on the disposition of the expressed protein in the cell. Within the infected 293 cell production protocol, non-secreted proteins can also be effectively obtained.
- Insect cells can be infected with recombinant baculovirus, commonly derived from Autographa californica nuclear polyhedrosis virus (AcNPV) according to methods known in the art.
- Recombinant baculovirus can be produced through the use of a transposon-based system described by Luckow et al. (J. Virol. 67:4566-4579, 1993). This system, which utilizes transfer vectors, is commercially available in kit form (Bac-to-BacTM kit; Life Technologies, Rockville, Md.).
- An exemplary transfer vector (e.g., pFastBac1TM Life Technologies) contains a Tn7 transposon to transfer the DNA encoding the protein of interest into a baculovirus genome maintained in E. coli as a bacmid. See, Condreay et al., (2007) Current Drug Targets 8:1126-1131.
- transfer vectors can include an in-frame fusion with DNA encoding a polypeptide extension or affinity tag as disclosed above. Using techniques known in the art, a transfer vector containing nucleic acid sequence encoding a variant serum albumin fusion is transformed into E.
- coli host cells and the cells are screened for bacmids which contain an interrupted lacZ gene indicative of recombinant baculovirus.
- the bacmid DNA containing the recombinant baculovirus genome is isolated, using common techniques, and used to transfect Spodoptera frugiperda cells, such as Sf9 cells.
- Recombinant virus that expresses a protein containing a serum albumin domain is subsequently produced.
- Recombinant viral stocks are made by methods commonly used the art.
- the recombinant virus is used to infect host cells, typically a cell line derived from the fall armyworm, Spodoptera frugiperda (e.g., Sf9 or Sf21 cells) or Trichoplusia ni (e.g., High FiveTM cells; Invitrogen, Carlsbad, Calif.). See, for example, U.S. Pat. No. 5,300,435. Serum-free media are used to grow and maintain the cells. Suitable media formulations are known in the art and can be obtained from commercial suppliers.
- the cells are grown up from an inoculation density of approximately 2 ⁇ 5 ⁇ 10 5 cells to a density of 1 ⁇ 2 ⁇ 10 6 cells, at which time a recombinant viral stock is added at a multiplicity of infection (MOI) of 0.1 to 10, more typically near 3.
- MOI multiplicity of infection
- Agrobacterium rhizogenes can be used as a vector for expressing genes in plant cells. See e.g., O'Neill et al. (2008) Biotechnol. Prog. 24:372-376.
- Fungal cells including yeast cells, can also be used within the present invention.
- Yeast species of particular interest in this regard include Saccharomyces cerevisiae, Hansenula polymorpha, Kluyveromyces lactis, Pichia pastoris , and Pichia methanotica .
- Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g., leucine).
- a particular nutrient e.g., leucine
- Production of recombinant proteins in Pichia methanolica is described, e.g., in U.S. Pat. No. 5,716,808, U.S. Pat. No. 5,736,383, U.S. Pat. No. 5,854,039, and U.S. Pat. No. 5,888,768.
- the binding protein is recovered from the culture medium and can be purified.
- Various methods of protein purification can be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzymology, 182 (1990); and Scopes, Protein Purification: Principles and Practice , Springer-Verlag, New York (2010) (ISBN: 1441928332).
- Purified variant serum albumin fusion proteins can be concentrated using standard protein concentration techniques.
- Exemplary of purification procedures include: ion exchange chromatography, size exclusion chromatography, and affinity chromatography as appropriate.
- variant serum albumin fusion proteins can be purified with a HSA affinity matrix.
- a variant serum albumin fusion protein is typically at least 10, 20, 50, 70, 80, 90, 95, 98, 99, or 99.99% pure and typically free of other proteins including undesired human proteins and proteins of the cell from which it is produced. It can be the only protein in the composition or the only active protein in the composition or one of a selected set of purified proteins.
- Purified preparations of a variant serum albumin fusion protein described herein can include at least 50, 100, 200, or 500 micrograms, or at least 5, 50, 100, 200, or 500 milligrams, or at least 1, 2, or 3 grams of the binding protein. Accordingly, also featured herein are such purified and isolated forms of the binding proteins described herein.
- isolated refers to material that is removed from its original environment (e.g., the cells or materials from which the binding protein is produced).
- a VSA is associated with an agent (e.g., a diagnostic or therapeutic agent), e.g., for the purpose of improving a functional property (e.g., extending the PK) of the agent.
- the VSA is physically attached to the agent.
- the VSA can be directly attached to the agent or it can be attached to the agent via a linker.
- a heterologous protein that comprises a VSA and an additional agent is made using recombinant DNA techniques.
- the VSA is produced (e.g., using recombinant DNA techniques) and subsequently linked to the agent, e.g., by chemical means.
- linkers can be used to join a polypeptide component of an agent to domain III or a variant serum albumin.
- the linker can be a molecule or group of molecules (such as a monomer or polymer) that connects two molecules and optionally to place the two molecules in a particular configuration.
- Exemplary linkers include polypeptide linkages between N- and C-termini of proteins or protein domains, linkage via disulfide bonds, and linkage via chemical cross-linking reagents.
- the linker includes one or more peptide bonds, e.g., generated by recombinant techniques or peptide synthesis.
- the linker can contain one or more amino acid residues that provide flexibility.
- the linker peptide predominantly includes the following amino acid residues: Gly, Ser, Ala, and/or Thr.
- the linker peptide should have a length that is adequate to link two molecules in such a way that they assume the correct conformation relative to one another so that they retain the desired activity. Suitable lengths for this purpose include at least one and not more than 30 amino acid residues.
- the linker is from about 1 to 30 amino acids in length.
- a linker can also be, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 amino acids in length.
- Exemplary linkers include glycine-serine polymers (including, for example, (GS)n, (GSGGS)n, (SEQ ID NO: 23), (GGGGS)n (SEQ ID NO: 24) and (GGGS)n (SEQ ID NO: 25), where n is an integer of at least one, e.g., one, two, three, or four), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers.
- Glycine-serine polymers can serve as a neutral tether between components.
- serine is hydrophilic and therefore able to solubilize what could be a globular glycine chain.
- linkers can also be identified from three-dimensional structures in structure databases for natural linkers that bridge the gap between two polypeptide chains.
- the linker is from a human protein and/or is not immunogenic in a human.
- linkers can be chosen such that they have low immunogenicity or are thought to have low immunogenicity.
- a linker can be chosen that exists naturally in a human.
- the linker has the sequence of the hinge region of an antibody, that is the sequence that links the antibody Fab and Fc regions; alternatively the linker has a sequence that comprises part of the hinge region, or a sequence that is substantially similar to the hinge region of an antibody.
- Another way of obtaining a suitable linker is by optimizing a simple linker, e.g., (Gly4Ser)n (SEQ ID NO: 24), through random mutagenesis.
- additional linker polypeptides can be created to select amino acids that more optimally interact with the domains being linked.
- Other types of linkers include artificial polypeptide linkers and inteins.
- disulfide bonds are designed to link the two molecules.
- peptide linkers described in U.S. Pat. No. 5,073,627, the disclosure of which is hereby incorporated by reference.
- the diagnostic or therapeutic protein itself can be a linker by fusing tandem copies of the peptide to a variant serum albumin polypeptide.
- charged residues including arginine, lysine, aspartic acid, or glutamic acid can be incorporated into the linker sequence in order to form a charged linker.
- linkers are formed by bonds from chemical cross-linking agents.
- a variety of bifunctional protein coupling agents can be used, including but not limited to N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate, iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluor
- SPDP
- Chemical linkers can enable chelation of an isotope.
- C 14 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid is an exemplary chelating agent for conjugation of radionucleotide to the antibody (see PCT WO 94/11026).
- the linker can be cleavable, facilitating release of a payload, e.g., in the cell or a particular milieu
- a payload e.g., in the cell or a particular milieu
- an acid-labile linker, peptidase-sensitive linker, dimethyl linker or disulfide-containing linker (Chari et al., Cancer Research 52:127-131 (1992)) can be used.
- the linker includes a non-proteinaceous polymer, e.g., polyethylene glycol (PEG), polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol and polypropylene glycol.
- the variant serum albumin fusion of the present invention is conjugated or operably linked to another therapeutic compound, referred to herein as a conjugate.
- the conjugate can be a cytotoxic agent, a chemotherapeutic agent, a cytokine, an anti-angiogenic agent, a tyrosine kinase inhibitor, a toxin, a radioisotope, or other therapeutically active agent.
- Chemotherapeutic agents, cytokines, anti-angiogenic agents, tyrosine kinase inhibitors, and other therapeutic agents have been described above, and all of these aforementioned therapeutic agents can find use as variant serum albumin fusion conjugates.
- the variant serum albumin fusion is conjugated or operably linked to a toxin, including but not limited to small molecule toxins and enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof.
- Small molecule toxins include but are not limited to calicheamicin, maytansine (U.S. Pat. No. 5,208,020), trichothene, and CC1065.
- the variant serum albumin fusion is conjugated to one or more maytansine molecules (e.g. about 1 to about 10 maytansine molecules per antibody molecule).
- Maytansine can, for example, be converted to May-SS-Me which can be reduced to May-SH3 and reacted with a variant serum albumin fusion (Chari et al., 1992, Cancer Research 52: 127-131) to generate a maytansinoid-antibody or maytansinoid-Fc fusion conjugate.
- Another conjugate of interest comprises a variant serum albumin fusion conjugated to one or more calicheamicin molecules.
- the calicheamicin family of antibiotics are capable of producing double-stranded DNA breaks at sub-picomolar concentrations.
- Structural analogues of calicheamicin that can be used include but are not limited to ⁇ 1 1 , ⁇ 2 1 , ⁇ alpha 3 , N-acetyl- ⁇ 1 1 , PSAG, and ⁇ 1 1 , (Hinman et al., 1993, Cancer Research 53:3336-3342; Lode et al., 1998, Cancer Research 58:2925-2928) (U.S. Pat. No. 5,714,586; U.S. Pat. No. 5,712,374; U.S. Pat. No. 5,264,586; U.S. Pat. No. 5,773,001).
- Dolastatin 10 analogs such as auristatin E (AE) and monomethylauristatin E (MMAE) can find use as conjugates for the variant serum albumin fusions of the present invention (Doronina et al., 2003, Nat Biotechnol 21:778-84; Francisco et al., 2003 Blood 102:1458-65).
- AE auristatin E
- MMAE monomethylauristatin E
- Useful enzymatically active toxins include but are not limited to diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa ), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes.
- the present invention further contemplates a conjugate or fusion formed between a variant serum albumin fusion of the present invention and a compound with nucleolytic activity, for example a ribonuclease or DNA endonuclease such as a deoxyribonuclease (DNase).
- a compound with nucleolytic activity for example a ribonuclease or DNA endonuclease such as a deoxyribonuclease (DNase).
- DNase deoxyribonuclease
- a variant serum albumin fusion of the present invention can be conjugated or operably linked to a radioisotope to form a radioconjugate.
- a radioactive isotopes are available for the production of radioconjugate variant serum albumin fusions. Examples include, but are not limited to, At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 and radioactive isotopes of Lu.
- Binding of a serum albumin or a domain thereof to FcRn can be evaluated in vitro, e.g., by surface plasmon resonance, (see, e.g., Example 2), ELISA (see, e.g., Example 4) or other binding assay known in the art.
- FcRn can be produced as a single chain molecule, e.g., in CHO cells.
- An exemplary method for producing single chain FcRn is described in Feng et al., Protein Expression and Purification, 79:66-71 (2011).
- the half-life of a protein that includes serum albumin or a domain thereof in vivo can be evaluated in a mammal, e.g., a murine model that includes a human FcRn. See e.g., Example 3.
- the protein that is evaluated can be a protein that includes serum albumin or a domain thereof and a therapeutic agent.
- an agent e.g., a therapeutic agent
- methods known in the art for testing the activity of the agent can be used. The following description provides examples of such methods.
- assays that can be used to test the activity of a FVII entity are known in the art.
- the following exemplary coagulation assays are adapted from Wildgoose et al., Blood, 80:25-28 (1992). All plasma factor VIIa levels are measured in a one-stage clotting assay using an ACL300R automated coagulation instrument which can be purchased from Instrumentation Laboratories (Ascoli Piceno, Italy). Test samples are diluted fivefold in 0.1 mol/L NaCl10.05 mol/L Tris-HCl/0.1% BSA pH 7.4 (TBSIBSA) and mixed with an equal volume of hereditary factor VII deficient plasma to yield a total volume of 100 pL.
- TBSA Tris-HCl/0.1% BSA pH 7.4
- Coagulation is then initiated by the addition of a 100-kL aliquot of 10 nmol/L TF1.218 diluted in 12.5 mmol/L CaCl 2 /0.1 mol/L NaCl/0.05 mol/L Tris/1% BSA pH 7.4. Coagulation times are subsequently converted to factor VIIa concentration (nanograms per milliliter) by comparison to a standard curve constructed with varying concentrations (0.05 to 50 ng/mL) of purified recombinant factor VIIa diluted in TBS/BSA.
- Venipunctures are performed atraumatically and blood samples drawn into citrated vacutainers.
- the citrated samples are centrifuged for 15 minutes at 1,200 ⁇ g after which time the plasma is removed with a plastic pipette and stored at ⁇ 80° C.
- Normal plasma samples are collected from 10 fasting and 10 nonfasting individuals who have a negative history for bleeding as well as thrombosis and are not taking any medications at the time of sample collection. Samples are obtained from 13 severe hemophilia A and seven hemophilia B subjects ( ⁇ 1% FV1II:C and ⁇ 1% FIXC). Subjects are excluded from the study if they have received factor concentrates, cryoprecipitate, and/or antifibrinolytics within the previous 48 hours.
- Coagulation factor VII is assessed in plasma samples drawn before ingestion of the test meal and 3, 6, and 12 hours thereafter.
- Factor VIIc is determined as described in van Deijk et al., Haemostasis, 13:192-97 (1983) in an LODE coagulometer (Groningen, the Netherlands). Briefly, 100pL of diluted plasma sample, 100/xh of factor Vll-deficient plasma (Helena Laboratories, Beaumont, Tex.), and 100 ⁇ L of human brain thromboplastin (prepared according to Owren and Aas, Scand J.
- Factor VII amidolytic activity (VIIam) is determined with a commercially available kit (Coa-Set FVII; Chromogenix, M61ndal, Sweden).
- Factor VII antigen (VII:Ag) concentration is determined with an enzyme immunoassay kit (Novoclone Factor VII EIA kit, Novo Nordic A/S, Bagsvaerd, Denmark). Results are expressed in units per milliliter, one unit being the amount or activity of factor VII present in 1 mL of a standard pooled plasma. Ratios of VIIa:B to VIIc and of VIIa:B to VII:Ag are also calculated for evaluation of the activity state of factor VII in plasma.
- Control experiments are performed to rule out the possibility of a direct effect of high plasma concentrations of TG-rich lipoproteins on the factor VII levels obtained in the different assays.
- An Sf 20 to 400 lipoprotein fraction is isolated from blood that had been drawn from a healthy control subject 3 hours after intake of a fat load. Addition of this lipoprotein fraction to control plasma to a final plasma level 500% of normal does not influence factor VII measurements.
- clotting assays that can be adapted for use to assess the activity of a FVII in association with a VSA are described in the following publications: Broze and Majerus, J. Biol. Chem. 255:1242-47 (1980); Morrissey et al., Blood, 81:734-44 (1993); Herzog et al., Nature Medicine, 5:56-63 (1999); and Sorensen and Ingerslav, J. Thrombosis and Haemostasis, 2:102-110 (2004).
- serum iron levels can be used as an indicator of iron overload.
- Tests include the serum ferritin test.
- a subject can be considered to be suffering from iron overload if their serum iron levels are in excess of about 350 ⁇ g/dL (mild iron toxicity); generally in excess of about 500 ⁇ g/dL (serious iron toxicity).
- a subject is considered to be at risk of iron overload if their serum iron levels are high normal or above normal ranges. Normal iron range is considered to be from about 40 to about 220 ⁇ g/dL; for example, from about 50 to about 160 ⁇ g/dL for adult males.
- Normal iron ranges for adult females are approximately 5 to 10 percent lower than that for adult males. ‘High normal’ iron concentration is considered to be in the upper quarter (25%) of the normal range; generally in the upper tenth (10%) of the normal range. See, Jacobs & DeMott, Laboratory Test Handbook, 5 th ed., (LexiComp Inc, Hudson, Ohio)(2001) at p. 203-205).
- ‘normal ranges’ of iron and iron binding capacity can vary depending upon the specific laboratory and test.
- Other parameters that can be used to evaluate a patient for iron overload and/or risk of overload include: measurement of hepcidin levels (see U.S. Pat. No. 7,998,691); genetic testing for the presence of mutations in one or more genes related to hemochromatosis, such as juvenile hemochromatosis (HFE2A and HFE2B genes) (see U.S. Pat. No. 8,080,651)
- BRIN-BD11 cells are cultured in RPMI-1640 tissue culture medium containing 10% (v/v) foetal calf serum, 1% (v/v) antibiotics (100 U/ml penicillin, 0.1 mg/ml streptomycin), and 11.1 mM glucose.
- BRIN-BD11 cells are produced by electrofusion of a New England Deaconess Hospital (NEDH) rat pancreatic ⁇ -cell with RINm5F cell to produce and immortal, glucose sensitive cell line which is described in detail elsewhere. McClenaghan et al., Diabetes (1996) 45:1132-40. All cells are maintained in sterile tissue culture flasks (Corning Glass Works, Sunderland, UK) at 37° C. in an atmosphere of 5% CO 2 and 95% air using a LEEC incubator (Laboratory Technical Engineering, Nottingham, UK). [Green et al., Id.]
- BRIN-BD11 cells are seeded into 24-well plates (3 ⁇ 10 5 /well) and cultured for 48 h before being pre-incubated in media supplemented with tritiated adenine (2 mC i ) for 16 h.
- the cells are washed twice with cold Hanks' buffered saline (HBS) and test solution (400 ⁇ l; 37° C.) is added.
- HBS Hanks' buffered saline
- test solution 400 ⁇ l; 37° C.
- the cells are then exposed to varying concentrations (10 ⁇ 10 -10 ⁇ 5 M) of GLP-1 glycopeptides in HBS buffer, in the presence of 1 mM IBMX and 5.6 mM glucose (20 min; 37° C.).
- BRIN-BD11 cells are seeded into 24-multiwell plates at a density of 1 ⁇ 10 5 /well, and allowed to attach during overnight culture. Acute studies of insulin release are preceded by a 40 minute pre-incubation at 37° C. in 1.0 ml Krebs-Ringer bicarbonate buffer (115 mM NaCl, 4.7 mM KCl, 1.28 mM CaCl 2 .2H 2 O, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 .7H 2 O, 10 mM NaHCO 3 , and 5 g/L bovine serum albumin, pH 7.4) supplemented with 1.1 mM glucose. Test incubations are performed at 37° C.
- the in vivo biological activity of variant serum albumin/GLP-1 fusion proteins can be assessed in 12-16 week old obese diabetic (ob/ob) mice.
- the animals are housed individually in an air-conditioned room at 22 ⁇ 2° C. with a 12 hour light:12 hour dark cycle. Animals are allowed drinking water ad libitum and continuous access to standard rodent maintenance diet (Trouw Nutrition, Cheshire, UK). Mice are fasted for 18 hours and intraperitoneally administered 8 ml/kg body weight with saline (9 g/L NaCl), glucose alone (18 mM/kg body weight), or in combination with GLP-1 or a variant serum albumin/GLP-1 fusion protein (25 nM/kg body weight).
- Plasma glucose levels are determined using an Analox glucose analyser (Hammersmith, London, UK), which employs the glucose oxidase method. Insulin levels are assayed by dextran-coated charcoal radioimmunoassay. Incremental areas under plasma glucose and insulin curves (AUC) are calculated using GraphPad PRISM version 3.0 (Graphpad Software, San Diego, Calif., USA), which employs the trapezoidal rule. Results are expressed as means ⁇ SEM and data are compared as appropriate using Student's t test, repeated measures ANOVA or one-way ANOVA, followed by the Student-Newman-Keuls post hoc test. Groups of data are considered significantly different if P ⁇ 0.05.
- Binding affinity is assessed by measuring the inhibition of radiolabeled GLP-1 binding to human GLP-1 receptor-expressing chinese hamster ovary (CHO) cell membrane.
- Cell membrane fractions (5 ⁇ g) are incubated with 62 pM [125I]GLP-1 and variant serum albumin/GLP-1 fusion protein (final conc. 10-11 to 10-6 M) in 25 mM HEPES (pH 7.4) containing 5 mM MgCl, 1 mM CaCl 2 , 0.25 mg/mL bacitracin, and 0.1% bovine serum albumin (BSA) at room temperature for 2 hours (100 ⁇ L).
- BSA bovine serum albumin
- Membranes are filtered onto a 96-well GF/C plate (PerkinElmer, Inc.) that had been presoaked in 1% polyethylenimine containing 0.5% BSA, and then washed with 25 mM HEPES buffer containing 0.5% BSA (pH 7.4). Radioactivity associated with the lysates is determined using a gamma counter. Nonspecific binding is determined by the amount of binding in the presence of 1 ⁇ M unlabeled GLP-1. Dose-response curves are plotted for the individual compounds. IC50 values are calculated using XLfit software (IDBS Inc.).
- human GLP-1 receptor expressing CHO cells are passaged into multiwell plates (4000 cells/well) and cultured for an additional 48 h.
- the cells are washed with assay buffer (Hanks balanced salt solution containing 20 mM HEPES, 0.1% BSA, pH 7.4) and then exposed to variant serum albumin/GLP-1 fusion proteins (final conc. 10-12 to 10-6 M) in assay buffer containing 0.33 mM isobutylmethylxanthine and 0.67 mM RO20-1724 at room temperature for 1 h.
- the cells are lysed with 1% Triton X-100, and the cAMP formed is measured using a cAMP femtomolar kit (Cis Bio international). Dose-response curves are plotted for the individual compounds. EC50 values are calculated using XLfit software. [Ueda et al., J. ACS, 2009 131:6237-45]
- GLP-1 or variant serum albumin/GLP-1 fusion protein (20-500 ⁇ M) is incubated at 37° C. in 100 mM HEPES buffer containing 0.05% Tween80 and 1 mM EDTA-2Na (pH 7.5) with 0.33 ⁇ g/mL, 0.66 ⁇ g/mL (19), or 1.32 ⁇ g/mL recombinant human DPP-IV (60 ⁇ L). At 5 or 10 min intervals, 7 ⁇ L is removed from the reaction mixture, and the reaction is terminated by the addition of 28 ⁇ L of 8 M GuHCl solution.
- the reaction products are subjected to RP-HPLC on a Develosil RPAQUEOUS-AR-3 2.0°—100 mm at 30° C., and the C-terminal degradation product is quantified by using UV absorption at 210 nm.
- the initial rate of the degradation reaction is determined from the slope of the linear part obtained by plotting product concentration versus time. The resulting initial rates are plotted versus peptide concentration, and kinetic parameters (KM and KM/kcat) are determined using XLfit software based on the Michaelis-Menten kinetic equation. [Ueda et al., Id.]
- the 125 ⁇ M GLP-1 or variant serum albumin/GLP-1 fusion protein is incubated at 37° C. in 50 mM HEPES buffer containing 50 mM NaCl, and 0.05% Tween 80 with 4 ⁇ g/mL recombinant human NEP 24.11 (pH 7.4, 84 ⁇ L). After 0.5, 1, 2, 3.5, and 5 h, 8 ⁇ L is removed from the reaction mixture, and the reaction is terminated by addition of 32 ⁇ L of 8 M GuHCl solution.
- reaction products are subjected to RP-HPLC on a Develosil ODSHG-54.6°-150 mm at 30° C., and the area of intact variant serum albumin/GLP-1 fusion protein is measured using UV absorption at 210 nm.
- mice Male BKS.Cg-+Leprdb/+Leprdb mice (13-15 weeks of age) are allowed ad libitum access to food and water until the start of the experiment. At t) ⁇ 2 h, access to food is restricted, and the tip of the tail is cut. At t) 0 min, a 1 ⁇ L blood sample is collected Immediately thereafter, each mouse is injected subcutaneously with test sample (100 nmol/kg) or vehicle, and additional blood samples are collected. The vehicle is saline containing 1% BSA. Blood glucose levels are measured with a glucose oxidase biosensor (DIAMETERR; Arkray, Inc.).
- DIAMETERR glucose oxidase biosensor
- Methods for assessing uric acid levels and/or function as well as gout are known in the art. Methods for measurements of uric acid, e.g., in urine can be employed, as disclosed, e.g., in Ballesta-Clayer et al., Analytica Chimica Acta, 702:254-61 (2011) and WO 2000/08207.
- a VSA composition (a composition comprising a VSA or a VSA associated therapeutic agent) is administered in a therapeutically effective amount to a subject to treat a disease or condition, or ameliorate one or more symptoms of a disease or condition.
- Methods for delivering a therapeutic composition are known in the art and can be used to administer a VSA composition e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells that can expressing the VSA compound, receptor-mediated endocytosis (e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432).
- Methods of introduction can be enteral or parenteral, including but not limited to, intradermal, transdermal, intramuscular, intraperitoneal, intravenous, subcutaneous, pulmonary, intranasal, intraocular, epidural, topical, intramuscular, subcutaneous, intravenous, intravascular, and intrapericardial administration and oral routes.
- a VSA composition can also be administered, for example, by infusion or bolus injection, by absorption through epithelial or mucosa (e.g., oral mucosa, rectal, or intestinal mucosa) and can be administered together with other biologically active agents. Administration can be systemic or local.
- Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.
- the disclosure provides a composition comprising the HSA variant or the chimeric polypeptide of the disclosure, and a pharmaceutically acceptable carrier.
- VSA composition is delivered locally to an area in need of treatment (e.g., muscle); this may be achieved, for example, by local infusion, topical application, by injection, by catheter, or by implant (e.g., an implant of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, fibers, or commercial skin substitutes).
- a VSA composition is delivered in a vesicle such as a liposome (see Langer, 1990, Science 249: 1527-1533), a controlled release system, or with a pump (see Langer, 1990, supra), or using polymeric materials can be used (see Howard et al, 1989, J. Neurosurg. 71: 105).
- a vesicle such as a liposome (see Langer, 1990, Science 249: 1527-1533), a controlled release system, or with a pump (see Langer, 1990, supra), or using polymeric materials can be used (see Howard et al, 1989, J. Neurosurg. 71: 105).
- cDNA encoding mature human serum albumin was cloned into a modified version of the pYC2/CT yeast expression vector (Invitrogen) containing a Trp marker, app8 leader peptide (see Rakestraw et al., Biotechnology and Bioengineering, 103:1192-1201 (2009) for leader sequence), and N-terminal His 6 tag (SEQ ID NO: 26) and Factor Xa cleavage site. Point mutations, either alone or in combination, were introduced by Quikchange® mutagenesis (Agilent). The vector was transformed into BJ5 ⁇ S.
- SDCAA+ura plates 2% glucose, 0.67% yeast nitrogen base, 0.5% casamino acids, 0.54% Na 2 PO 4 , 0.86% NaH 2 PO 4 .H 2 O, 18.2% sorbitol, 1.5% agar, and 40 mg/L uracil).
- Selected colonies were grown in 5 mL liquid SDCAA+ura overnight at 30° C. with shaking at 250 RPM. The 5 mL overnight culture was diluted into 50 mL SDCAA+ura in a 250 mL baffled flask and grown at 30° C./250 RPM to an OD600 ⁇ 5.
- YPG media 2% galactose, 2% peptone, 1% yeast extract, 0.54% Na 2 PO 4 , 0.86% NaH 2 PO 4 .H 2 O
- the secreted human serum albumin was purified by affinity chromatography using either Ni-NTA resin (Invitrogen), CaptureSelect HSA affinity resin (BAC), or Vivapure anti-HSA kit (Sartorius-Stedin).
- Eluted protein was buffer exchanged into PBS by several rounds of concentration and dilution using Amicon Ultra-15 spin concentrators with a 10 kDa cutoff (Millipore). Protein purity was assessed by SDS-PAGE and concentration determined by absorbance at 280.
- DNA encoding human beta-2 microglobulin fused to the extracellular domain of human FcRn heavy chain through a (G 4 S) 3 linker (SEQ ID NO: 27) was synthesized by DNA2.0.
- the scFcRn DNA was cloned into a modified version of the pcDNA3.1(+) vector (Invitrogen) containing an IL-2 leader sequence and C-terminal FLAG tag by standard digestion and ligation.
- Bound protein was eluted with 100 mM glycine-HCl, pH 3.5 and exchanged into PBS, pH 7.4 by several rounds of concentration and dilution using Amicon Ultra-15 spin concentrators with a 10 kDa cutoff (Millipore). Protein purity was assessed by SDS-PAGE and concentration determined by absorbance at 280.
- a library of albumin variants with random mutations in domain III was generated and displayed on the surface of yeast. FACS selections were performed to enrich for variants with improved binding to soluble FcRn at pH 5.6. After three to four rounds of selection, a population was identified with significantly increased binding compared to a wild type human serum albumin (HSA). Twelve clones from the population after sort three and eight clones from the population after sort four were cloned and sequenced. The sequence alignments revealed mutations appearing in multiple clones after sort four: K402E (2/8), V424I (2/8), P447L/S (3/8), E492G (3/8), E505G (5/8) and V547 (6/8).
- the library had enriched to a single clone with the following mutations: V418M, T420A, E505R, V424I, and N429D.
- SPR was used to characterize binding of the selected variants to human FcRn at pH values from 5.5 to 7.5.
- An exemplary apparatus that can be used is a Reichert SR7000C® machine. FLAG-tagged, single-chain human FcRn was immobilized on a 500,000 Da carboxymethyl dextran chip by NHS/EDC chemistry. Unconjungated sites were blocked with 1 M ethanolamine. A reference channel was generated in parallel with no FcRn. HSA variants at concentrations of 1 nM-100 ⁇ M were injected at a flow rate of 50 ⁇ L/min and the difference in signal between the FcRn channel and reference channel was recorded over time to assess association.
- VSAs can be generated that have increased affinity for FcRn at endosomal pH without significantly altering the affinity for FcRn at a neutral pH (e.g., a pH associated with blood).
- PK studies were performed for selected variants in human FcRn mice to determine the effect of FcRn affinity on plasma clearance.
- the mouse strains 4919 and 14565 from Jackson Laboratories are homozygous for mouse FcRn knockout and either hemi- or homozygous for human FcRn knock-in.
- Selected HSA variants were injected intravenously into such mice and bleeds were collected at various time intervals.
- the plasma concentration of the HSA at each time point was assessed using a non-mouse cross-reactive HSA ELISA and plotted to calculate clearance rates and plasma AUC.
- HSA variants were immobilized in a 96 well flat bottom EIA plate (Costar 9018) at 4° C. overnight. Coated wells were then blocked with 200 ⁇ L PBS+2% fish gelatin, pH 7.4 for 2 hours at room temperature. After blocking, wells were washed 3 ⁇ with 200 ⁇ L PBS+0.1% Tween-20 at the appropriate pH (5.5-7.4).
- VSAs including HSA-15, HSA-13, HSA-12, HSA-7, HSA-21, HSA-11, HSA-2, HSA-14, HSA-5, HSA-10, HSA-6, HSA-9, and HSA-18 had improved affinity for FcRn compared with wild type HSA. Additional related information, including the mutations present in the VSAs, is provided in Example 5, infra.
- the data of FIG. 3 demonstrate that the binding of these VSAs to FcRn, as assessed by ELISA, preserved the pH dependence of native albumin (greater binding at pH 5.5 than at pH 7.4).
- the amino acid sequence of Domain 3 of human serum albumin has the following sequence:
- Exemplary human serum albumin variants that were prepared include the sequences in the following table:
- HSA-3 is Full length HSA (sequence corresponding to SEQ ID NO:2) with the indicated mutations (numbering of the mutations is based on SEQ ID NO:2).
- HSA-3 is Domain 3 only of HSA with the sequence corresponding to SEQ ID NO:22.
- domain 3 only versions of HSA-5 and HSA-13 were also made; these versions also demonstrated improved affinity.
- the anti-HSA sandwich ELISA utilized in the mouse PK studies is unable to detect HSA spiked into cynomolgus monkey plasma due to the high homology of human and monkey albumin. Therefore, we developed a novel assay utilizing an epitope tag genetically fused to albumin and an anti-tag capture antibody.
- HSA-wt FLAG-tagged HSA-wt, HSA-5, HSA-7, HSA-11, and HSA-13 were administered into two monkeys each as a 5 mg/kg iv bolus dose.
- a 1 mg/kg dose of HA-tagged HSA-wt was co-dosed into each animal. Bleeds were drawn at 15 minutes, 2 hours, 6 hours, 1 day, 2 days, 5 days, 9 days, 12 days, 16 days, and 21 days, and HSA concentrations were measured by both anti-FLAG and anti-HA ELISAs.
- the anti-HSA and anti-HA ELISA's measured HSA concentrations consistent with each other and with previous measurement of untagged HSA in mice suggesting that the HA tag accurately reflected the concentration of plasma HSA.
- the anti-FLAG ELISA measured a significantly lower concentration of FLAG-HSA compared to the anti-HSA ELISA confirming that the tag was cleaved or obscured in a way that distorted the HSA measurement.
- HSA variant binding to mouse FcRn was measured in an ELISA in which recombinant mouse FcRn (R&D Systems, cat#6775-FC-050) was directly immobilized on a Costar Maxisorp® plate. After blocking for 3 hours with PBS+4% fish gelatin, HSA variants at concentrations of 500 nM to 685 ⁇ M in PBS+0.1% Tween+0.1% fish gelatin, pH 5.5 were added to each well and incubated for 2.5 hours at RT. Bound HSA was detected with a HRP conjugated goat anti-HSA antibody. The rank order of binding affinity was HSA-13>HSA-7>HSA-11>HSA-5>HSA-wt.
- VSAs pharmacokinetics
- HSA-5 and HSA-7 which have minimal pH 7.4 binding (see also FIG. 1 ) have extended PK in the FcRn transgenic mouse, as shown in FIG. 5 .
- mouse albumin has a high affinity for human FcRn so it is reasonable to expect that a murine model under predicts the improvement that would be observed in humans. Therefore, selection of VSAs suitable for use in humans should not be tested solely in a murine model.
- cynomologus monkeys were injected with an iv bolus dose of 1 mg/kg or 5 mg/kg dose of HSA-7 or wild type HSA (HSA-wt). Two monkeys were analyzed per group by assaying plasma HSA concentration over time using an anti-epitope tag ELISA.
- FIG. 6 provides the PK parameters of this experiment, demonstrating that the VSA (HSA-7) has a longer plasma half-life and reduced beta phase clearance in a primate model.
- cDNA encoding mature human IL-2 was PCR amplified with a 5′ primer that introduces 20-40 by of homology with the app8 yeast leader sequence and a 3′ primer that introduces a (G 4 S) 3 linker (SEQ ID NO: 27) followed by 20-40 by of homology with the N-terminus of mature HSA.
- the human IL-2 cDNA was PCR amplified with a 5′ primer that introduces 20-40 by of homology with the C-terminus of HSA followed by a (G 4 S) 3 linker (SEQ ID NO: 27) and a 3′ primer that introduces 20-40 by of homology with the stop codon and downstream sequence of the pYC2/CT vector.
- a Quikchange® mutagenesis reaction (Agilent) was then performed in which a selected HSA variant was used as the template and the IL-2 PCR product was used in place of the primers.
- DpnI treated reactions were transformed into XL-1 Blue E. coli cells (Agilent) and selected on LB+Amp plates.
- DNA encoding a variant of IL-2 such as those described in U.S. Pat. Nos. 7,569,215 and 7,951,360, can be fused to the selected HSA variant.
- Plasmids encoding the desired fusion sequence were transformed into BJ5 ⁇ S. cerevisiae cells using the EZ-yeast kit (Zymo Research) and transformants selected on SDCAA+ura plates. Selected colonies were grown in liquid SDCAA+ura media at 30° C. with shaking at 250 RPM to an OD600-5. Cells were then pelleted at 3000 RPM and resuspended in YPG media to induce albumin expression. After 48 hours in YPG at 20° C./250 RPM, the cells were pelleted at 3000 RPM and the cleared supernatant filter sterilized. The secreted fusion protein was purified by affinity chromatography using CaptureSelect® HSA affinity resin (BAC).
- BAC CaptureSelect® HSA affinity resin
- Both mouse and human IL-2 fused to the N-terminus of HSA-wt or HSA-13 through a (G4S) 2 linker were also cloned into the pLVX-Puro mammalian expression plasmid. Fusion sequences were amplified by PCR using primers that introduced an N-terminal XhoI site and C-terminal MluI site.
- the PCR product and pLVX-Puro plasmid were both double digested with XhoI/MluI in NEBuffer 3+BSA and ligated with the Quick Ligation kit (New England Biolabs) according to manufacturer's instructions. Plasmids were transiently transfected in Hek-293 cells using PEI as a transfection reagent and cultured for 4-7 days at 37° C./8% CO 2 .
- Transient transfections were performed in Hek-293 cells to express HSA, IL-2-GS10-HSA, IL-2-GS25-HSA, hepcidin-GS10-HSA, or factor VII-GS10-HSA. Expressed proteins were evaluated using non-reducing SDS-PAGE. All of the tested proteins were expressed and run on the gel in a manner consistent with their expected molecular weights. Subsequently, products of such transient transfections were purified using an anti-HSA resin. Purified products (murine IL-2-HSA wild type and IL-2-HSA-13) were injected iv into mice at a dose of 0.5 mg/kg.
- VSA fusion i.e., HSA-13 fusion
- HSA-13 fusion extended the PK of IL-2 to a greater degree than did the fusion to wild type HSA (shown in FIG. 7 ).
- the IL2-HSA-13 fusion protein had increased half-life, greater AUC, and reduced clearance.
- VSA as described herein can be used to improve the PK of another agent, e.g., a therapeutic protein, e.g., IL-2.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- The present application claims priority to U.S. Application Ser. No. 61/561,785, filed Nov. 18, 2011; U.S. Application Ser. No. 61/576,491, filed Dec. 16, 2011; and U.S. Application Ser. No. 61/710,476, filed Oct. 5, 2012. The entire content of each of the foregoing applications is hereby incorporated herein by reference.
- The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Nov. 16, 2012, is named D2046703.txt and is 43,129 bytes in size.
- The present invention relates to the area of therapeutic and diagnostic proteins, materials for producing such proteins, and methods for their production and use.
- Serum albumin is an abundant plasma protein that that is essential for maintaining oncotic pressure and is useful in regulating the volume of circulating blood. Serum albumin has therapeutic uses and is indicated, for example, to treat hypovolemia and hypoalbuminemia (e.g., hypoalbuminemia associated with inadequate production, excessive catabolism, hemorrhage, excessive renal excretion, redistribution within the body e.g., due to surgery or inflammatory conditions, burns, adult respiratory distress syndrome, nephrosis), and may be used prior to or during cardiopulmonary bypass surgery or to treat hemolytic disease of the newborn. Serum albumin can also be used in association with other agents.
- There is a need for improved variant sequences of serum albumin. Such variant sequences can be used, e.g., to prepare or provide a protein product (e.g., a therapeutic or diagnostic protein product). In embodiments the protein product has improved properties (e.g., higher recycling fraction via an FcRn mechanism and/or improved pharmacokinetic properties, e.g., increased half-life and/or reduced clearance), e.g., as compared with a protein product that is prepared using a corresponding native (e.g., wild type) serum albumin sequence (e.g., a mammalian serum albumin, e.g., human serum albumin or bovine serum albumin). As used herein, a “corresponding native serum albumin” (e.g., a naturally occurring serum albumin or a wild type serum albumin) refers to a corresponding full length native serum albumin sequence, or fragment thereof, of which the variant serum albumin polypeptide (VSA) is a variant. The disclosure provided herein includes disclosure of proteins that comprise variant serum albumin sequences and methods of using such proteins.
- In some aspects, the disclosure provides a variant serum albumin polypeptide (VSA). In some embodiments, the variant is a variant of a full-length serum albumin polypeptide sequence (e.g., a human serum albumin polypeptide sequence, or a serum albumin polypeptide sequence from another species, e.g., a bovine serum albumin polypeptide sequence). In other embodiments, the variant is a variant of a fragment of a serum albumin polypeptide sequence (e.g., a fragment of the human serum albumin polypeptide sequence, or a fragment of a serum albumin polypeptide sequence from another species, e.g., a fragment of the bovine serum albumin polypeptide sequence). In some embodiments, the fragment comprises a domain III of a serum albumin polypeptide sequence (e.g., domain III of the human serum albumin polypeptide sequence).
- In some aspects, the present disclosure provides an isolated, recombinant protein that comprises a VSA, e.g., a VSA that is or comprises a variant of domain III of a naturally-occurring serum albumin. In some embodiments, the VSA is in a polypeptide that also includes a heterologous sequence, e.g., a heterologous sequence as described herein. For example, a fusion polypeptide can comprise a VSA and a heterologous sequence.
- In some embodiments, the VSA has or comprises a mutation at one or more of the positions corresponding to V418, T420, V424, E505 and V547 of serum albumin.
- In some embodiments, the VSA can bind to an FcRn (e.g., human FcRn) at a pH in the range of 5.5 to 6.0 (e.g., at a pH of 5.5, 5.6, 5.7, 5.8, 5.9, or 6.0). In some embodiments, the VSA binds to an FcRn (e.g., human FcRn) with higher affinity than does a corresponding native serum albumin. In some embodiments, the higher affinity binding occurs at a specified pH (e.g., at a pH of 5.5, 5.6, 5.7, 5.8, 5.9, 6.0) or in a specified pH range, e.g., at a pH in the range of 5.5-6.0 or 6.0-6.5.
- In some embodiments, the ratio of the binding affinity of the VSA, or of the recombinant protein comprising the VSA, at a pH of 5.5 to 6.0 to the binding affinity at a pH of 7.0 to 7.4 is greater than or equal to the ratio for a corresponding native serum albumin (e.g., a corresponding native human serum albumin). In some embodiments, the ratio of the binding affinity of the VSA, or of the recombinant protein comprising the VSA, at a pH of 5.5 to 6.0 to that at a pH of 7.0 to 7.4 is 5; 10; 50; 100; 1000; 10,000; 100,000; or 1 million times that of a corresponding native human albumin.
- In some embodiments, the VSA, or the recombinant protein comprising the VSA, binds to FcRn at a pH in the range of 7.0 to 7.4 with an affinity not greater than a corresponding native human albumin.
- In some embodiments, the disclosure provides an isolated, recombinant protein comprising a VSA that has altered binding properties for an FcRn (e.g., a human FcRn) relative to a corresponding native serum albumin sequence (e.g., the wild-type human serum albumin sequence). The protein can include a heterologous sequence as described herein. In some embodiments, the recombinant protein comprising aVSA binds to FcRn with an affinity that is altered compared to a recombinant protein comprising a wild type albumin (e.g., a wild type human albumin) and the heterologous sequence. In some embodiments, the VSA or recombinant protein comprising the VSA binds to FcRn with a dissociation constant (KD) of less than 50 nM at pH 5.5. In some embodiments, the VSA or recombinant protein has an affinity for FcRn at pH 7.4 that is less than or equal to its affinity for FcRn of a wild type albumin at pH 7.4.
- In some embodiments, the VSA has a KD that is below 100 nM. In some embodiments, the VSA has a KD that is below 75 nM, below 50 nM, below 40 nM, below 30 nM, below 25 nM, below 20 nM, below 15 nM, below 10 nM, below 9 nM, below 8 nM, below 7 nM, below 6 nM, below 5 nM, or below 4 nM. In some embodiments, the protein has a KD that is 3 nM or less.
- In certain embodiments, the VSA comprises a substitution of V418 with another amino acid, for example, with a methionine. In certain embodiments, the VSA comprises a substitution of T420 with another amino acid, for example, an uncharged amino acid, such as alanine. In certain embodiments, the VSA comprises a substitution of V424 with another amino acid, for example, an uncharged amino acid, such as isoleucine. In certain embodiments, the VSA comprises a substitution of E505 with another amino acid, for example, an uncharged amino acid, such as glycine, or a positively charged amino acid, such as lysine or arginine. In certain embodiments, the VSA comprises a substitution of V547 with another amino acid, for example, an uncharged amino acid, such as alanine.
- In some embodiments, the VSA comprises substitutions at two or more (e.g., at two, three, four, or five) of the positions corresponding to V418, T420, V424, E505 and V547. For example, the VSA can comprise two, three, four, or five substitutions selected from V418M, T420A, V424I, E505(R/K/G) and V547A. In a particular embodiment, the VSA comprises the substitutions V418M, T420A and E505R. In another particular embodiment, the VSA comprises the substitutions V418M, T420A, E505G and V547A.
- In some embodiments, the VSA comprises one or more additional substitutions at positions selected from N429, M446, A449, T467, and A552. In some embodiments, the substitutions are selected from N429D, M446V, A449V, T467M, and A552T.
- In some embodiments, a protein provided herein includes a VSA that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, but less than 100% identical to domain III of a naturally occurring serum albumin, e.g., a human serum albumin. In certain embodiments, the protein includes a VSA that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, but less than 100% identical to domain III of human serum albumin.
- In some embodiments, a protein provided herein includes a VSA that differs by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 residues from a corresponding native serum albumin, e.g., a corresponding human serum albumin sequence. In some embodiments, a protein provided herein includes a VSA that differs by at least 1, but no more than 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 residues from a corresponding native serum albumin e.g., a corresponding human serum albumin sequence. In embodiments the differences are in domain III, e.g., in domain III of human serum albumin.
- In some aspects, the disclosure provides an agent in association with a VSA, e.g., a VSA as described herein. In some embodiments, the agent is a therapeutic or diagnostic agent, e.g., an agent as described herein. In some embodiments, the agent is fused to the VSA or to a protein that comprises the VSA, e.g., in the form of a fusion protein. For example, a VSA can be fused to a heterologous sequence using recombinant genetic techniques. A heterologous sequence can comprise, e.g., the agent, a protein that comprises the agent, or a sequence to which the agent is attached or can be attached.
- In some aspects, the disclosure provides an isolated, recombinant protein that comprises a VSA as described herein and a heterologous sequence, e.g., a heterologous sequence as described herein (e.g., the heterologous sequence can be a cytokine, immunoglobulin, cell surface receptor, coagulation protein, or functional fragment of any of these). The protein can also include more than one heterologous sequence.
- In some embodiments, the VSA is a variant of domain III of a naturally-occurring serum albumin. In some embodiments the recombinant protein is a fusion protein.
- In some embodiments, the heterologous sequence comprises a cytokine domain, for example, an amino acid sequence originating or derived from an interleukin-2. In some embodiments, the heterologous sequence comprises an immunoglobulin single-chain variable domain, e.g., an scFv. In some embodiments, the heterologous domain is a scaffold, e.g., an anti-calin, a DARPin, a Surrobody™ Adnectin™, a Domain antibody, Affibody, or fragment of any of the foregoing. In some embodiments, the heterologous sequence comprises a soluble fragment of a cell surface receptor. In some embodiments, the heterologous sequence comprises an enzyme. In still other embodiments, the heterologous sequence comprises a component of a coagulation protein, such as an amino acid sequence originating or derived from coagulation factor VII (FVII) or coagulation factor VIII (FVIII). In some embodiments, the heterologous sequence comprises two or more of the foregoing.
- In certain aspects, the protein comprises a first and a second heterologous sequence. In some embodiments, the first and the second heterologous sequence are identical. In some embodiments, the first and second heterologous sequence are in tandem. In other embodiments, the first heterologous sequence is located N-terminal to the variant sequence and the second heterologous sequence is located C-terminal to the variant sequence.
- In another aspect, the present disclosure provides an isolated recombinant DNA molecule and/or nucleotide sequence that encodes a polypeptide, peptide, protein or recombinant protein disclosed herein. The recombinant DNA molecule and/or nucleotide sequence comprises a variant nucleotide sequence that encodes a VSA. In some embodiments, the VSA includes at least a variant of domain III of a naturally-occurring serum albumin.
- In other aspects, the present disclosure provides a recombinant host cell (e.g., a recombinant CHO cell, or a Saccharomyces cerevisiae cell) that has been transformed with a recombinant DNA molecule or nucleotide sequence that encodes a polypeptide, peptide, protein or recombinant protein as disclosed herein. Unless otherwise noted, the term protein includes polypeptides and peptides.
- In some aspects, the disclosure provides a method of treatment or diagnosis, the method comprising administering to a subject (e.g., a human or non-human animal) a VSA (e.g., a VSA as described herein), or a pharmaceutical composition comprising a VSA, e.g., a VSA as described herein. In some embodiments, the subject is suffering from a disease or condition in which albumin is indicated. In some embodiments the disease or condition is selected from hypovolemia, hypoalbuminemia, a burn, adult respiratory distress syndrome, nephrosis, and hemolytic disease of the newborn.
- In some aspects, the disclosure provides a method of treatment and/or a method of diagnosis, wherein the method comprises administering to a subject an agent (e.g., a therapeutic or diagnostic agent) in association with a VSA (e.g., a VSA as described herein). In some embodiments, the method is a method of treatment that comprises administering to a subject a therapeutic agent in association with a VSA, e.g., a VSA as described herein. In some embodiments, the method is a method of diagnosis that comprises administering to a subject a diagnostic agent in association with a VSA, e.g., a VSA as described herein.
- The agent can be any biologically or pharmaceutically active moiety (e.g., a biologic, such as a peptide or nucleotide sequence or a chemical entity such as a small molecule). Typically, the agent is administered in an effective amount and at an effective frequency, e.g., in an amount and frequency that is effective for the desired therapeutic or diagnostic purpose. In some embodiments, the agent is a known therapeutic or diagnostic agent. In some embodiments, the agent comprises an entire known protein, nucleotide sequence or chemical entity. In some embodiments, the agent comprises a fragment or variant of a known protein, nucleotide sequence or chemical entity. The fragment or variant can have the same or similar activity as does the known protein, nucleotide sequence or chemical entity, or the fragment or variant can have altered activity, e.g., an increased desirable activity or a reduced undesirable activity compared with the known protein, nucleotide sequence or chemical entity.
- In some embodiments, administering the agent in association with the VSA results in an improved function of the agent. In some embodiments, the improved function is an improved pharmacokinetic property (e.g., increased half-life and/or reduced clearance) of the agent. In some embodiments, the improved function is a reduced effective dosage and/or a reduced effective frequency of administration of the agent compared with the agent when it is administered without the association with VSA. In some embodiments, the improved function is a more desirable delivery level of the agent (e.g., a higher, more consistent, and/or less variable level of delivery). An improved function of the agent can be established, e.g., by comparing the function of the agent when it is administered in association with the VSA with the same function of the agent when it is administered without the association with the VSA (e.g., when the agent is administered alone or when it is administered in association with a corresponding native serum albumin sequence).
- In some embodiments in which the agent (e.g., therapeutic or diagnostic agent) is in association with the VSA, the agent is fused to the VSA. In some embodiments, the agent is fused to the VSA via a covalent bond. In some embodiments, the agent is fused to the VSA via a peptide bond. In some embodiments, the agent is fused to the VSA via a non-peptide bond. In some embodiments, the agent is fused to the VSA via a linker, e.g., a linker as described herein. In some embodiments, the agent is fused to the VSA using recombinant genetic methods. In some embodiments, the agent is fused to the VSA using chemical methods.
- In some embodiments in which the agent (e.g., therapeutic or diagnostic agent) is in association with the VSA, the agent is not fused to the VSA. In some embodiments, the agent is not fused to the VSA and is stably associated with the VSA. “Stably associated” means that the VSA and the agent can be or remain physically associated at a pH at which they are intended to function, e.g., at an endosomal pH. Typically, the agent and VSA also can be or remain physically associated at a neutral pH. In embodiments, the agent can be associated with the VSA by any means known in the art. For example, the agent can be conjugated to a moiety that is capable of binding the VSA. In some embodiments, the moiety is an albumin binding protein. In some embodiments the moiety is a fatty acid. In some embodiments, the agent is non-covalently bound to the VSA. In embodiments wherein the agent is not fused to the VSA, the agent can be administered before, after, or concurrently with the VSA. In some embodiments, the agent is administered concurrently with the VSA. In some embodiments, the agent is administered at the same frequency as is the VSA. In some embodiments, the agent is administered more or less frequently than the VSA. An advantage of using a VSA can be that a VSA can retain lipophilic features of an albumin, thereby improving solubility of a molecule (e.g., a therapeutic agent).
- In some aspects, the disclosure provides a method of treating a subject, the method comprising administering to the subject an effective amount of a therapeutic agent in association with a VSA (e.g., a VSA as described herein), such that the dosage and/or frequency of administration at which the agent produces a therapeutic effect is reduced relative to the dosage and/or frequency of administration at which the agent produces a therapeutic effect when it is not in association with the albumin protein. In some embodiments, In some embodiments, the agent comprises a polypeptide component that is fused to the VSA or to a protein comprising the VSA. In some embodiments, the polypeptide component and the VSA or protein that comprises the VSA are separated by a linker sequence. In some embodiments, the polypeptide component and the VSA or protein that comprises the VSA are covalently linked by a non-peptide bond. In some embodiments, the polypeptide component and the VSA or protein that comprises the VSA are non-covalently and stably associated.
- In additional aspects, the present disclosure provides a method of engineering a VSA associated therapeutic agent or a VSA associated diagnostic agent. The method comprises providing a biologically or pharmaceutically active agent (e.g., an agent as described herein) and associating the agent with a VSA as described herein to provide a VSA associated agent; i.e., a VSA associated therapeutic agent or a VSA associated diagnostic agent. “Associating” the agent with the VSA can be done by any means known in the art or any means described herein, e.g., by fusing the agent to the VSA using recombinant genetic and/or chemical means, by conjugating the agent to a moiety that is capable of binding the VSA, or by non-covalent methods.
- In some embodiments, the method further comprises formulating the albumin modified agent, or providing a formulation or pharmaceutical composition, for administration to a subject, such as a human subject. In embodiments including an albumin modified diagnostic agent, the method may further comprise administering the albumin modified diagnostic agent to a subject and detecting the albumin modified diagnostic agent, for example, a method wherein the subject is imaged. In embodiments the formulation is in a storage or delivery device, e.g., a syringe.
- In some aspects, the present disclosure provides a formulation that comprises a biologically or pharmaceutically active agent (e.g., an agent as described herein) in association with VSA.
- Calculations of “homology” or “sequence identity” between two sequences (the terms are used interchangeably herein) can be performed as follows. The sequences are aligned according to the alignments provided herein, or, in the absence of an appropriate alignment, the optimal alignment determined as the best score using the Needleman and Wunsch algorithm as implemented in the Needle algorithm of the EMBOSS package using a Blosum 62 scoring matrix with a gap penalty of 10, and a gap extend penalty of 1. (See Needleman, S. B. and Wunsch, C. D. (1970) J. Mol. Biol. 48: 443-453; Kruskal, J. B. (1983) An overview of sequence comparison In D. Sankoff and J. B. Kruskal, (Eds.), Time Warps, String Edits and Macromolecules: the Theory and Practice of Sequence Comparison, pp. 1-44, Addison Wesley, and tools available from the European Bioinformatics Institute (Cambridge UK), described in Rice, P. et al. (2000) Trends in Genetics 16(6): 276-277 and available online at www.ebi.ac.uk/Tools/emboss/align/index.html and emboss.open-bio.org/wiki/Appdoc:Needle.) The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences. To determine collective identity of one sequence of interest to a group of reference sequences, a position is considered to be identical if it is identical to at least one amino acid at a corresponding position in any one or more of the group of reference sequences. With respect to lists of segments, features, or regions, identity can be calculated collectively for all members of such list to arrive an overall percentage identity.
- Provided herein are sequences that are at least 60, 65, 70, 75, 80, 82, 85, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to sequences disclosed herein.
- As used herein, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise.
- All patents, patent applications, scientific publications and other references cited in this specification are hereby incorporated herein for all purposes, and for the disclosure for which they have been cited.
-
FIG. 1 is a set of graphs depicting the results of SPR experiments determining the binding of the variant serum albumin polypeptides (VSAs) HSA-5, HSA-11, HSA-7, and HSA-13 to human FcRn at pH 5.5, pH 6.0, pH 6.5, and pH 7.4. -
FIG. 2 is a table depicting the KDs as determined by ELISA of variant serum albumin polypeptides (VSAs) at pH 5.5. -
FIG. 3 is a set of graphs depicting the results of ELISA that determining the binding of VSAs and wild type HSA to human FcRn at pH 5.5, 6.0, and 7.4. -
FIG. 4 is s set of graphs depicting the pharmacokinetics of VSAs (HSA-5, HSA-11, and HSA-13) and wild type human serum albumin (wt-HSA) in wild type mice. The left panel shows plasma concentration over time. The right upper panel shows half-life, and the right lower panel shows clearance. -
FIG. 5 is s set of graphs that depicting the pharmacokinetics of VSAs (HSA-5, HSA-11, and HSA-13) and wild type HSA in human FcRn transgenic mice. The left panel shows plasma concentration over time. The right upper panel shows half-life, and the right lower panel shows clearance. -
FIG. 6 is a table depicting the PK parameters of a wild type HSA (HSA-wt) and a VSA (HSA-7) in a primate. -
FIG. 7 is a graph and a table depicting the pharmacokinetics of IL-2 fused to wild type HSA and to a VSA (HSA-13) in C57Bl/6J mice. - One limitation of certain agents (e.g., therapeutic or diagnostic agents) can be their suboptimal pharmacokinetics (PK), particularly when administered systemically. Relatively short PKs (as assessed, e.g., by plasma half-life of the agents) can mean, for example, that a therapeutic must be administered at a relatively high frequency. The present disclosure provides VSAs that have improved functional properties, e.g., improved pharmacokinetics (e.g., increased half-life, reduced clearance, and/or reduced beta phase clearance). The VSAs can be useful themselves, e.g., for therapeutic or diagnostic uses. The VSAs can be used to improve the functional properties, e.g., the pharmacokinetics, of other agents.
- The present disclosure provides variant serum albumin polypeptides (VSAs). As used herein, a variant serum albumin polypeptide (VSA) can refer to a variant of a full length native serum albumin or to a variant of a fragment of a native serum albumin (e.g., a variant of a functional fragment of a native serum albumin). Typically, a VSA that is a variant of a fragment of a native serum albumin has a minimal length that provides functionality (e.g., an ability to bind FcRnat endosomal pH). In some embodiments, the variant comprises or consists of a sequence that is a variant of the domain III sequence of a native serum albumin. In some embodiments, the variant comprises a sequence that is a variant of the domain III sequence of a native human serum albumin sequence. In some embodiments, the affinity of a VSA for an FcRn is increased at an endosomal pH (e.g., pH 5.5 or 6.0) compared to the affinity of wild type albumin corresponding to the VSA. In certain embodiments, the affinity of a VSA for an FcRn is increased at an endosomal pH (e.g., pH 5.5 or 6.0) compared to the affinity of wild type albumin corresponding to the VSA and the affinity of the VSA for FcRn at a neutral pH (e.g., pH 7.0 or 7.4) is the same or less than the affinity of a corresponding wild type albumin for an FcRn. In some cases, Applicants have found that in selecting a VSA that is useful, e.g., as a therapeutic, it is necessary to evaluate the affinity for FcRn at both endosomal and neutral pH, noting that a VSA with the greatest affinity for FcRn at endosomal pH may be unsuitable for use because it also has an increased affinity at a neutral pH.
- In some embodiments, a VSA comprises an amino acid substitution or deletion at one or more (e.g., 1, 2, 3, 4, 5, or more) positions disclosed herein, e.g., at the positions that were mutated in the experiments disclosed in the Examples and Figures. In some embodiments, a VSA comprises a substitution described herein, e.g., one or more substitutions of a specific amino acid at a specific position as described herein, e.g., as disclosed in the Examples and Figures.
- In some embodiments, a VSA has one or more of the following mutations (amino acid residue numbers defined in accordance with the mature human amino acid sequence of SEQ ID NO:2): V418M; T420A; V424I; N429D; M446V; A449V; T467M; E505(R/K/G); V547A; and A552T, wherein “(X/Z)” means that the amino acid sequence may alternatively comprise amino acid X or amino acid Z at that residue. In certain embodiments, the VSA can include one or more of the following mutations: V418M; T420A; V424I; E505(R/K/G); and V547A.
- In some embodiments, a VSA comprises a mutation that is present in a VSA disclosed herein, e.g., a VSA selected from one or more of the following variants described herein: HSA-15, HSA-13, HSA-12, HSA-7, HSA-21, HSA-11, HSA-14, HSA-5, HSA-10, HSA-6, HSA-9, and HSA-18. In some embodiments, a VSA includes each of the mutations that are present in a variant described herein, e.g., a variant selected from HSA-15, HSA-13, HSA-12, HSA-7, HSA-21, HSA-11, HSA-2, HSA-14, HSA-5, HSA-10, HSA-6, HSA-9, and HSA-18. In some embodiments, a VSA has the sequence of HSA-15, HSA-13, HSA-12, HSA-7, HSA-21, HSA-11, HSA-14, HSA-5, HSA-10, HSA-6, HSA-9, or HSA-18.
- Typically, the VSAs provided herein have improved functional properties (e.g., higher affinity for FcRn at endosomal pH and/or extended pharmacokinetics, e.g., increased half-life and/or reduced clearance) compared with a corresponding native serum albumin sequence. Such VSAs can be useful for therapeutic or diagnostic applications. For example, VSAs can be useful for treating, or for producing formulations that are useful for treating, conditions for which serum albumin is indicated. A VSA that has improved properties compared with a corresponding native serum albumin sequence has therapeutic advantages. For example, a VSA that has extended PK compared with a corresponding native serum albumin polypeptide can have therapeutic advantages, such as less frequent and/or reduced dosing and/or more consistent delivery levels. A VSA can also be less expensive to administer because fewer doses are required.
- Native human serum albumin (HSA) binds to human FcRn at pH 6.0 with an affinity of about 1-10 micromolar, and about 400 micromolar affinity at pH 7.4. The VSAs described herein can have improved binding to FcRn at endosomal pH, e.g., at pH 6.0 compared with a native serum albumin (e.g., a corresponding native serum albumin, e.g., the corresponding full length native serum albumin or fragment thereof of which the VSA is a variant).
- In some embodiments, the VSA binds to FcRn with a KD that is less than a value selected from 2 micromolor, 1.5 micromolar, 1 micromolar, and 0.5 micromolar. In some embodiments, the VSA binds to FcRn with a KD that is less than a value selected from 100 nM, 95 nM, 90 nM, 85 nM, 80 nM, 75 nM, 70 nM, 65 nM, 60 nM, 55 nM, 50 nM, 45 nM, 40 nM, 35 nM, 30 nM, 25 nM, 20 nM, 15 nM, 10 nM, and 5 nM. The KD can be determined as described herein or using any method known in the art.
- The KD is pH dependent. In some embodiments, the VSA exhibits improved binding to FcRn at a specified pH, e.g., at pH 5.0, 5.2, 5.5, 5.6, 5.7, 5.8, 5.9, 6.2, 6.0, or 6.2. In some embodiments, the VSA exhibits improved binding to FcRn at an endosomal pH, for example at pH 5.0-6.2, pH 5.0-6.2, pH 5.0-6.0, or pH 5.5-6.0. In some embodiments, the VSA exhibits improved binding to FcRn at pH 5.5 or 6.0. In some embodiments, the VSA binds to FcRn at an endosomal pH, e.g., at pH 5.5 or pH 6.0, with a KD that is less than a value selected from 2 micromolar, 1.5 micromolar, 1 micromolar, and 0.5 micromolar. In some embodiments, the VSA binds to FcRn at an endosomal pH, e.g., at pH 5.5 or pH 6.0 with a KD that is less than a value selected from 100 nM, 95 nM, 90 nM, 85 nM, 80 nM, 75 nM, 70 nM, 65 nM, 60 nM, 55 nM, 50 nM, 45 nM, 40 nM, 35 nM, 30 nM, 25 nM, 20 nM, 15 nM, 10 nM, and 5 nM.
- In some embodiments, the serum albumin variants have a KD for FcRn at pH 5.5 that is less than 23 nM. In some embodiments, the serum albumin variants have a KD for FcRn at pH 5.5 that is less or equal to 75 nM, 50 nM, 25 nM, 15 nM, 10 nM, 5 nM, or 3 nM.
- In some embodiments, the VSA binds to FcRn at an endosomal pH, e.g., pH 5.5 or pH 6.0, but does not bind to FcRn at pH 7.4. In some embodiments, the VSA binds to FcRn at an endosomal pH, e.g., pH 5.5 or pH 6.0, and shows reduced binding to FcRn at pH 7.4 compared with its binding to FcRn at pH 5.5 (e.g., the binding to FcRn at pH 7.4 is less than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 60% of the level observed at pH 5.5).
- In some embodiments, the VSA binds to FcRn at pH 5.5 and shows reduced binding to FcRn at pH 7.4 compared with its binding to FcRn at an endosomal pH, e.g., pH 5.5 or pH 6.0 (e.g., the binding to FcRn at pH 7.4 is less than 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 60% of the level observed at pH 5.5), and the VSA has improved pharmacokinetics (e.g., increased plasma half-life and/or reduced clearance, e.g., reduced beta phase clearance) compared with a corresponding native serum albumin.
- In some embodiments, the VSA has a decreased KD for FcRn at an endosomal pH, e.g. pH5.5 or pH 6.0, compared to the KD of a wild type albumin (e.g., an HSA) at endosomal pH, and has the same or increased KD for FcRn at a neutral pH, e.g., pH 7.0 or pH 7.4.
- The ratio of the KDs of wild type HSA to FcRn at pH 7.4 and 5.5 is 40-400, depending on the report. In some embodiments, the ratio of KDs of the VSA to FcRn at pH 7.4 and 5.5 is greater than for wild type HSA (e.g., a ratio of 500; 1000; 5000; 10,000; 100,000; or 1 million). In some embodiments, the binding of VSA to FcRn is assessed using SPR. In some embodiments, the binding of VSA to FcRn is assessed using ELISA.
- In some embodiments, the half life (T½) of the VSA is greater than the T½ of a corresponding native serum albumin. In some embodiments, the T½ of the VSA is increased by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared with the T½ of a corresponding native serum albumin.
- In some embodiments, the T½ of the VSA is at least two times, three times, or four times as long as the T½ of a corresponding native serum albumin. In some embodiments, the T½ of the VSA is at least twice as long as the T½ of a corresponding native serum albumin.
- Wild type HSA has a half-life (T½) in plasma of about 15-20 days in humans. A variant serum albumin described herein can have a longer serum half-life than a corresponding albumin, e.g., T½ at least about 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days. In some embodiments, the VSA. In some embodiments, the VSA has a longer serum T½ in an animal compared to the corresponding wild type VSA, e.g., a VSA has a longer serum T½ in a monkey than the T½ of a human wild type albumin in a monkey.
- Wild type HSA (UniProt DB Accession No. P02768; SEQ ID NO:1 below) is a 609 amino acid protein, comprising an 18 amino acid signal peptide; a 6 amino acid propeptide, extending from
amino acid 19 to 24;Domain 1, extending fromamino acid 25 to 210;Domain 2, extending from amino acid 211 to 403; andDomain 3, extending from amino acid 404 to 601 or amino acid 404 to 609 of Sequence ID No. 1. An exemplary sequence of a human serum albumin (including its leader sequence) is as follows: -
[SEQ ID NO: 1] 10 20 30 40 MKWVTFISLL FLFSSAYSRG VFRRDAHKSE VAHRFKDLGE 50 60 70 80 ENFKALVLIA FAQYLQQCPF EDHVKLVNEV TEFAKTCVAD 90 100 110 120 ESAENCDKSL HTLFGDKLCT VATLRETYGE MADCCAKQEP 130 140 150 160 ERNECFLQHK DDNPNLPRLV RPEVDVMCTA FHDNEETFLK 170 180 190 200 KYLYEIARRH PYFYAPELLF FAKRYKAAFT ECCQAADKAA 210 220 230 240 CLLPKLDELR DEGKASSAKQ RLKCASLQKF GERAFKAWAV 250 260 270 280 ARLSQRFPKA EFAEVSKLVT DLTKVHTECC HGDLLECADD 290 300 310 320 RADLAKYICE NQDSISSKLK ECCEKPLLEK SHCIAEVEND 330 340 350 360 EMPADLPSLA ADFVESKDVC KNYAEAKDVF LGMFLYEYAR 370 380 390 400 RHPDYSVVLL LRLAKTYETT LEKCCAAADP HECYAKVFDE 410 420 430 440 FKPLVEEPQN LIKQNCELFE QLGEYKFQNA LLVRYTKKVP 450 460 470 480 QVSTPTLVEV SRNLGKVGSK CCKHPEAKRM PCAEDYLSVV 490 500 510 520 LNQLCVLHEK TPVSDRVTKC CTESLVNRRP CFSALEVDET 530 540 550 560 YVPKEFNAET FTFHADICTL SEKERQIKKQ TALVELVKHK 570 580 590 600 PKATKEQLKA VMDDFAAFVE KCCKADDKET CFAEEGKKLV 609 AASQAALGL - An exemplary sequence of a human serum albumin (HSA) (in its mature form) is a 585 amino acid polypeptide as follows in SEQ ID NO:2. In some embodiments, the VSAs as described herein comprise variant domain III regions. Typically, such variant domain III regions retain the three-dimensional fold of domain III of serum albumin.
- Exemplary variant domain III regions are at least 80% identical to domain III of a naturally occurring serum albumin, e.g., at least 90% identical to the domain III of a human serum albumin (e.g., amino acids 404 to 609 of SEQ ID NO:1 or amino acids 380 to 585 of SEQ ID NO:2 below).
- A variant serum albumin polypeptide can have one or more (e.g., 1, 2, 3, 4, 5, or more) substitutions, insertions, or deletions relative to a corresponding native serum albumin. For example, the variant polypeptide can include a domain III with at least one, two, three, four or five substitutions relative to a domain III of HSA.
-
[SEQ ID NO: 2] 10 20 30 40 DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV 50 60 70 80 KLVNEVTEFA KTCVADESAE NCDKSLHTLF GDKLCTVATL 90 100 110 120 RETYGEMADC CAKQEPERNE CFLQHKDDNP NLPRLVRPEV 130 140 150 160 DVMCTAFHDN EETFLKKYLY EIARRHPYFY APELLFFAKR 170 180 190 200 YKAAFTECCQ AADKAACLLP KLDELRDEGK ASSAKQRLKC 210 220 230 240 ASLQKFGERA FKAWAVARLS QRFPKAEFAE VSKLVTDLTK 250 260 270 280 VHTECCHGDL LECADDRADL AKYICENQDS ISSKLKECCE 290 300 310 320 KPLLEKSHCI AEVENDEMPA DLPSLAADFV ESKDVCKNYA 330 340 350 360 EAKDVFLGMF LYEYARRHPD YSVVLLLRLA KTYETTLEKC 370 380 390 400 CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE 410 420 430 440 YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH 450 460 470 480 PEAKRMPCAE DYLSVVLNQL CVLHEKTPVS DRVTKCCTES 490 500 510 520 LVNRRPCFSA LEVDETYVPK EFNAETFTFH ADICTLSEKE 530 540 550 560 RQIKKQTALV ELVKHKPKAT KEQLKAVMDD FAAFVEKCCK 570 580 ADDKETCFAE EGKKLVAASQ AALGL - Typically, a VSA is a polypeptide that has a three-dimensional fold that is similar or identical to that of a native serum albumin, e.g., as described in PDB files 1A06 (Sugio et al. (1999) Protein Eng. Jun; 12(6):439-46); or 1E78 (Bhattacharya et al., (2000) J. Biol. Chem., 275:38731)); or 1E7H (Bhattacharya et al., (2000) J. Mol. Biol., 303:721).
- Exemplary variant serum albumin polypeptides are at least 70% identical to a naturally occurring serum albumin, e.g., at least 75%, 80%, 85%, 90%, or 95% identical to a human serum albumin (e.g., SEQ ID NO:1 above). A variant serum albumin polypeptide can have one or more substitutions, insertions, or deletions. For example, the variant polypeptide can have at least one, two, three, four, or five substitutions relative to HSA.
- The sequences of serum albumins from other species, particularly mammalian species are also known. Exemplary sequences include albumin sequences from Bos taurus (CAA76847, P02769, CAA41735, 229552, AAF28806, AAF28805, AAF28804, AAA51411); Sus scrofa (P08835, CAA30970, AAA30988); Equus caballus (AAG40944, P35747, CAA52194); Ovis aries (P14639, CAA34903); Salmo salar (CAA36643, CAA43187); Gallus gallus (P19121, CAA43098); Felis catus (P49064, 557632, CAA59279, JC4660); Canis familiaris (P49822, 529749, CAB64867). Variations, e.g., substitutions described herein in HSA, can also be introduced at corresponding positions into serum albumins from other species, e.g., into mammalian serum albumins, including, e.g., bovine serum albumin.
- Serum albumin can be divided into at least three domains, termed Domain I, Domain II, and Domain III. A serum albumin protein useful in the present invention typically includes at least a domain III, and can also include domain I and domain II. Exemplary domains I, II, and III can have at least 60, 65, 70, 75, 80, 85, 90, 95% identity to respective domains from a mammalian serum albumin. In some embodiments, the variant serum albumin polypeptide of the present invention comprises domain III of human HSA, that is, amino acids 404 to 601 or 404 to 609 of SEQ ID NO:1, or amino acids 380 to 585 of SEQ ID NO:2, into which at least one, two, three, four, or five substitutions have been engineered relative to domain III of HSA.
- In some embodiments, a residue that is within less than 7 angstroms of position H464 is substituted with another amino acid. For example, the residue is amino acid 415, 418, 458, 459, 460, 461, 462, 463, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, or 477. In some embodiments, a residue that is within less than 7 angstroms of position H510 is substituted with another amino acid. For example, the residue is amino acid 508, 509, 511, 512, 513, 514, 554, 555, 559, 564, 565, 568, or 569. In some embodiments, a residue that is within less than 7 angstroms of position H535 is substituted with another amino acid. For example, the residue is
amino acid 412, 497, 498, 499, 500, 501, 502, 503, 507, 529, 530, 531, 532, 533, 534, 536, 537, 538, 580, or 583. - In some embodiments, residue V418 is altered, e.g., to a residue other than valine, e.g., to an hydrophobic residue such as methionine. In some embodiments, a residue that is within less than 7 angstroms of position V418 is substituted with another amino acid. For example, the residue is amino acid 411, 412, 415, 416, 417, 419, 420, 421, 422, 423, 424, 426, 460, 464, 469, 470, 473, 497, 530, or 534.
- In some embodiments, residue T420 is altered, e.g., to a residue other than threonine, e.g., to an uncharged residue, e.g., a small uncharged residue such as alanine or glycine. In some embodiments, a residue that is within less than 7 angstroms of position T420 is substituted with another amino acid. For example, the residue is
amino acid 408, 412, 416, 417, 418, 419, 421, 422, 423, 424, 425, 500, 526, 527, 528, 529, 530, 531, or 534. - In some embodiments, residue V424 is altered, e.g., to a residue other than valine, e.g., to an uncharged residue, e.g., to isoleucine. In some embodiments, a residue that is within less than 7 angstroms of position V424 is substituted with another amino acid. For example, the residue is amino acid 404, 408, 412, 418, 419, 420, 421, 422, 423, 425, 426, 427, 428, 429, 430, 522, 523, 524, 526, 527, 528, or 530.
- In some embodiments, residue E505 is altered, e.g., to a residue other than glutamic acid, e.g., to an uncharged residue, e.g., a small uncharged residue such as alanine or glycine, or to a positively charged residue, e.g. lysine or arginine. In some embodiments, a residue that is within less than 7 angstroms of position E505 is substituted with another amino acid. For example, the residue is amino acid 502, 503, 504, 506, 507, 508, or 509.
- In some embodiments, residue V547 is altered, e.g., to a residue other than valine, e.g., to an uncharged residue, e.g., a small uncharged residue such as alanine or glycine. In some embodiments, a residue that is within less than 7 angstroms of position V547 is substituted with another amino acid. For example, the residue is amino acid 529, 532, 542, 543, 544, 545, 546, 548, 549, 550, 551, or 552.
- Variant serum albumin polypeptides can be incorporated into a fusion protein, with the N- or C-terminus thereof fused to the N- or C-terminus of a diagnostic or therapeutic protein, or variant thereof. In certain embodiments, the variant serum albumin polypeptide and the diagnostic or therapeutic protein are joined through a linker moiety, such as a peptide linker Linkers useful in the present invention are described in greater detail further herein.
- A VSA can be used as a therapeutic, e.g., in uses for which albumin such as human albumin is typically used. For such uses, a VSA as described herein can have the advantage of extended PK, which can enable less frequent and/or reduced dosing for albumin replacement or supplementation. Such uses include, for example, hypovolemia, hypoalbuminemia, burns, adult respiratory distress syndrome, nephrosis, and hemolytic disease of the newborn. Hypoalbuminemia can result from, for example, inadequate production of albumin (e.g., due to malnutrition, burns, major injury, or infection), excessive catabolism of albumin (e.g., due to burn, major injury such as cardio-pulmonary bypass surgery, or pancreatitis), loss through bodily fluids (e.g., hemorrhage, excessive renal excretion, or burn exudates), deleterious distribution of albumin within the body (e.g., after or during surgery or in certain inflammatory conditions). Typically, for such uses, a VSA for such uses is administered by injection or iv in a solution that is from 5%-50% VSA (w/v), for example, 10%-40%, 15%-30%, 20%-25%, 20%, or 25%. Typically, administration is sufficient to produce a total albumin plus VSA concentration in a treated subject's serum that is 3.4-5.4 grams per deciliter (g/dL). Methods of assaying albumin concentration are well known in the art and can generally be used to assay total albumin plus VSA concentration.
- Also provided herein is a VSA, or a pharmaceutical composition comprising a VSA, for use in therapy. Also included is a VSA, or a pharmaceutica composition comprising a VSA, for use in the treatment of a disease, e.g., a disease or condition for which albumin is indicated. Other embodiments include the use of a VSA, or a pharmaceutical composition comprising aVSA, for the manufacture of a medicament for the treatment of a disease.
- Uses of VSAs in Association with Other Agents
- VSAs can also be used in association with other agents, e.g., therapeutic or diagnostic agents, to confer functional advantages, e.g., advantages of VSAs as described herein. The agent can be, e.g., any agent that is useful in the diagnosis or therapy of a disease or disorder, e.g., a disease or disorder that affects a human or a non-human animal.
- Advantages of VSAs include, e.g., lack of Fc effector function, high solubility, potential for high expression, low immunogenicity, and ability to be fused to another moiety at both termini to generate bivalent, bispecific, or bifunctional molecules.
- Disclosed herein are VSAs with improved binding to an FcRn at endosomal pH, thereby potentiating the ability of the VSA and an agent associated with that VSA to have improved PK.
- A VSA that has an extended PK can be associated with an agent (e.g., a therapeutic or diagnostic agent) to extend the PK of the agent. The extended PK can have advantages; for example, the agent can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the agent can be achieved.
- In some embodiments, associating a VSA with an agent improves the functional properties of the agent. In some embodiments, the dosage and/or frequency at which the agent is effective for producing a particular effect (e.g., a desired therapeutic effect) is reduced when the agent is used in association with the VSA. In some embodiments, associating a VSA with an agent improves the pharmacokinetic properties of the agent (e.g., increases its half-life and/or reduces its clearance). Any relevant pharmacokinetic parameters that are known in the art can be used to assess pharmacokinetic properties. The pharmacokinetics of a VSA or a VSA associated with an agent can be measured in any relevant biological sample, e.g., in blood, plasma, or serum.
- In some embodiments, associating a VSA with an agent improves the half life (T½) of the agent. In some embodiments, the T½ of the agent is increased by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%. In some embodiments, the T½ is at least two times, three times, or four times as long as the T½ of the agent when it is not associated with the VSA. In some embodiments, the T½ of the VSA is at least twice as long as the T½ of the agent when it is not associated with the VSA.
- In some embodiments, the dose at which the agent is effective for producing a particular effect (e.g., a desired therapeutic effect) is reduced when the agent is associated with the VSA. In some embodiments, the effective dose is reduced to 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10% of the dose that is required when the agent is not associated with the VSA.
- In some embodiments, the frequency of dosing of the agent that is effective for producing a particular effect (e.g., a desired therapeutic effect) is reduced when the agent is associated with the VSA. In some embodiments, the frequency of dosing at which the agent is effective when it is associated with the VSA is decreased by 10%, 20%, 30%, 40%, 50%, or more compared with the frequency at which the agent is effective when it is not associated with the VSA.
- In some embodiments, the frequency of dosing at which the agent is effective when it is associated with the VSA is decreased by at least 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 2 weeks, 3 weeks, or 4 weeks compared with the frequency at which the agent is effective when it is not associated with the VSA.
- The improvement in the properties of the agent can be assessed relative to any appropriate control. For example, the improvement in the properties of an agent that is associated with a VSA can be assessed by comparing the properties of the agent that is associated with the VSA with the properties of the agent when it is not in an association with the VSA. Alternatively, the improvement in the properties of an agent that is associated with a VSA can be assessed by comparing the properties of the agent that is associated with the VSA with the properties of the agent when it is in an association with a corresponding native serum albumin polypeptide.
- Also provided herein is a VSA, a VSA in association with another agent, a pharmaceutical composition comprising a VSA, or a pharmaceutical composition comprising a VSA in association with another agent, for use in therapy or for use in the treatment of a disease, e.g., a disease or condition described herein or described in U.S. Pat. No. 5,766,883, U.S. Pat. No. 5,875,969, U.S. Patent Publication No. US 2002/0151011, or International Publication No. WO 2011/103076, the entire contents of each of which are hereby incorporated herein by reference. Other embodiments include the use of a VSA, or a pharmaceutical composition comprising aVSA, a VSA in association with another agent, a pharmaceutical composition comprising a VSA, or a pharmaceutical composition comprising a VSA in association with another agent, for the manufacture of a medicament for the treatment of a disease.
- The agent can be another protein, e.g., a heterologous protein. In some embodiments, the agent is a diagnostic agent. In some embodiments, the agent is a therapeutic agent. For example, a protein that comprises a VSA can be used to extend the PK of a systemically administered therapeutic agent. The heterologous protein can be, for example, a therapeutic protein or a diagnostic protein. The serum albumin polypeptide with altered FcRn binding properties or a domain thereof (e.g., domain III) can be associated with (e.g., attached covalently to) the therapeutic protein, or to an active fragment or variant of the therapeutic protein. The variant serum albumin or a domain thereof can be in the same polypeptide chain as is at least a component of the therapeutic protein.
- A variant serum albumin (VSA) can be associated with another agent, e.g., a therapeutic agent or a diagnostic agent. The other agent (e.g., therapeutic agent) can be an entire protein (e.g., an entire therapeutic protein) or a biologically active fragment thereof. The activity of the agent (e.g., therapeutic agent) can be evaluated in an appropriate in vitro or in vivo assay for the agent's activity. In general, the activity of the agent fused to a VSA is not reduced, for example, by more than 50%, by more than 40%, by more than 30%, by more than 20%, by more than 10%, by more than 5%, or by more than 1% compared with the activity of the agent when it is not in association with the agent. Examples of methods for assessing the activity of certain agents are provided herein.
- In some embodiments, the VSA is attached to the agent by one or more covalent bonds to form a variant serum albumin fusion molecule. Any agent that can be linked to a VSA described herein can be used as the agent in a variant serum albumin fusion molecule. The agent can be a therapeutic or diagnostic agent. For example, the agent can be any polypeptide or drug known to one of skill in the art.
- In some embodiments, an agent (e.g., therapeutic or diagnostic agent) is stably associated with a VSA, but the agent is not fused to the VSA. In such embodiments, the agent can be associated with the VSA by any means known in the art. For example, the agent can be conjugated to a moiety that is capable of binding the VSA. In some embodiments, the moiety is an albumin binding protein. In some embodiments the moiety is a fatty acid. In some embodiments, the agent is non-covalently bound to the VSA, generally via the affinity of the VSA for small lipophilic moieties. In embodiments wherein the agent is not fused to the VSA, the agent can be administered before, after, or concurrently with the VSA. In some embodiments, the agent is administered concurrently with the VSA. In some embodiments, the agent is administered at the same frequency as is the VSA. In some embodiments, the agent is administered more or less frequently than the VSA.
- In some embodiments, the agent is a polypeptide consisting of at least 5, for example, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 or at least 100 amino acid residues. The agent can be derived from any protein for which an improved property is desired, e.g., an increase in serum levels and/or serum half-life of the agent; or a modified tissue distribution and/or tissue-targeting of the agent.
- In some embodiments, the agent is a cytokine or a variant thereof. Generally, a cytokine is a protein released by one cell population that acts on another cell as an intercellular mediator. Examples of such cytokines include lymphokines, monokines, and traditional polypeptide hormones. Specific examples include: interleukins (ILs) such as IL-1 (IL-1α and IL1β), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12; IL-15, IL-18, and IL-37; a tumor necrosis factor such as TNF-alpha or TNF-beta; growth hormone such as human growth hormone (HGH); somatotropin; somatrem; N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; insulin-like growth factors, such as insulin-like growth factors-1, -2, and -3 (IGF-1; IGF-2; IGF-3); proglucagon; glucagon and glucagon-like peptides, such as glucagon-like peptide-1 and -2 (GLP-1 and GLP-2); exendins, such as exendin-4; gastric inhibitory polypeptide (GIP); secretin; pancreatic polypeptide (PP); nicotinamide phosphoribosyltransferase (also known as visfatin); leptin; neuropeptide Y (NPY); interleukin IL-1Ra, including (N140Q); ghrelin; orexin; adiponectin; retinol-binding protein-4 (RBP-4); adropin; relaxin; prorelaxin; neurogenic differentiation factor 1 (NeuroD1); glicentin and glicentin-related peptide; cholecystokinin (previously known as pancreozymin); glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor; fibroblast growth factors (FGF) such as FGF-19, FGF-21 and FGF-23; prolactin; placental lactogen; tumor necrosis factor-alpha and -beta; mullerian-inhibiting substance; gonadotropin-associated peptide; luteinizing-hormone-releasing hormone (LHRH); inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); growth factors (e.g., platelet-derived growth factor, PDGF and its receptor, EGF and its receptor, nerve growth factors, such as NGF-beta and its receptor, and KGF, such as palifermin, and its receptor); platelet-growth factor (PGF); transforming growth factors (TGFs) such as TGF-alpha and TGF-beta; osteoinductive and growth and differentiation factors, such as osteocalcin, BMP-2, BMP-4, BMP-6 and BMP-7; interferons such as interferon-alpha, beta, and -gamma, including interferon-alpha2B; colony stimulating factors (CSFs) such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); erythropoietin (EPO); darbepoeitin alfa; tissue plasminogen activator (TPA) or alteplase; tenecteplase; dornase alfa; entanercept; calcitonin, oxyntomodulin; glucocerebrosidase; arginine deiminase, Arg-vasopressin, natriuretic peptides, including A-type natriuretic peptide; B-type natriuretic peptide, C-type natriuretic peptide and Dendroapsis natriuretic peptide (DNP); gonadotropin-releasing hormone (GnRH); endostatin; angiostatin, including (N211Q); Kiss-1; hepcidin; oxytocin; pancreatic polypeptide; calcitonin gene-related protein (CGRP); parathyroid hormone (PTH); adrenomedulin; delta-opioids; K-opioids; mu-opioids; deltorphins; enkephalins; dynorphins; endorphins; CD276, including (B7-H3); ephrin-B1; tweak-R, cyanovirin, including cyranovirin-N; gp41 peptides; 5-helix protein; prosaptide; apolipoprotein A1; BDNF; brain-derived neural protein; CNTF (Axokine®); Antithrombin III; FVIII A1 domain; Kringle-5; Apo A-1 Milano; Kunitz domains; vWF A1 domain; Peptide YY, including PYY1-36 and PYY3-36; urate oxidase; and other polypeptide factors including LIF and kit ligand (KL).
- In one embodiment, the agent is BMP peptide analogue (e.g., THR-184, Thrasos Therapeutics, Inc.).
- In one embodiment, the agent is GLP-2.
- In some embodiments, the therapeutic protein is a monomeric protein (such as a monomeric cytokine, e.g., an IL-1Ra, or an scFv). Albumin fusion proteins are known in the art; the variant serum albumin polypeptides with altered FcRn binding properties, described herein, can be used in place of serum albumin and linked to a therapeutic agent to form fusion proteins with improved properties, such as increased half-life.
- Examples of other polypeptides useful as the active agent include, but are not limited to, various types of antibodies, antibody fragments, such as antigen binding domains (e.g., scFv, Fv, Fab, F(ab)2, domain antibodies, and the like); Surrobodies, Adnectins™, anti-calin, affibody, or fragments of the foregoing. Also useful as active agents are receptor antagonists, such as IL-1Ra (e.g., anakinra), cell adhesion molecules (e.g., cadherins, such as cadherin-11, CTLA4, CD2, and CD28); anti-angiogenic factors such as endostatin; receptors, as well as soluble fragments of tissue-bound receptors.
- The agent, e.g., therapeutic moiety included in a fusion protein as described herein, can also be a therapeutic moiety such as a cytotoxin (e.g., a cytostatic or cytocidal agent), a non-peptide therapeutic agent or a radioactive element (e.g., alpha-emitters, gamma-emitters, etc.). Examples of cytostatic or cytocidal agents include, but are not limited to, paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Non-peptide therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cisdichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC), and anti-mitotic agents (e.g., vincristine and vinblastine). The present invention also encompasses fusing the variant serum albumin (VSA) moiety to an active agent that is a diagnostic agent. The VSA-diagnostic molecule of the invention can be used diagnostically to, for example, monitor the development or progression of a disease, disorder or infection as part of a clinical testing procedure to, e.g., determine the efficacy of a given 5 treatment regimen. Detection can be facilitated by coupling the pharmacologic enhancing molecule to a detectable substance. Examples of detectable substances include enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals, and nonradioactive paramagnetic metal ions. The detectable substance can be coupled or conjugated either directly to the antibody or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Pat. No. 4,741,900 for metal ions that can be conjugated to antibodies for use as a diagnostic according to the methods and compositions described herein. Examples of suitable enzymes include, e.g., horseradish peroxidase, alkaline phosphatase, O-galactosidase, or acetylcholinesterase; examples of suitable prosthetic groups include, e.g., complexes including, e.g. streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include, e.g., 125I, 131I, 111In or 99 mTc. See, for example, Plumridge et al., WO2011/051489; Lubman et al.; WO2010/141329.
- The nucleotide and amino acid sequences and structures for the above molecules that are useful as, or in preparing the active moiety to be fused to the variant serum albumin moiety in the present invention are known, and all of the publications and websites described as providing such information, such as Genbank, the protein database and Uniprot (www.ncbi.nlm.nih.gov/genbank; www.pdb.org; and www.uniprot.org, respectively), are incorporated herein by reference for this purpose. Non-limiting examples of therapeutic proteins that can be used in preparing some of the embodiments of the present invention are described in further detail below.
- Glucagon-Like Peptide 1 (GLP-1).
- In one embodiment, the therapeutic agent includes a GLP-1 or a biologically active variant or fragment thereof. GLP-1 is a 37 amino acid peptide that is formed from cleavage of glucagon, secreted by the L-cells of the intestine in response to food ingestion (Uniprot accession number: P01275). GLP-1 can stimulate insulin secretion, causing glucose uptake by cells and decreased serum glucose levels (e.g., Mojsov, Int. J. Peptide Protein Research, 40:333-343 (1992)). GLP-1 can be cleaved to produce a biologically active peptide GLP-1 (7-37)0H. In addition, numerous GLP-1 analogs and derivatives are known and include, e.g., exendins which are peptides found in Gila monster venom. Exendins have sequence homology to native GLP-1 and can bind the GLP-1 receptor and initiate the signal transduction cascade of GLP-1 (7-37)OH. GLP-1 compounds can have one or more of the following biological properties: ability to stimulate insulin release, lower glucagon secretion, inhibit gastric emptying, and enhance glucose utilization. (e.g., Nauck et al., Diabetologia 36:741-744 (1993); Gutniak et al., New England J. of Med. 326:1316-1322 (1992); Nauck et al., J. Clin. Invest. 91:301-307 (1993)). A therapeutic agent including GLP-1, GLP-1 (7-37)0H, an exendin, or biologically active variants or fragments thereof can be used for treating a diabetic disorder, e.g., non-insulin dependent diabetes mellitus (NIDDM).
- The amino acid sequence of human GLP-1 is as follows:
-
[SEQ ID NO: 3] HDEFERHAEG TFTSDVSSYL EGQAAKEFIA WLVKGRG - Advantages of using a VSA in association with a GLP-1 (e.g., using a VSA-GLP-1 fusion protein) include, e.g., extending the PK of the GLP-1. The extended PK can have advantages; for example, the GLP-1 can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the GLP-1 can be achieved.
- Insulin.
- In one embodiment, the therapeutic agent is an insulin. The insulin can be a full length insulin polypeptide or a biologically active variant or fragment thereof. For example, the insulin can be a glucose sensitive molecule that includes an insulin receptor agonist. An exemplary insulin polypeptide (110 amino acids) has the sequence:
-
[SEQ ID NO: 4] MALWMRLLPL LALLALWGPD PAAAFVNQHL CGSHLVEALY LVCGERGFFY TPKTRREAED LQVGQVELGG GPGAGSLQPL ALEGSLQKRG IVEQCCTSIC SLYQLENYCN. - The B-chain (1-30 or
-
[SEQ ID NO: 5] FVNQHL CGSHLVEALY LVCGERGFFY TPKT)
is present at amino acids 25-54. The A-chain (1-21 or -
[SEQ ID NO: 6] G IVEQCCTSIC SLYQLENYCN)
is present at amino acids 90-110. (See, Uniprot accession no. P01308). The C-peptide -
[SEQ ID NO: 7] (RREAED LQVGQVELGG GPGAGSLQPL ALEGSLQKR)
which links the B-chain and A-chain is present at amino acids 55-89. Therapeutic proteins as disclosed herein can include the B-chain and A-chain of insulin, linked by the C-peptide of insulin or another natural or artificial sequence, such as a peptide linker A number of adipose and muscle related cell lines can be used to test for glucose uptake/transport activity in the absence or presence of a combination of any one or more of the therapeutic drugs listed for the treatment of diabetes mellitus. In particular, the 3T3-L1 murine fibroblast cells and the L6 murine skeletal muscle cells can be differentiated into 3T3-L1 adipocytes and into myotubes, respectively, to serve as appropriate in vitro models for the [3H]-2-deoxyglucose uptake assay (Urso et al., J Biol Chem, 274:30864-73 (1999); Wang et al., J Mol Endocrinol, 19:241-8 (1997); Haspel et al., J Membr Biol, 169:45-53 (1999); Tsakiridis et al., Endocrinology, 136:4315-22 (1995)). Female NOD (non-obese diabetic) mice are characterized by displaying IDDM with a course which is similar to that found in humans, although the disease is more pronounced in female than male NOD mice. - Advantages of using a VSA in association with an insulin (e.g., using a VSA-insulin fusion protein) include, e.g., extending the PK of the insulin. The extended PK can have advantages; for example, the insulin can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the insulin can be achieved.
- Fibroblast Growth Factor 19 (FGF-19).
- In one embodiment, the therapeutic agent is an FGF-19 (e.g., human FGF-19) or a biologically active variant or fragment thereof. Human FGF-19 is a 216 amino acid protein, including a 24 amino acid N-terminal signal peptide. An exemplary FGF-19 peptide sequence is the sequence of human FGF-19 (Uniprot accession number: O95750):
-
[SEQ ID NO: 8] MRSGCVVVHV WILAGLWLAV AGRPLAFSDA GPHVHYGWGD PIRLRHLYTS GPHGLSSCFL RIRADGVVDC ARGQSAHSLL EIKAVALRTV AIKGVHSVRY LCMGADGKMQ GLLQYSEEDC AFEEEIRPDG YNVYRSEKHR LPVSLSSAKQ RQLYKNRGFL PLSHFLPMLP MVPEEPEDLR GHLESDMFSS PLETDSMDPF GLVTGLEAVR SPSFEK - FGF-19 is active in the suppression of bile acid biosynthesis and stimulates glucose uptake in adipocytes. Holt et al., Genes Dev. 17:1581-91 (2003). FGF-19 can be used for treatment of dietary and leptin-deficient diabetes. Fu et al., Endocrinology, 145:2594-603 (2004).
- Advantages of using a VSA in association with FGF-19 (e.g., using a VSA-FGF-19 fusion protein) include, e.g., extending the PK of the FGF-19. The extended PK can have advantages; for example, the FGF-19 can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the FGF-19 can be achieved.
- Fibroblast Growth Factor 21 (FGF-21).
- In one embodiment, the therapeutic agent is an FGF-21 (e.g., human FGF-21) or a biologically active variant or fragment thereof. Human FGF-21 is a 209 amino acid protein, including a 28 amino acid N-terminal signal peptide. An exemplary FGF-21 peptide sequence is the sequence of human FGF-21 (Uniprot accession number: Q9NSA1):
-
[SEQ ID NO: 9] MDSDETGFEH SGLWVSVLAG LLLGACQAHP IPDSSPLLQF GGQVRQRYLY TDDAQQTEAH LEIREDGTVG GAADQSPESL LQLKALKPGV IQILGVKTSR FLCQRPDGAL YGSLHFDPEA CSFRELLLED GYNVYQSEAH GLPLHLPGNK SPHRDPAPRG PARFLPLPGL PPALPEPPGI LAPQPPDVGS SDPLSMVGPS QGRSPSYAS - FGF-21 stimulates glucose uptake in differentiated adipocytes via the induction of the insulin-independent glucose transporter GLUT1. In ob/ob mice, FGF-21 has been demonstrated to have durable glucose control and triglyceride lowering effects with minimal adverse side effects. Kharitonenkov et al., J. Clin. Invest. 115:1627-35 (2005). Accordingly, FGF-21 is useful in treatment of diabetes.
- Advantages of using a VSA in association with FGF-21 (e.g., using a VSA-FGF-21 fusion protein) include, e.g., extending the PK of the FGF-21. The extended PK can have advantages; for example, the FGF-21 can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the FGF-21 can be achieved.
- Fibroblast Growth Factor 23 (FGF-23).
- In one embodiment, the therapeutic agent is an FGF-23 (e.g., human FGF-23) or a biologically active variant or fragment thereof. Human FGF-23 is a 251 amino acid protein, including a 24 amino acid N-terminal signal peptide. FGF-23 is cleaved by protein convertases into an N-terminal peptide of approximately 155 amino acids (amino acid 25-179); and a C-terminal peptide of approximately 72 amino acids (amino acids 180-251). An exemplary FGF-23 peptide sequence is the sequence of human FGF-23 (Uniprot accession number: Q9GZV9):
-
[SEQ ID NO: 10] MLGARLRLWV CALCSVCSMS VLRAYPNASP LLGSSWGGLI HLYTATARNS YHLQIHKNGH VDGAPHQTIY SALMIRSEDA GFVVITGVMS RRYLCMDFRG NIFGSHYFDP ENCRFQHQTL ENGYDVYHSP QYHFLVSLGR AKRAFLPGMN PPPYSQFLSR RNEIPLIHFN TPIPRRHTRS AEDDSERDPL NVLKPRARMT PAPASCSQEL PSAEDNSPMA SDPLGVVRGG RVNTHAGGTG PEGCRPFAKF I - FGF-23 is involved in regulating phosphate homeostasis. FGF-23 has been shown to inhibit renal tubule phosphate transport (Bowe et al., Biochem. Biophys. Res. Commun., 284:977-81 (2001)); to regulate vitamin D metabolism (Shimada et al., J. Bone Miner. Res., 19:429-35 (2004)); and to negatively regulate osteoblast differentiation and matrix mineralization (Wang et al., J. Bone Miner. Res., 23:939-48 (2008)). Accordingly, FGF-23 can be used in treatment of autosomal dominant hypophosphatemic rickets (ADHR) and tumor-induced osteomalacia (Riminucci et al., J. Clin. Invest., 112:683-92 (2003)).
- Advantages of using a VSA in association with FGF-23 (e.g., using a VSA-FGF-23 fusion protein) include, e.g., extending the PK of the FGF-23. The extended PK can have advantages; for example, the FGF-23 can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the FGF-23 can be achieved.
- Interleukin-2 (IL-2).
- In one embodiment, the therapeutic agent is an IL-2 (e.g., human IL-2) or a biologically active variant or fragment thereof. Human IL-2 is a 153 amino acid protein, including a 20 amino acid N-terminal signal peptide. An exemplary IL-2 peptide sequence is the sequence of human IL-2 (Uniprot accession number: P60568):
-
[SEQ ID NO: 11] MYRMQLLSCI ALSLALVTNS APTSSSTKKT QLQLEHLLLD LQMILNGINN YKNPKLTRML TFKFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFCQSIIS TLT - IL-2 can induce proliferation of antigen-activated T cells and stimulates natural killer (NK) cells, as well as stimulates proliferation of regulatory T cells (Tregs). The biological activity of IL-2 is mediated through a multi-subunit IL-2 receptor complex (IL-2R) of three polypeptide subunits that span the cell membrane: p55 (IL-2Rα, the alpha subunit, also known as CD25 in humans), p75 (IL-2Rβ, the beta subunit, also known as CD122 in humans) and p64 (IL-2Rγ, the gamma subunit, also known as CD132 in humans). IL-2-derived polypeptides can be used in cancer immunotherapies and to deliver therapeutic agents to CD25-positive cells in vivo or in cell culture. For example, Proleukin® is an approved biologic that contains IL-2. Exemplary agonists are described by Rao et al., Protein Engineering 16:1081-1087 (2003) and Rao et al., Biochemistry 44:10696-701 (2005), and in US Patent Application Publication 2005/0142106; see also U.S. Pat. Nos. 7,569,215 and 7,951,360. The therapeutic agent can also further include an IL-2 binding fragment of CD25, e.g., the sushi domain of IL-2Rα. The IL-2 binding fragment of CD25 can be covalently linked to the biologically active portion of IL-2 or can be non-covalently linked. Exemplary IL-2 antagonists that bind CD25 but do not activate the IL-2 receptor are described in US 2011/0091412. The IL-2 antagonists can be used to specifically target T regulatory cells and/or specifically inhibit T regulatory cell function. The ability of low-dose IL-2 to reduce inflammation and/or immune response may be particularly surprising in light of previous publications advocating low doses of IL-2 for stimulation of immune response. See, U.S. Pat. No. 6,509,313. Low-dose IL-2 can be used to specifically induce Treg proliferation and promote an anti-inflammatory state. In particular embodiments, low-dose IL-2 can be administered subcutaneously, for example using a self-administered pen or cartridge device, such as is used with other self-administered peptide biotherapeutic drugs, such as long-acting insulin. Particular indications for which low-dose IL-2 can be appropriate include, for example, graft-vs-host-disease; for example, in connection with bone marrow transplantation. Administration of low-dose IL-2 can be advantageous in reducing the need for pre-graft conditioning and/or post-graft treatment with immunosuppressant drugs. Ferrara et al., Biology of Blood and Marrow Transplantation, 5:347-56 (1999). Additional advantages can include avoiding the adverse effects of short-term, high dose IL-2. See Sykes et al., Blood, 83:2560-69 (1994).
- Advantages of using a VSA in association with IL-2 (e.g., using a VSA-IL-2 fusion protein) include, e.g., extending the PK of the IL-2. The extended PK can have advantages; for example, the IL-2 can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the IL-2 can be achieved.
- Interleukin-15 (IL-15).
- In one embodiment, the therapeutic agent is an IL-15 (e.g., human IL-15) or a biologically active variant or fragment thereof. Human IL-15 is a 162 amino acid protein, including a 29 amino acid N-terminal signal peptide. An exemplary IL-15 peptide sequence is the sequence of human IL-15 (Uniurot accession number: P409331:
-
[SEQ ID NO: 12] MRISKPHLRS ISIQCYLCLL LNSHFLTEAG IHVFILGCFS AGLPKTEANW VNVISDLKKI EDLIQSMHID ATLYTESDVH PSCKVTAMKC FLLELQVISL ESGDASIHDT VENLIILANN SLSSNGNVTE SGCKECEELE EKNIKEFLQS FVHIVQMFIN TS - IL-15 can induce proliferation of antigen-activated T cells and stimulate natural killer (NK) cells. The biological activity of IL-15 is mediated through a multi-subunit receptor complex (IL-15R) which shares the beta (CD122) and gamma (CD132) subunits of the IL-2 receptor complex, but has a unique alpha subunit (IL-15Ra, also known as CD215 in humans). IL-15 derived polypeptides can be used in cancer immunotherapies. The therapeutic agent can also further include an IL-15 binding fragment of the IL-15Ra receptor, e.g., the sushi domain of IL-2Rα. The IL-15 binding fragment of IL-15Ra can be covalently linked to the biologically active portion of IL-15 or can be non-covalently linked.
- Advantages of using a VSA in association with IL-15 (e.g., using a VSA-IL-15 fusion protein) include, e.g., extending the PK of the IL-15. The extended PK can have advantages; for example, the IL-15 can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the IL-15 can be achieved.
- Hepcidin.
- In certain embodiments, the therapeutic agent is a hepcidin (e.g., human hepcidin), or a biologically active variant of hepcidin. Human hepcidin is an 84 amino acid protein (Uniprot Accession number P81172), including a 24 amino acid N-terminal signal peptide, a thirty amino acid propeptide, and a 25 amino acid mature peptide (
amino acids 60 to 84); hepcidin can be alternately cleaved to form a 20 amino acid mature peptide (amino acids 65 to 84). -
[SEQ ID NO: 13] MALSSQIWAA CLLLLLLLAS LTSGSVFPQQ TGQLAELQPQ DRAGARASWM PMFQRRRRRD THFPICIFCC GCCHRSKCGM CCKT - Hepcidin is known to be involved in iron homeostasis (e.g., Laftah et al., Blood, 103:3940-44 (2004); U.S. Pat. No. 7,169,758). Accordingly, hepcidin can be used an agent for regulation of iron absorption and homeostasis. It can be used to treat abnormal iron absorption, e.g., in individuals with β-thalassemia and related disorders.
- The therapeutic agent can comprise a hepcidin peptide, or a variant of such peptide containing one or more amino acid variations from the mature hepcidin peptide. In a particular embodiment, two mature hepcidin peptides are fused or joined to each end of an albumin moiety, such as a VSA, such that the hepcidin molecules are able to interact with the natural binding partner for hepcidin, ferroportin. Ferroportin is known to exist in dimers, and both monomers must be capable of binding hepcidin for Jak2 to bind to ferroportin.
- Advantages of using a VSA in association with a hepcidin (e.g., using a VSA-hepcidin fusion protein) include, e.g., extending the PK of the hepcidin. The extended PK can have advantages; for example, the hepcidin can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the hepcidin can be achieved.
- Coagulation Factor VII (FVII). In certain embodiments, the therapeutic agent is an FVII (e.g., a human FVII) or a biologically active variant or fragment thereof. Human FVII is a 466 amino acid protein, including a 20 amino acid N-terminal signal peptide and a 40 amino acid propeptide, a 152 amino acid light chain and a 254 amino acid heavy chain. Thim et al., Biochemistry, 27:7785-93 (1998); Hagen et al., PNAS USA 83:2412-16 (1986); O'Hara et al., PNAS USA 84:5158-62 (1987) and Sabater-Lleal et al., Hum Genet. 118:741-51 (2006); Hagen, U.S. Pat. No. 4,784,950; Uniprot Accession No. P08709. Thus, the mature FVII is a single chain glycoprotein (mol. wt. 50,000) of 406 amino acids that is secreted into the blood where it circulates in a zymogen form. FVII comprises a 45 amino acid Gla domain (amino acids 61 through 105); a potentially calcium-binding 37 amino acid EGF-like domain (amino acids 106 through 142); a 42 amino acid EGF-like domain (amino acids 147 through 188) and a 240 amino acid serine peptidase domain (amino acids 213 through 452). In vitro, FVII can be proteolytically cleaved to form activated FVII, or FVIIa, by the action of activated coagulation factors Factor X (FXa), Factor IX (FIXa), Factor XII (FXIIa) or Factor II (FIIa). FVIIa does not promote coagulation by itself, but can complex with tissue factor (TF) exposed at the site of injury. The FVIIa/TF complex can convert FX to FXa, and FIX to FIXa, thereby inducing local hemostasis at the site of injury. Activation of FVII to FVIIa involves proteolytic cleavage at a single peptide bond between Arg-152 and Ile-153, resulting in a two-chain molecule consisting of a light chain of 152 amino acid residues and a heavy chain of 254 amino acid residues held together by a single disulfide bond. Persons with hemophilia may have normal levels of FVII. However, they suffer from a relative deficiency in FVIIa and other activated clotting factors.
- It is known that basal levels of Factor VIIa in plasma are greatly reduced in subjects with hemophilia B (Factor IX deficiency) and, to a lesser extent, subjects with hemophilia A (Factor VIII deficiency). Wildgoose et al., Blood 1:25-28 (1992). In the absence of activated FVIIa, the intrinsic blood clotting pathway involving FVII and FIX, is severely limited in effective coagulation. Recently, recombinant activated Factor VII (rFVIIa, NovoSeven®, Novo, Nordisk) has been shown to have therapeutic value to bypass or correct the coagulation defects in hemophilia A and B subjects with inhibitors, especially in subjects with inhibitors who were undergoing surgical procedures. NovoSeven® is a 406 amino acid glycoprotein that is structurally similar to plasma-derived FVIIa. However, recombinant FVIIa is expensive to manufacture. Another critical problem is the short half-life (2 hours) of recombinant FVIIa. Therefore, recombinant FVIIa therapy requires an intravenous infusion of high doses of the protein every 2 hours. Accordingly, sequences useful as the therapeutic agent in the present invention include sequences encoding FVII and FVIIa.
- In particular embodiments, the agent used herein can be a Factor VII or Factor VIIa peptide. In particular embodiments, the Factor VII peptide can contain one or more mutations to provide an enzymatic cleavage site, such as an enzymatic cleavage site susceptible to cleavage by SKI-1 or furin (e.g., U.S. Pat. No. 7,615,537).
- Advantages of using a VSA in association with a FVII (e.g., using a VSA-FVII fusion protein) include, e.g., extending the PK of the FVII. The extended PK can have advantages; for example, the FVII can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the FVII can be achieved.
- Coagulation Factor VIII (FVIII).
- In certain embodiments, the therapeutic agent is an FVIII (e.g., human FVIII) or a biologically active variant or fragment thereof. For example, Toole, U.S. Pat. No. 4,757,006 discloses the amino acid sequence of the full-length wild-type human FVIII, and for example, Toole, U.S. Pat. No. 4,868,112 discloses the amino acid sequence of human FVIII, wherein the B-domain has been deleted. FVIII, also commonly referred to as antihemophilic factor (AHF) is a large, 2351 amino acid protein that is processed into multiple chains in a complex manner, including a 19 amino acid signal peptide (
amino acids 1 to 19); a 1313 amino acid (amino acids 20 through 1332) or 740 amino acid (amino acids 20 through 759) light chain; a 573 amino acid B chain (amino acids 760 through 1332); and a 684 amino acid light chain (amino acids 1668 through 2351). Wood et al., Nature 312:330-37 (1984); Toole et al., Nature, 312:342-47 (1984); UniProt Accession No. P00451. AHF molecules have been approved as therapeutic treatments for subjects with hemophilia A (Recombinate®, Baxter Healthcare/Wyeth BioPharma; Advate®, Baxter Healthcare; Kogenate®, Bayer Healthcare; Xyntha® Wyeth Pharmaceuticals; Monoclate-P®, CSL Behring LLC). It has been found that the B-domain is not essential to activity, Pittman et al., Blood, 81:2925-35 (1993), and therefore, B-domain-deleted Factor VIII molecules have also been approved as a therapeutic treatment for hemophilia A (ReFacto®; Genetics Institute/Wyeth Pharmaceuticals). See, also, U.S. Pat. No. 7,572,619. Accordingly, sequences useful as the therapeutic agent in the present invention include sequences encoding FVIII and B-domain deleted FVIII. - FVIII and B-domain-deleted FVIII may be expressed and/or administered in conjunction with von Willebrand's Factor (VWF). VWF is a large (2,813 amino acid) protein comprising multiple repetitive domains which form multimers and acts as a chaperone protein for FVIII. Accession number P04275. VWF/FVIII complex has been approved as a therapeutic treatment for spontaneous or trauma-induced bleeding episodes in patients with moderate or severe von Willebrand Disease (Wilate®, Octapharma).
- Advantages of using a VSA in association with a FVIII (e.g., using a VSA-FVIII fusion protein) include, e.g., extending the PK of the FVIII. The extended PK can have advantages; for example, the FVIII can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the FVIII can be achieved.
- Coagulation Factor IX (FIX).
- In certain embodiments, the therapeutic agent is an FIX (e.g., a human FIX) or a biologically active variant or fragment thereof. Human FIX is a 461 amino acid secreted protein, including a 28 amino acid N-terminal signal peptide and an 18 amino acid propeptide. The protein comprises a 415 amino acid chain [amino acids 47 through 461]; or can be processed by human Factor XIa to form a 145 amino acid Factor IXa light chain [amino acids 47 through 191]; a 35 amino acid propeptide/activation peptide [amino acids 192 through 226]; and a 235 amino acid Factor IXa heavy chain [amino acids 227 through 461]. Kurachi and Davie, PNAS USA 79:6461-64 (1982); Anson et al., Nucleic Acids Res. 11:2325-35 (1983); UniProt Accession No. P00740.
Coagulation Factor 1× therapy has been approved as therapeutic treatment for subjects suffering from hemophilia B, including BeneFIX® (Wyeth); Mononine (Behring); and Alphanine (Grifols Biologics). Accordingly, sequences useful as the therapeutic agent in the present invention include sequences encoding FIX (below) and FIXa. -
[SEQ ID NO: 14] MQRVNMIMAE SPGLITICLL GYLLSAECTV FLDHENANKI LNRPKRYNSG KLEEFVQGNL ERECMEEKCS FEEAREVFEN TERTTEFWKQ YVDGDQCESN PCLNGGSCKD DINSYECWCP FGFEGKNCEL DVTCNIKNGR CEQFCKNSAD NKVVCSCTEG YRLAENQKSC EPAVPFPCGR VSVSQTSKLT RAETVFPDVD YVNSTEAETI LDNITQSTQS FNDFTRVVGG EDAKPGQFPW QVVLNGKVDA FCGGSIVNEK WIVTAAHCVE TGVKITVVAG EHNIEETEHT EQKRNVIRII PHHNYNAAIN KYNHDIALLE LDEPLVLNSY VTPICIADKE YTNIFLKFGS GYVSGWGRVF HKGRSALVLQ YLRVPLVDRA TCLRSTKFTI YNNMFCAGFH EGGRDSCQGD SGGPHVTEVE GTSFLTGIIS WGEECAMKGK YGIYTKVSRY VNWIKEKTKL T - Advantages of using a VSA in association with a FIX (e.g., using a VSA-FIX fusion protein) include, e.g., extending the PK of the FIX. The extended PK can have advantages; for example, the FIX can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the FIX can be achieved.
- Erythropoietin (EPO).
- In one embodiment, the therapeutic agent is an EPO (e.g., a human EPO) or a biologically active variant or fragment thereof. Human EPO is a 193 amino acid protein, including a 27 amino acid N-terminal signal peptide. (Uniprot Accession Number: P01588). For example, the therapeutic agent can have the ability to increase red blood cell production. EPO is an approved therapeutic for treatment of anemia, and is marketed as Epogen® (Amgen, Thousand Oaks, Calif.); Recormon® (Roche, South San Francisco, Calif.) and under a number of other marketed names. An exemplary amino acid sequence encoding human EPO is:
-
[SEQ ID NO: 15] MGVHECPAWL WLLLSLLSLP LGLPVLGAPP RLICDSRVLE RYLLEAKEAE NITTGCAEHC SLNENITVPD TKVNFYAWKR MEVGQQAVEV WQGLALLSEA VLRGQALLVN SSQPWEPLQL HVDKAVSGLR SLTTLLRALG AQKEAISPPD AASAAPLRTI TADTFRKLFR VYSNFLRGKL KLYTGEACRT GDR - Advantages of using a VSA in association with an EPO (e.g., using a VSA-EPO fusion protein) include, e.g., extending the PK of the EPO. The extended PK can have advantages; for example, the EPO can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the EPO can be achieved.
- Granulocyte Colony Stimulating Factor (G-CSF).
- In one embodiment, the therapeutic agent is a G-CSF (e.g., human G-CSF) or a biologically active variant or fragment thereof. Human G-CSF is a 207 amino acid protein, including a 29 amino acid N-terminal signal peptide. (Uniprot Accession No. P09919). For example, the therapeutic agent can have the ability to increase the level of neutrophils in the blood. G-CSF is an approved therapeutic for the treatment of neutropenia, that is low neutrophil levels, and is marketed as Neupogen® (Amgen); and as Granocyte® (Chugai, Turnham Green, UK). An exemplary amino acid sequence encoding human G-CSF is:
-
[SEQ ID NO: 16] MAGPATQSPM KLMALQLLLW HSALWTVQEA TPLGPASSLP QSFLLKCLEQ VRKIQGDGAA LQEKLVSECA TYKLCHPEEL VLLGHSLGIP WAPLSSCPSQ ALQLAGCLSQ LHSGLFLYQG LLQALEGISP ELGPTLDTLQ LDVADFATTI WQQMEELGMA PALQPTQGAM PAFASAFQRR AGGVLVASHL QSFLEVSYRV LRHLAQP - Advantages of using a VSA in association with an G-CSF (e.g., using a VSA-G-CSF fusion protein) include, e.g., extending the PK of the G-CSF. The extended PK can have advantages; for example, the G-CSF can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the G-CSF can be achieved.
- Interferon.
- In one embodiment, the therapeutic agent is an interferon (e.g., a human interferon) or a biologically active variant or fragment thereof. In some embodiments, the interferon is a human alpha interferon, beta interferon or gamma interferon. For example, the therapeutic can have antiviral, antibacterial or anticancer activities, and important immunoregulatory activity, such as activation of macrophages.
- Alpha interferons are a family of closely related proteins. Alpha interferon-2 is a 188 amino acid protein, including a 23 amino acid N-terminal signal peptide. (Uniprot Accession No. P01563). Alpha interferon-2 is an approved therapeutic for the treatment of various cancers, and is marketed as Roferon-A® (Roche); and Intron-A® (Schering-Plough). An exemplary amino acid sequence of human alpha interferon-2 is:
-
[SEQ ID NO: 17] MALTFALLVA LLVLSCKSSC SVGCDLPQTH SLGSRRTLML LAQMRKISLF SCLKDRHDFG FPQEEFGNQF QKAETIPVLH EMIQQIFNLF STKDSSAAWD ETLLDKFYTE LYQQLNDLEA CVIQGVGVTE TPLMKEDSIL AVRKYFQRIT LYLKEKKYSP CAWEVVRAEI MRSFSLSTNL QESLRSKE - Beta interferon is a 187 amino acid protein, including a 21 N-terminal amino acid signal peptide. (Uniprot Accession No. P01574). Beta interferon is an approved therapeutic for the treatment of multiple sclerosis, and is marketed as Avonex® (Biogen Idec, Cambridge, Mass.); Betaseron® (Berlex) and Rebif® (Ares-Serono). See also, Houghton et al., Nucleic Acids Res., 8:2885-94 (1980). An exemplary amino acid sequence of human beta interferon is:
-
[SEQ ID NO: 18] MTNKCLLQIA LLLCFSTTAL SMSYNLLGFL QRSSNFQCQK LLWQLNGRLE YCLKDRMNFD IPEEIKQLQQ FQKEDAALTI YEMLQNIFAI FRQDSSSTGW NETIVENLLA NVYHQINHLK TVLEEKLEKE DFTRGKLMSS LHLKRYYGRI LHYLKAKEYS HCAWTIVRVE ILRNFYFINR LTGYLRN - Gamma interferon is a 166 amino acid protein, including a 23 amino acid N-terminal signal peptide, and a 5 amino acid propeptide [residues 162-166]. (Uniprot Accession No. P01579). Gamma interferon is an approved therapeutic for the treatment of serious infections, such as those associated with chronic granulomatous disease, and is marketed as Actimmune® (Genentech). See also, Rinderknecht et al., J. Biol. Chem., 259:6790-97 (1984). An exemplary amino acid sequence of human gamma interferon is:
-
[SEQ ID NO: 19] MKYTSYILAF QLCIVLGSLG CYCQDPYVKE AENLKKYFNA GHSDVADNGT LFLGILKNWK EESDRKIMQS QIVSFYFKLF KNFKDDQSIQ KSVETIKEDM NVKFFNSNKK KRDDFEKLTN YSVTDLNVQR KAIHELIQVM AELSPAAKTG KRKRSQMLFR GRRASQ - Advantages of using a VSA in association with an interferon (e.g., using a VSA-interferon fusion protein) include, e.g., extending the PK of the interferon. The extended PK can have advantages; for example, the interferon can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the interferon can be achieved.
- Cytokine Antagonists.
- In some embodiments, the therapeutic agent is an antagonist of cytokine signaling, e.g., an antagonist of interleukin or interferon signaling. For example, the therapeutic agent is an IL-1 receptor antagonist (IL-1ra) such as Kineret® (Amgen) or a variant thereof (see, e.g., U.S. Pat. No. 6,599,873). Human IL-1Ra is a 177 amino acid protein, including a 25 amino acid N-terminal signal peptide (Uniprot Accession No. P018510). IL1-Ra is an approved therapeutic for rheumatoid arthritis. An exemplary IL-1 receptor antagonist (IL-1ra) includes the following human amino acid sequence:
-
[SEQ ID NO: 20] MEICRGLRSH LITLLLFLFH SETICRPSGR KSSKMQAFRI WDVNQKTFYL RNNQLVAGYL QGPNVNLEEK IDVVPIEPHA LFLGIHGGKM CLSCVKSGDE TRLQLEAVNI TDLSENRKQD KRFAFIRSDS GPTTSFESAA CPGWFLCTAM EADQPVSLTN MPDEGVMVTK FYFQEDE - In some embodiments, the antagonist is a variant cytokine can be a cytokine with altered function, e.g., a dominant negative cytokine. Exemplary variant cytokines include IL-17 molecules described in WO2011/044563 and IL-23 molecules described in WO2011/011797.
- Advantages of using a VSA in association with a cytokine antagonist (e.g., using a VSA-cytokine antagonist fusion protein) include, e.g., extending the PK of the cytokine antagonist. The extended PK can have advantages; for example, the cytokine antagonist can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the cytokine antagonist can be achieved.
- Urate Oxidase
- In one embodiment, the therapeutic agent is a urate oxidase, also known as uricase, or a biologically active variant or fragment thereof. An exemplary urate oxidase sequence is the sequence from Aspergillus flavus:
-
[SEQ ID NO: 21] MSAVKAARYG KDNVRVYKVH KDEKTGVQTV YEMTVCVLLE GEIETSYTKA DNSVIVATDS IKNTIYITAK QNPVTPPELF GSILGTHFIE KYNHIHAAHV NIVCHRWTRM DIDGKPHPHS FIRDSEEKRN VQVDVVEGKG IDIKSSLSGL TVLKSTNSQF WGFLRDEYTT LKETWDRILS TDVDATWQWK NFSGLQEVRS HVPKFDATWA TAREVTLKTF AEDNSASVQA TMYKMAEQIL ARQQLIETVE YSLPNKHYFE IDLSWHKGLQ NTGKNAEVFA PQSDPNGLIK CTVGRSSLKS KL - Both humans and certain other primates lack a naturally occurring urate oxidase protein, presumably due to an adaptive evolution. (Wu et al., PNAS USA, 86:9412-16 (1989)). However, many mammalian species of urate oxidase are known, including pig (Uniprot Accession No. P16164); cynomogus monkey (Uniprot Accession No. Q8 MHW6); baboon (Uniprot Accession No. P25689); rabbit (Uniprot Accession No. P011645); rat (Uniprot Accession No. P09118); and mouse (Uniprot Accession No. P25688). Urate oxidase catalyzes the oxidation or uric acid to 5-hydroxyisourate, leading to increased solubility and renal excretion, which can prevent symptoms of gout. Urate oxidase is an approved therapeutic for the treatment of hyperuricaemia, and is marketed as Rasburicase® (recombinant uricase from aspergillus flavus produced in saccharomyces cerevisiae; Sanofi-Aventis) or Krystexxa® (recombinant pegylated chimeric uricase, sequence from pig/baboon, produced in saccharomyces cerevisiae, Savient Pharmaceuticals, Inc.). These products have been reported to be immunogenic, which can limit the ability to treat patients repeatedly. For this reason, the approaches provided herein can have additional advantages in that the VSA can serve to prevent or impede the native immune system from readily accessing the biologically active uricase moiety, and thereby can reduce or prevent the formation of antibodies to the biologically active uricase moiety after administration.
- Advantages of using a VSA in association with a urate oxidase (e.g., using a VSA-urate oxidase fusion protein) include, e.g., extending the PK of the urate oxidase. The extended PK can have advantages; for example, the urate oxidase can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the urate oxidase can be achieved.
- C-Natriuretic Peptide (CNP).
- In one embodiment, the therapeutic agent is a CNP (e.g., human CNP) or a biologically active variant or fragment thereof. Human CNP is a 126 amino acid protein, including a 23 amino acid N-terminal signal peptide; a 50 amino acid propeptide (amino acids 24-73); and a 53 amino acid CNP-53 peptide (amino acids 74-126). The 53 amino acid CNP-53 peptide may be further processed to a 29 amino acid CNP-29 peptide (amino acids 98-126) or a 22 amino acid CNP-22 peptide (amino acids 105-126) (Uniprot Accession No. P23582). An exemplary amino acid sequence encoding human CNP is:
-
[SEQ ID NO: 22] MHLSQLLACA LLLTLLSLRP SEAKPGAPPK VPRTPPAEEL AEPQAAGGGQ KKGDKAPGGG GANLKGDRSR LLRDLRVDTK SRAAWARLLQ EHPNARKYKG ANKKGLSKGC FGLKLDRIGS MSGLGC - CNP has been implicated in a number of physiological processes, including vasorelaxant with powerful venodilator effects, exhibiting the ability to reduce mean arterial pressure, atrial pressure and cardiac output in mammals; dose-dependent relaxant effects on bronchial smooth muscle and pulmonary arterial relaxation; and can also have involvement in neurotransmission. See, Barr et al., Peptides 17:1243-51 (1996).
- Advantages of using a VSA in association with a CNP (e.g., using a VSA-CNP fusion protein) include, e.g., extending the PK of the CNP. The extended PK can have advantages; for example, the CNP can be administered less frequently and/or at reduced concentrations and/or more consistent delivery levels of the CNP can be achieved.
- A variety of molecular biology techniques can be used to design nucleic acid constructs encoding a protein that includes a serum albumin or a domain thereof. The nucleic acid sequences can be any sequences that code for the VSA of interest. For example, a nucleic acid sequence can be based on a known sequence that enclodes a corresponding native (e.g., wild type) serum albumin. For example, a sequence that encodes a wild type albumin can be that corresponding to UniProt DB Accession No. P02768, e.g., ENI database sequence V00494.1 (www.ebi.ac.uk/ena/data/viewN00494).
- The coding sequence can include, e.g., a sequence encoding a protein described herein, a variant of such sequence, or a sequence that hybridizes to such sequences. An exemplary coding sequence for mammalian expression can further include an intron. Coding sequences can be obtained, e.g., by a variety of methods including direct cloning, PCR, and the construction of synthetic genes. Various methods are available to construct useful synthetic genes, see, e.g., the GeneArt® GeneOptimizer® from Life Technologies, Inc. (Carlsbad, Calif.), Sandhu et. al. (2008) In Silico Biology 8: 0016; Gao et al. (2004) Biotechnol Prog, 20: 443-8; Cai et al. (2010) J Bioinformatics Sequence Analysis 2: 25-29; and Graf et al (2000), J Virol 74: 10822-10826.
- The coding sequence generally employs one or more codons according to the codon tables for eukaryotic or prokaryotic expression. A coding sequence can be generated with specific codons (e.g., preferred codons) and/or one or more degenerate codons. A possible set of degenerate codons is set forth in the table below.
-
TABLE 1 Amino Degen- acid Code Codons erate Cys C TGC TGT TGY Ser S AGC AGT TCA TCC TCG TCT WSN Thr T ACA ACC ACG ACT ACN Pro P CCA CCC CCG CCT CCN Ala A GCA GCC GCG GCT GCN Gly G GGA GGC GGG GGT GGN Asn N AAC AAT AAY Asp D GAC GAT GAY Glu E GAA GAG GAR Gln Q CAA CAG CAR His H CAC CAT CAY Arg R AGA AGG CGA CGC CGG CGT MGN Lys K AAA AAG AAR Met M ATG ATG Ile I ATA ATC ATT ATH Leu L CTA CTC CTG CTT TTA TTG YTN Val V GTA GTC GTG GTT GTN Phe F TTC TTT TTY Tyr Y TAC TAT TAY Trp W TGG TGG Stop • TAA TAG TGA TRR - The degenerate codon can be representative of all possible codons encoding each amino acid, but may not always be unambiguous. For example, the degenerate codon for serine (WSN) can, in some circumstances, encode arginine (AGR), and the degenerate codon for arginine (MGN) can, in some circumstances, encode serine (AGY). A similar relationship exists between codons encoding phenylalanine and leucine. Thus, some polynucleotides encompassed by the degenerate sequence may encode variant amino acid sequences, but one of ordinary skill in the art can easily identify such variant sequences by reference to the amino acid sequences disclosed herein. Variant sequences can be readily tested for functionality as described herein.
- In some embodiments, the coding sequence includes one or more preferred codons for the cell in which it is to be expressed. Generally preferred codons are those that are translated most efficiently and can include the codons that are most frequently used by cells of the species in question. Each species can exhibit its own codon preferences. See, e.g. Gustafsson et al. (2004) Trends in Biotechnol. 22:346-353; Grantham et al. (1980) Nuc. Acids Res. 8:1893 912; Haas et al. (1996) Curr. Biol. 6:315 24; Wain-Hobson et al. (1981) Gene 13:355 64; Grosjean and Fiers (1982) Gene 18:199 209; Holm (1986) Nuc. Acids Res. 14:3075 87; Ikemura (1982) J. Mol. Biol. 158:573 97. For example, the amino acid threonine (Thr) can be encoded by ACA, ACC, ACG, or ACT. In mammalian cells, ACC is the most commonly used Thr codon, whereas different Thr codons may be preferred in other species. Preferred codons for a particular species can be introduced into coding sequences by a variety of methods, including direct cloning, PCR mutagenesis, and the construction of synthetic genes. Introduction of preferred codon sequences into recombinant DNA can increase translational efficiency. In some embodiments, at least 10, 20, 30, 50, 60, 70, or 80% of the codons in a coding sequence are preferred codons. Sequences containing preferred codons can be constructed, and tested for expression in various species.
- A protein described herein, such as a protein containing a serum albumin domain described herein, can be expressed in bacterial, yeast, plant, insect, or mammalian cells.
- Exemplary mammalian host cells for recombinant expression include Chinese Hamster Ovary (CHO cells) (including dhfr-CHO cells, described in Urlaub and Chasin (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220, used with a DHFR selectable marker, e.g., as described in Kaufman and Sharp (1982) Mol. Biol. 159:601-621), lymphocytic cell lines, e.g., NS0 myeloma cells and SP2 cells, COS cells, K562, and a cell from a transgenic animal, e.g., a transgenic mammal. For example, the cell can be a mammary epithelial cell.
- Coding nucleic acid sequences can be maintained in recombinant expression vectors that include additional nucleic acid sequences, such as a sequence that regulate replications of the vector in host cells (e.g., origins of replication) and a selectable marker gene. The selectable marker gene facilitates selection of host cells into which the vector has been introduced. Exemplary selectable marker genes appropriate for mammalian cells include the dihydrofolate reductase (DHFR) gene (for use in dhfr host cells with methotrexate selection/amplification) and the neo gene (for G418 selection).
- Within the recombinant expression vector, the coding nucleic acid sequences can be operatively linked to transcriptional control sequences (e.g., enhancer/promoter regulatory elements) to drive high levels of transcription of the genes. Examples of eukaryotic transcriptional control sequences include the metallothionein gene promoter, promoters and enhancers derived from eukaryotic viruses, such as SV40, CMV, adenovirus and the like. Specific examples include sequences including a CMV enhancer/AdMLP promoter regulatory element or an SV40 enhancer/AdMLP promoter regulatory element.
- An exemplary recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection/amplification. The selected transformant host cells are cultured to allow for expression of the protein.
- An adenovirus system can also be used for protein production. By culturing adenovirus-infected non-293 cells under conditions where the cells are not rapidly dividing, the cells can produce proteins for extended periods of time. For instance, BHK cells are grown to confluence in cell factories, and exposed to the adenoviral vector encoding the secreted protein of interest. The cells are then grown under serum-free conditions, which allows infected cells to survive for several weeks without significant cell division. In another method, adenovirus vector-infected 293 cells can be grown as adherent cells or in suspension culture at relatively high cell density to produce significant amounts of protein (See Garnier et al., (1994) Cytotechnol. 15:145-55, and Liu et al., (2009) J. Bioscience and Bioengineering, 107:524-529). The expressed, secreted heterologous protein can be repeatedly isolated from the cell culture supernatant, lysate, or membrane fractions depending on the disposition of the expressed protein in the cell. Within the infected 293 cell production protocol, non-secreted proteins can also be effectively obtained.
- Insect cells can be infected with recombinant baculovirus, commonly derived from Autographa californica nuclear polyhedrosis virus (AcNPV) according to methods known in the art. Recombinant baculovirus can be produced through the use of a transposon-based system described by Luckow et al. (J. Virol. 67:4566-4579, 1993). This system, which utilizes transfer vectors, is commercially available in kit form (Bac-to-Bac™ kit; Life Technologies, Rockville, Md.). An exemplary transfer vector (e.g., pFastBac1™ Life Technologies) contains a Tn7 transposon to transfer the DNA encoding the protein of interest into a baculovirus genome maintained in E. coli as a bacmid. See, Condreay et al., (2007) Current Drug Targets 8:1126-1131. In addition, transfer vectors can include an in-frame fusion with DNA encoding a polypeptide extension or affinity tag as disclosed above. Using techniques known in the art, a transfer vector containing nucleic acid sequence encoding a variant serum albumin fusion is transformed into E. coli host cells, and the cells are screened for bacmids which contain an interrupted lacZ gene indicative of recombinant baculovirus. The bacmid DNA containing the recombinant baculovirus genome is isolated, using common techniques, and used to transfect Spodoptera frugiperda cells, such as Sf9 cells. Recombinant virus that expresses a protein containing a serum albumin domain is subsequently produced. Recombinant viral stocks are made by methods commonly used the art.
- For protein production, the recombinant virus is used to infect host cells, typically a cell line derived from the fall armyworm, Spodoptera frugiperda (e.g., Sf9 or Sf21 cells) or Trichoplusia ni (e.g., High Five™ cells; Invitrogen, Carlsbad, Calif.). See, for example, U.S. Pat. No. 5,300,435. Serum-free media are used to grow and maintain the cells. Suitable media formulations are known in the art and can be obtained from commercial suppliers. The cells are grown up from an inoculation density of approximately 2−5×105 cells to a density of 1−2×106 cells, at which time a recombinant viral stock is added at a multiplicity of infection (MOI) of 0.1 to 10, more typically near 3. Procedures used are generally known in the art.
- Other higher eukaryotic cells can also be used as hosts, including plant cells and avian cells. Agrobacterium rhizogenes can be used as a vector for expressing genes in plant cells. See e.g., O'Neill et al. (2008) Biotechnol. Prog. 24:372-376.
- Fungal cells, including yeast cells, can also be used within the present invention. Yeast species of particular interest in this regard include Saccharomyces cerevisiae, Hansenula polymorpha, Kluyveromyces lactis, Pichia pastoris, and Pichia methanotica. Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g., leucine). Production of recombinant proteins in Pichia methanolica is described, e.g., in U.S. Pat. No. 5,716,808, U.S. Pat. No. 5,736,383, U.S. Pat. No. 5,854,039, and U.S. Pat. No. 5,888,768.
- The binding protein is recovered from the culture medium and can be purified. Various methods of protein purification can be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzymology, 182 (1990); and Scopes, Protein Purification: Principles and Practice, Springer-Verlag, New York (2010) (ISBN: 1441928332). Purified variant serum albumin fusion proteins can be concentrated using standard protein concentration techniques.
- Exemplary of purification procedures include: ion exchange chromatography, size exclusion chromatography, and affinity chromatography as appropriate. For example, variant serum albumin fusion proteins can be purified with a HSA affinity matrix.
- To prepare the pharmaceutical composition a variant serum albumin fusion protein is typically at least 10, 20, 50, 70, 80, 90, 95, 98, 99, or 99.99% pure and typically free of other proteins including undesired human proteins and proteins of the cell from which it is produced. It can be the only protein in the composition or the only active protein in the composition or one of a selected set of purified proteins. Purified preparations of a variant serum albumin fusion protein described herein can include at least 50, 100, 200, or 500 micrograms, or at least 5, 50, 100, 200, or 500 milligrams, or at least 1, 2, or 3 grams of the binding protein. Accordingly, also featured herein are such purified and isolated forms of the binding proteins described herein. The term “isolated” refers to material that is removed from its original environment (e.g., the cells or materials from which the binding protein is produced).
- In some embodiments described herein, a VSA is associated with an agent (e.g., a diagnostic or therapeutic agent), e.g., for the purpose of improving a functional property (e.g., extending the PK) of the agent. In some embodiments, the VSA is physically attached to the agent. The VSA can be directly attached to the agent or it can be attached to the agent via a linker.
- In some embodiments, a heterologous protein that comprises a VSA and an additional agent (e.g., a diagnostic or therapeutic agent) is made using recombinant DNA techniques. In some embodiments, the VSA is produced (e.g., using recombinant DNA techniques) and subsequently linked to the agent, e.g., by chemical means.
- A variety of linkers can be used to join a polypeptide component of an agent to domain III or a variant serum albumin. The linker can be a molecule or group of molecules (such as a monomer or polymer) that connects two molecules and optionally to place the two molecules in a particular configuration. Exemplary linkers include polypeptide linkages between N- and C-termini of proteins or protein domains, linkage via disulfide bonds, and linkage via chemical cross-linking reagents.
- In some embodiments, the linker includes one or more peptide bonds, e.g., generated by recombinant techniques or peptide synthesis. The linker can contain one or more amino acid residues that provide flexibility. In some embodiments, the linker peptide predominantly includes the following amino acid residues: Gly, Ser, Ala, and/or Thr. The linker peptide should have a length that is adequate to link two molecules in such a way that they assume the correct conformation relative to one another so that they retain the desired activity. Suitable lengths for this purpose include at least one and not more than 30 amino acid residues. For example, the linker is from about 1 to 30 amino acids in length. A linker can also be, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 amino acids in length.
- Exemplary linkers include glycine-serine polymers (including, for example, (GS)n, (GSGGS)n, (SEQ ID NO: 23), (GGGGS)n (SEQ ID NO: 24) and (GGGS)n (SEQ ID NO: 25), where n is an integer of at least one, e.g., one, two, three, or four), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers. Glycine-serine polymers can serve as a neutral tether between components. Secondly, serine is hydrophilic and therefore able to solubilize what could be a globular glycine chain. Third, similar chains have been shown to be effective in joining subunits of recombinant proteins such as single chain antibodies. Suitable linkers can also be identified from three-dimensional structures in structure databases for natural linkers that bridge the gap between two polypeptide chains. In some embodiments, the linker is from a human protein and/or is not immunogenic in a human. Thus linkers can be chosen such that they have low immunogenicity or are thought to have low immunogenicity. For example, a linker can be chosen that exists naturally in a human. In certain embodiments the linker has the sequence of the hinge region of an antibody, that is the sequence that links the antibody Fab and Fc regions; alternatively the linker has a sequence that comprises part of the hinge region, or a sequence that is substantially similar to the hinge region of an antibody. Another way of obtaining a suitable linker is by optimizing a simple linker, e.g., (Gly4Ser)n (SEQ ID NO: 24), through random mutagenesis. Alternatively, once a suitable polypeptide linker is defined, additional linker polypeptides can be created to select amino acids that more optimally interact with the domains being linked. Other types of linkers include artificial polypeptide linkers and inteins. In another embodiment, disulfide bonds are designed to link the two molecules. Other examples include peptide linkers described in U.S. Pat. No. 5,073,627, the disclosure of which is hereby incorporated by reference. In certain cases, the diagnostic or therapeutic protein itself can be a linker by fusing tandem copies of the peptide to a variant serum albumin polypeptide. In certain embodiments, charged residues including arginine, lysine, aspartic acid, or glutamic acid can be incorporated into the linker sequence in order to form a charged linker.
- In another embodiment, linkers are formed by bonds from chemical cross-linking agents. For example, a variety of bifunctional protein coupling agents can be used, including but not limited to N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate, iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as
tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). Chemical linkers can enable chelation of an isotope. For example, C14 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody (see PCT WO 94/11026). - The linker can be cleavable, facilitating release of a payload, e.g., in the cell or a particular milieu For example, an acid-labile linker, peptidase-sensitive linker, dimethyl linker or disulfide-containing linker (Chari et al., Cancer Research 52:127-131 (1992)) can be used. In some embodiments, the linker includes a non-proteinaceous polymer, e.g., polyethylene glycol (PEG), polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol and polypropylene glycol.
- In one embodiment, the variant serum albumin fusion of the present invention is conjugated or operably linked to another therapeutic compound, referred to herein as a conjugate. The conjugate can be a cytotoxic agent, a chemotherapeutic agent, a cytokine, an anti-angiogenic agent, a tyrosine kinase inhibitor, a toxin, a radioisotope, or other therapeutically active agent. Chemotherapeutic agents, cytokines, anti-angiogenic agents, tyrosine kinase inhibitors, and other therapeutic agents have been described above, and all of these aforementioned therapeutic agents can find use as variant serum albumin fusion conjugates. In an alternate embodiment, the variant serum albumin fusion is conjugated or operably linked to a toxin, including but not limited to small molecule toxins and enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof. Small molecule toxins include but are not limited to calicheamicin, maytansine (U.S. Pat. No. 5,208,020), trichothene, and CC1065. In one embodiment of the invention, the variant serum albumin fusion is conjugated to one or more maytansine molecules (e.g. about 1 to about 10 maytansine molecules per antibody molecule). Maytansine can, for example, be converted to May-SS-Me which can be reduced to May-SH3 and reacted with a variant serum albumin fusion (Chari et al., 1992, Cancer Research 52: 127-131) to generate a maytansinoid-antibody or maytansinoid-Fc fusion conjugate. Another conjugate of interest comprises a variant serum albumin fusion conjugated to one or more calicheamicin molecules. The calicheamicin family of antibiotics are capable of producing double-stranded DNA breaks at sub-picomolar concentrations. Structural analogues of calicheamicin that can be used include but are not limited to γ1 1, α2 1, αalpha3, N-acetyl-γ1 1, PSAG, and θ1 1, (Hinman et al., 1993, Cancer Research 53:3336-3342; Lode et al., 1998, Cancer Research 58:2925-2928) (U.S. Pat. No. 5,714,586; U.S. Pat. No. 5,712,374; U.S. Pat. No. 5,264,586; U.S. Pat. No. 5,773,001).
Dolastatin 10 analogs such as auristatin E (AE) and monomethylauristatin E (MMAE) can find use as conjugates for the variant serum albumin fusions of the present invention (Doronina et al., 2003, Nat Biotechnol 21:778-84; Francisco et al., 2003 Blood 102:1458-65). Useful enzymatically active toxins include but are not limited to diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes. See, for example, PCT WO 93/21232. The present invention further contemplates a conjugate or fusion formed between a variant serum albumin fusion of the present invention and a compound with nucleolytic activity, for example a ribonuclease or DNA endonuclease such as a deoxyribonuclease (DNase). - In an alternate embodiment, a variant serum albumin fusion of the present invention can be conjugated or operably linked to a radioisotope to form a radioconjugate. A variety of radioactive isotopes are available for the production of radioconjugate variant serum albumin fusions. Examples include, but are not limited to, At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32 and radioactive isotopes of Lu.
- Binding of a serum albumin or a domain thereof to FcRn can be evaluated in vitro, e.g., by surface plasmon resonance, (see, e.g., Example 2), ELISA (see, e.g., Example 4) or other binding assay known in the art.
- FcRn can be produced as a single chain molecule, e.g., in CHO cells. An exemplary method for producing single chain FcRn is described in Feng et al., Protein Expression and Purification, 79:66-71 (2011).
- The half-life of a protein that includes serum albumin or a domain thereof in vivo can be evaluated in a mammal, e.g., a murine model that includes a human FcRn. See e.g., Example 3. For example, the protein that is evaluated can be a protein that includes serum albumin or a domain thereof and a therapeutic agent.
- To assess the activity of an agent (e.g., a therapeutic agent) that is associated with a VSA as described herein, methods known in the art for testing the activity of the agent can be used. The following description provides examples of such methods.
- Assays for Testing the Activity of a FVII
- Examples of assays that can be used to test the activity of a FVII entity are known in the art. The following exemplary coagulation assays are adapted from Wildgoose et al., Blood, 80:25-28 (1992). All plasma factor VIIa levels are measured in a one-stage clotting assay using an ACL300R automated coagulation instrument which can be purchased from Instrumentation Laboratories (Ascoli Piceno, Italy). Test samples are diluted fivefold in 0.1 mol/L NaCl10.05 mol/L Tris-HCl/0.1% BSA pH 7.4 (TBSIBSA) and mixed with an equal volume of hereditary factor VII deficient plasma to yield a total volume of 100 pL. Each aliquot is subsequently incubated for 5 minutes at 37° C. with 50 KL of bovine phospholipids (Thrombofax). Coagulation is then initiated by the addition of a 100-kL aliquot of 10 nmol/L TF1.218 diluted in 12.5 mmol/L CaCl2/0.1 mol/L NaCl/0.05 mol/L Tris/1% BSA pH 7.4. Coagulation times are subsequently converted to factor VIIa concentration (nanograms per milliliter) by comparison to a standard curve constructed with varying concentrations (0.05 to 50 ng/mL) of purified recombinant factor VIIa diluted in TBS/BSA.
- Venipunctures are performed atraumatically and blood samples drawn into citrated vacutainers. The citrated samples are centrifuged for 15 minutes at 1,200×g after which time the plasma is removed with a plastic pipette and stored at −80° C. Normal plasma samples are collected from 10 fasting and 10 nonfasting individuals who have a negative history for bleeding as well as thrombosis and are not taking any medications at the time of sample collection. Samples are obtained from 13 severe hemophilia A and seven hemophilia B subjects (<1% FV1II:C and <1% FIXC). Subjects are excluded from the study if they have received factor concentrates, cryoprecipitate, and/or antifibrinolytics within the previous 48 hours.
- The following assay is adapted from Silveira et al., Arteriosclerosis and Thrombosis, 14:60-69 (1994). Coagulation factor VII is assessed in plasma samples drawn before ingestion of the test meal and 3, 6, and 12 hours thereafter. Factor VIIc is determined as described in van Deijk et al., Haemostasis, 13:192-97 (1983) in an LODE coagulometer (Groningen, the Netherlands). Briefly, 100pL of diluted plasma sample, 100/xh of factor Vll-deficient plasma (Helena Laboratories, Beaumont, Tex.), and 100 μL of human brain thromboplastin (prepared according to Owren and Aas, Scand J. Clin Lab Invest 3:201-18 (1951) are incubated together at 37° C. for 30 seconds. Calcium, 100 μL of a 33 mmol/L solution, is added and the clotting time recorded. Factor VIIa is determined with either Thrombotest (a bovine brain thromboplastin preparation that also contains adsorbed bovine plasma; Nyegaard & Co, Oslo, Norway) (VIIa:A) or bovine brain thromboplastin (Diagnostic Reagents Ltd, Thames, Oxon, UK) (VIIa:B) in clotting assays that are otherwise essentially as described above. Factor VII amidolytic activity (VIIam) is determined with a commercially available kit (Coa-Set FVII; Chromogenix, M61ndal, Sweden). Factor VII antigen (VII:Ag) concentration is determined with an enzyme immunoassay kit (Novoclone Factor VII EIA kit, Novo Nordic A/S, Bagsvaerd, Denmark). Results are expressed in units per milliliter, one unit being the amount or activity of factor VII present in 1 mL of a standard pooled plasma. Ratios of VIIa:B to VIIc and of VIIa:B to VII:Ag are also calculated for evaluation of the activity state of factor VII in plasma. Control experiments are performed to rule out the possibility of a direct effect of high plasma concentrations of TG-rich lipoproteins on the factor VII levels obtained in the different assays. An
Sf 20 to 400 lipoprotein fraction is isolated from blood that had been drawn from a healthy control subject 3 hours after intake of a fat load. Addition of this lipoprotein fraction to control plasma to afinal plasma level 500% of normal does not influence factor VII measurements. - Additional examples of clotting assays that can be adapted for use to assess the activity of a FVII in association with a VSA are described in the following publications: Broze and Majerus, J. Biol. Chem. 255:1242-47 (1980); Morrissey et al., Blood, 81:734-44 (1993); Herzog et al., Nature Medicine, 5:56-63 (1999); and Sorensen and Ingerslav, J. Thrombosis and Haemostasis, 2:102-110 (2004).
- Several significant factors can be assayed to evaluate a subject for iron overload and/or risk of iron overload. First, serum iron levels can be used as an indicator of iron overload. Tests include the serum ferritin test. A subject can be considered to be suffering from iron overload if their serum iron levels are in excess of about 350 μg/dL (mild iron toxicity); generally in excess of about 500 μg/dL (serious iron toxicity). A subject is considered to be at risk of iron overload if their serum iron levels are high normal or above normal ranges. Normal iron range is considered to be from about 40 to about 220 μg/dL; for example, from about 50 to about 160 μg/dL for adult males. Normal iron ranges for adult females are approximately 5 to 10 percent lower than that for adult males. ‘High normal’ iron concentration is considered to be in the upper quarter (25%) of the normal range; generally in the upper tenth (10%) of the normal range. See, Jacobs & DeMott, Laboratory Test Handbook, 5th ed., (LexiComp Inc, Hudson, Ohio)(2001) at p. 203-205). As is known to those skilled in the art, ‘normal ranges’ of iron and iron binding capacity can vary depending upon the specific laboratory and test. Other parameters that can be used to evaluate a patient for iron overload and/or risk of overload include: measurement of hepcidin levels (see U.S. Pat. No. 7,998,691); genetic testing for the presence of mutations in one or more genes related to hemochromatosis, such as juvenile hemochromatosis (HFE2A and HFE2B genes) (see U.S. Pat. No. 8,080,651)
- Assays for Assessing the Activity of a GLP-1
- Culture of BRIN-BD11 Cells.
- BRIN-BD11 cells are cultured in RPMI-1640 tissue culture medium containing 10% (v/v) foetal calf serum, 1% (v/v) antibiotics (100 U/ml penicillin, 0.1 mg/ml streptomycin), and 11.1 mM glucose. BRIN-BD11 cells are produced by electrofusion of a New England Deaconess Hospital (NEDH) rat pancreatic β-cell with RINm5F cell to produce and immortal, glucose sensitive cell line which is described in detail elsewhere. McClenaghan et al., Diabetes (1996) 45:1132-40. All cells are maintained in sterile tissue culture flasks (Corning Glass Works, Sunderland, UK) at 37° C. in an atmosphere of 5% CO2 and 95% air using a LEEC incubator (Laboratory Technical Engineering, Nottingham, UK). [Green et al., Id.]
- Stimulation of Adenylate Cyclase.
- BRIN-BD11 cells are seeded into 24-well plates (3×105/well) and cultured for 48 h before being pre-incubated in media supplemented with tritiated adenine (2 mCi) for 16 h. The cells are washed twice with cold Hanks' buffered saline (HBS) and test solution (400 μl; 37° C.) is added. The cells are then exposed to varying concentrations (10−10-10−5M) of GLP-1 glycopeptides in HBS buffer, in the presence of 1 mM IBMX and 5.6 mM glucose (20 min; 37° C.). Following incubation, test solutions are removed and 300 μl of lysis solution (5% TFA, 3% SDS, 5 mM of unlabelled ATP, and 300 μM of unlabelled cAMP) is added. Dowex and alumina exchange resins are used to separate tritiated cAMP from tritiated adenine and ATP in the cell lysate, as described previously. [Miguel et al., Biochem Pharm. (2003) 65:283-92]. The highest concentration of GLP-1 (10−5 M) is used as a maximum. Each peptide is tested by single experiment (n=3) which incorporated an internal control incubation of GLP-1 (60 nM) to ensure consistency and accuracy. [Green et al., Id.]
- Insulin Secretory Responses in the Pancreatic β-Cell.
- BRIN-BD11 cells are seeded into 24-multiwell plates at a density of 1×105/well, and allowed to attach during overnight culture. Acute studies of insulin release are preceded by a 40 minute pre-incubation at 37° C. in 1.0 ml Krebs-Ringer bicarbonate buffer (115 mM NaCl, 4.7 mM KCl, 1.28 mM CaCl2.2H2O, 1.2 mM KH2PO4, 1.2 mM MgSO4.7H2O, 10 mM NaHCO3, and 5 g/L bovine serum albumin, pH 7.4) supplemented with 1.1 mM glucose. Test incubations are performed at 37° C. in the presence of 5.6 mM glucose with a range of concentrations of GLP-1 glycopeptides (10−12-10−6M). After a 20 minute incubation, the buffer is removed from each well and aliquots are stored at −20° C. for measurement of insulin. [Green et al., Id.]
- Glucose-Lowering and Insulin Secretory Activity in Obese Diabetic (Ob/Ob) Mice.
- The in vivo biological activity of variant serum albumin/GLP-1 fusion proteins can be assessed in 12-16 week old obese diabetic (ob/ob) mice. The animals are housed individually in an air-conditioned room at 22±2° C. with a 12 hour light:12 hour dark cycle. Animals are allowed drinking water ad libitum and continuous access to standard rodent maintenance diet (Trouw Nutrition, Cheshire, UK). Mice are fasted for 18 hours and intraperitoneally administered 8 ml/kg body weight with saline (9 g/L NaCl), glucose alone (18 mM/kg body weight), or in combination with GLP-1 or a variant serum albumin/GLP-1 fusion protein (25 nM/kg body weight). Blood samples are collected into chilled fluoride/heparin microcentrifuge tubes (Sarstedt, Numbrecht, Germany) immediately prior to injection and at 15, 30, and 60 minutes post injection, and the plasma obtained is stored at −20° C. All animal studies are carried out in accord with the UK Animals (Scientific Procedures) Act 1986 [Green et al., Id.] or other applicable laws.
- Analyses and Statistics.
- Plasma glucose levels are determined using an Analox glucose analyser (Hammersmith, London, UK), which employs the glucose oxidase method. Insulin levels are assayed by dextran-coated charcoal radioimmunoassay. Incremental areas under plasma glucose and insulin curves (AUC) are calculated using GraphPad PRISM version 3.0 (Graphpad Software, San Diego, Calif., USA), which employs the trapezoidal rule. Results are expressed as means±SEM and data are compared as appropriate using Student's t test, repeated measures ANOVA or one-way ANOVA, followed by the Student-Newman-Keuls post hoc test. Groups of data are considered significantly different if P<0.05.
- Measurement of Binding Affinity and cAMP Production.
- Binding affinity is assessed by measuring the inhibition of radiolabeled GLP-1 binding to human GLP-1 receptor-expressing chinese hamster ovary (CHO) cell membrane. Cell membrane fractions (5 μg) are incubated with 62 pM [125I]GLP-1 and variant serum albumin/GLP-1 fusion protein (final conc. 10-11 to 10-6 M) in 25 mM HEPES (pH 7.4) containing 5 mM MgCl, 1 mM CaCl2, 0.25 mg/mL bacitracin, and 0.1% bovine serum albumin (BSA) at room temperature for 2 hours (100 μL). Membranes are filtered onto a 96-well GF/C plate (PerkinElmer, Inc.) that had been presoaked in 1% polyethylenimine containing 0.5% BSA, and then washed with 25 mM HEPES buffer containing 0.5% BSA (pH 7.4). Radioactivity associated with the lysates is determined using a gamma counter. Nonspecific binding is determined by the amount of binding in the presence of 1 μM unlabeled GLP-1. Dose-response curves are plotted for the individual compounds. IC50 values are calculated using XLfit software (IDBS Inc.). For measurement of cAMP production, human GLP-1 receptor expressing CHO cells are passaged into multiwell plates (4000 cells/well) and cultured for an additional 48 h. The cells are washed with assay buffer (Hanks balanced salt solution containing 20 mM HEPES, 0.1% BSA, pH 7.4) and then exposed to variant serum albumin/GLP-1 fusion proteins (final conc. 10-12 to 10-6 M) in assay buffer containing 0.33 mM isobutylmethylxanthine and 0.67 mM RO20-1724 at room temperature for 1 h. The cells are lysed with 1% Triton X-100, and the cAMP formed is measured using a cAMP femtomolar kit (Cis Bio international). Dose-response curves are plotted for the individual compounds. EC50 values are calculated using XLfit software. [Ueda et al., J. ACS, 2009 131:6237-45]
- Characterization of Stability Against Recombinant Human DPP-IV.
- GLP-1 or variant serum albumin/GLP-1 fusion protein (20-500 μM) is incubated at 37° C. in 100 mM HEPES buffer containing 0.05% Tween80 and 1 mM EDTA-2Na (pH 7.5) with 0.33 μg/mL, 0.66 μg/mL (19), or 1.32 μg/mL recombinant human DPP-IV (60 μL). At 5 or 10 min intervals, 7 μL is removed from the reaction mixture, and the reaction is terminated by the addition of 28 μL of 8 M GuHCl solution. The reaction products are subjected to RP-HPLC on a Develosil RPAQUEOUS-AR-3 2.0°—100 mm at 30° C., and the C-terminal degradation product is quantified by using UV absorption at 210 nm. The initial rate of the degradation reaction is determined from the slope of the linear part obtained by plotting product concentration versus time. The resulting initial rates are plotted versus peptide concentration, and kinetic parameters (KM and KM/kcat) are determined using XLfit software based on the Michaelis-Menten kinetic equation. [Ueda et al., Id.]
- Characterization of Stability Against Recombinant Human NEP 24.11.
- The 125 μM GLP-1 or variant serum albumin/GLP-1 fusion protein is incubated at 37° C. in 50 mM HEPES buffer containing 50 mM NaCl, and 0.05
% Tween 80 with 4 μg/mL recombinant human NEP 24.11 (pH 7.4, 84 μL). After 0.5, 1, 2, 3.5, and 5 h, 8 μL is removed from the reaction mixture, and the reaction is terminated by addition of 32 μL of 8 M GuHCl solution. The reaction products are subjected to RP-HPLC on a Develosil ODSHG-54.6°-150 mm at 30° C., and the area of intact variant serum albumin/GLP-1 fusion protein is measured using UV absorption at 210 nm. [Ueda et al., Id.] - Blood Glucose-Lowering Activity in Obese Diabetic Db/Db Mice.
- Male BKS.Cg-+Leprdb/+Leprdb mice (13-15 weeks of age) are allowed ad libitum access to food and water until the start of the experiment. At t) −2 h, access to food is restricted, and the tip of the tail is cut. At t) 0 min, a 1 μL blood sample is collected Immediately thereafter, each mouse is injected subcutaneously with test sample (100 nmol/kg) or vehicle, and additional blood samples are collected. The vehicle is saline containing 1% BSA. Blood glucose levels are measured with a glucose oxidase biosensor (DIAMETERR; Arkray, Inc.). The effects of the test samples on blood glucose are expressed as % change relative to the respective pretreatment (t) 0 min) level. The number of mice tested is 6-7 for each group. Data are presented as means (SEM. Statistical differences are analyzed using the Dunnett's multiple comparison test, and P values less than 0.05 are regarded as significant. [Ueda et al., Id.]
- Assays for Assessing Uric Acid/Gout
- Methods for assessing uric acid levels and/or function as well as gout are known in the art. Methods for measurements of uric acid, e.g., in urine can be employed, as disclosed, e.g., in Ballesta-Clayer et al., Analytica Chimica Acta, 702:254-61 (2011) and WO 2000/08207.
- Therapeutic Administration of a VSA Composition
- In certain embodiments, a VSA composition (a composition comprising a VSA or a VSA associated therapeutic agent) is administered in a therapeutically effective amount to a subject to treat a disease or condition, or ameliorate one or more symptoms of a disease or condition. Methods for delivering a therapeutic composition are known in the art and can be used to administer a VSA composition e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells that can expressing the VSA compound, receptor-mediated endocytosis (e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432). Methods of introduction can be enteral or parenteral, including but not limited to, intradermal, transdermal, intramuscular, intraperitoneal, intravenous, subcutaneous, pulmonary, intranasal, intraocular, epidural, topical, intramuscular, subcutaneous, intravenous, intravascular, and intrapericardial administration and oral routes. A VSA composition can also be administered, for example, by infusion or bolus injection, by absorption through epithelial or mucosa (e.g., oral mucosa, rectal, or intestinal mucosa) and can be administered together with other biologically active agents. Administration can be systemic or local. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent. In certain aspects, the disclosure provides a composition comprising the HSA variant or the chimeric polypeptide of the disclosure, and a pharmaceutically acceptable carrier. In certain embodiments, VSA composition is delivered locally to an area in need of treatment (e.g., muscle); this may be achieved, for example, by local infusion, topical application, by injection, by catheter, or by implant (e.g., an implant of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, fibers, or commercial skin substitutes). In some embodiments, a VSA composition is delivered in a vesicle such as a liposome (see Langer, 1990, Science 249: 1527-1533), a controlled release system, or with a pump (see Langer, 1990, supra), or using polymeric materials can be used (see Howard et al, 1989, J. Neurosurg. 71: 105).
- Further illustration of the invention is provided by the following non-limiting examples.
- cDNA encoding mature human serum albumin was cloned into a modified version of the pYC2/CT yeast expression vector (Invitrogen) containing a Trp marker, app8 leader peptide (see Rakestraw et al., Biotechnology and Bioengineering, 103:1192-1201 (2009) for leader sequence), and N-terminal His6 tag (SEQ ID NO: 26) and Factor Xa cleavage site. Point mutations, either alone or in combination, were introduced by Quikchange® mutagenesis (Agilent). The vector was transformed into BJ5α S. cerevisiae cells using the EZ-yeast kit (Zymo Research) and transformants selected on SDCAA+ura plates (2% glucose, 0.67% yeast nitrogen base, 0.5% casamino acids, 0.54% Na2PO4, 0.86% NaH2PO4.H2O, 18.2% sorbitol, 1.5% agar, and 40 mg/L uracil). Selected colonies were grown in 5 mL liquid SDCAA+ura overnight at 30° C. with shaking at 250 RPM. The 5 mL overnight culture was diluted into 50 mL SDCAA+ura in a 250 mL baffled flask and grown at 30° C./250 RPM to an OD600˜5. Cells were then pelleted at 3000 RPM and resuspended in 50 mL YPG media (2% galactose, 2% peptone, 1% yeast extract, 0.54% Na2PO4, 0.86% NaH2PO4.H2O) to induce albumin expression. After 48 hours in YPG at 20° C./250 RPM, the cells were pelleted at 3000 RPM and the cleared supernatant filter sterilized. The secreted human serum albumin was purified by affinity chromatography using either Ni-NTA resin (Invitrogen), CaptureSelect HSA affinity resin (BAC), or Vivapure anti-HSA kit (Sartorius-Stedin). Eluted protein was buffer exchanged into PBS by several rounds of concentration and dilution using Amicon Ultra-15 spin concentrators with a 10 kDa cutoff (Millipore). Protein purity was assessed by SDS-PAGE and concentration determined by absorbance at 280.
- For single-chain FcRn production, DNA encoding human beta-2 microglobulin fused to the extracellular domain of human FcRn heavy chain through a (G4S)3 linker (SEQ ID NO: 27) was synthesized by DNA2.0. The scFcRn DNA was cloned into a modified version of the pcDNA3.1(+) vector (Invitrogen) containing an IL-2 leader sequence and C-terminal FLAG tag by standard digestion and ligation. 80 mL of Freestyle-CHO-S cells (Invitrogen) at 1×106 cells/mL were transiently transfected with scFcRn-FLAG using the Freestyle®-MAX reagent (Invitrogen) according to manufacturer's instructions. Transfected cells were incubated at 37° C., 8% CO2, with shaking at 130 rpm for 6 days. The supernatant was clarified by centrifugation and the scFcRn-FLAG protein purified on a 0.5 mL M2 anti-FLAG agarose gravity-flow column (Sigma). Bound protein was eluted with 100 mM glycine-HCl, pH 3.5 and exchanged into PBS, pH 7.4 by several rounds of concentration and dilution using Amicon Ultra-15 spin concentrators with a 10 kDa cutoff (Millipore). Protein purity was assessed by SDS-PAGE and concentration determined by absorbance at 280.
- A library of albumin variants with random mutations in domain III was generated and displayed on the surface of yeast. FACS selections were performed to enrich for variants with improved binding to soluble FcRn at pH 5.6. After three to four rounds of selection, a population was identified with significantly increased binding compared to a wild type human serum albumin (HSA). Twelve clones from the population after sort three and eight clones from the population after sort four were cloned and sequenced. The sequence alignments revealed mutations appearing in multiple clones after sort four: K402E (2/8), V424I (2/8), P447L/S (3/8), E492G (3/8), E505G (5/8) and V547 (6/8).
- Populations after sorts three, four, five and six were also sequenced to identify other enriched mutations and the following mutations were identified: V418M, T420A, V424I, N429D, M446V, A449V, T467M, E505G/K/R, A552T, V547A.
- After round seven, the library had enriched to a single clone with the following mutations: V418M, T420A, E505R, V424I, and N429D.
- These data demonstrate a method for identifying mutations that can be useful for modulating FcRn binding. Further selection can be carried out by identifying mutations located near residues involved in FcRn binding, e.g., near His residues, for example H510 and H535. These data also demonstrate specific sites in an HSA useful for modulating the PK of an albumin molecule.
- SPR was used to characterize binding of the selected variants to human FcRn at pH values from 5.5 to 7.5. An exemplary apparatus that can be used is a Reichert SR7000C® machine. FLAG-tagged, single-chain human FcRn was immobilized on a 500,000 Da carboxymethyl dextran chip by NHS/EDC chemistry. Unconjungated sites were blocked with 1 M ethanolamine. A reference channel was generated in parallel with no FcRn. HSA variants at concentrations of 1 nM-100 μM were injected at a flow rate of 50 μL/min and the difference in signal between the FcRn channel and reference channel was recorded over time to assess association. Wash buffer (PBS+0.01% Tween-20) was flowed through the channels to assess dissociation. Experiments were repeated at pH 5.5, 6.0, 6.5, and 7.4 to assess the pH dependency of binding. The results are shown in
FIG. 1 . The VSAs that were used are described in Example 5. These results demonstrate that affinity of certain VSAs to FcRn at pH 5.5 had increased, as did the affinity of some of these to FcRn at pH 7.4. In particular, HSA-5 and HSA-7 bound FcRn at pH 5.5 (a typical endosomal pH), but not at pH 7.4 (a typical pH of blood). In each case, the pH dependence of FcRn binding as known for native albumin was preserved. - These data demonstrate that VSAs can be generated that have increased affinity for FcRn at endosomal pH without significantly altering the affinity for FcRn at a neutral pH (e.g., a pH associated with blood).
- PK studies were performed for selected variants in human FcRn mice to determine the effect of FcRn affinity on plasma clearance. The mouse strains 4919 and 14565 from Jackson Laboratories are homozygous for mouse FcRn knockout and either hemi- or homozygous for human FcRn knock-in. Selected HSA variants were injected intravenously into such mice and bleeds were collected at various time intervals. The plasma concentration of the HSA at each time point was assessed using a non-mouse cross-reactive HSA ELISA and plotted to calculate clearance rates and plasma AUC.
- ELISA studies were performed to characterize the binding of selected HSA variants to human FcRn at pH values of 5.5-7.4. Purified HSA variants at 1 μg/mL in PBS were immobilized in a 96 well flat bottom EIA plate (Costar 9018) at 4° C. overnight. Coated wells were then blocked with 200 μL PBS+2% fish gelatin, pH 7.4 for 2 hours at room temperature. After blocking, wells were washed 3× with 200 μL PBS+0.1% Tween-20 at the appropriate pH (5.5-7.4). 100 μL of FLAG-tagged single-chain FcRn diluted to concentrations of 50 pM-200 nM in PBS+0.1% fish gelatin at pH 5.5-7.4 was added to each well and incubated for 2 hours at room temperature. Wells were then washed 3× with 200 μL PBS+0.1% Tween-20 at the appropriate pH. 100 μL of anti-FLAG-HRP (Sigma) diluted 1:1000 in PBS+0.1% fish gelatin at pH 5.5-7.4 was added to each well and incubated for 60 minutes at room temperature. Wells were washed as above and 100 μL TMB substrate (Pierce) added to each well. Color development was stopped after two minutes with 2 M sulfuric acid and the signal read at absorbance 450-550 on a Spectramax M5 plate reader.
- Experiments were carried out in which thet binding of various VSAs and HSA to FLAG-tagged FcRn was assessed at different pHs. Results demonstrated a range of affinities for the VSAs, which were tested at pH 5.5, pH 6.0, and pH 7.4 for binding to 0.2 nM to 200 nM FcRn-FLAG. A table summarizing the results of such an experiment is shown in
FIG. 2 . The VSAs had KDs from 3 nM to >100 nM at pH 5.5. Wild type HSA is known to have a KD of about 1-2 μM at pH 5.5. Many of the VSAs, including HSA-15, HSA-13, HSA-12, HSA-7, HSA-21, HSA-11, HSA-2, HSA-14, HSA-5, HSA-10, HSA-6, HSA-9, and HSA-18 had improved affinity for FcRn compared with wild type HSA. Additional related information, including the mutations present in the VSAs, is provided in Example 5, infra. The data ofFIG. 3 demonstrate that the binding of these VSAs to FcRn, as assessed by ELISA, preserved the pH dependence of native albumin (greater binding at pH 5.5 than at pH 7.4). - These data demonstrate that VSAs with modified affinity compared to wild type HSA can be generated and provide guidance for generation of additional VSAs with increased affinity of FcRn at selected pHs.
- The amino acid sequence of
Domain 3 of human serum albumin has the following sequence: -
[SEQ ID NO: 28] LVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSR NLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCC TESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQ TALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKL VAASQAALGL - Exemplary human serum albumin variants that were prepared include the sequences in the following table:
-
TABLE 2 Human Serum Albumin Variants and FcRn Binding FcRn BINDING AMINO ACID VARIATIONS FROM [Kd@pH 5.5] VARIANT DOMAIN 3 OF WILD-TYPE Compared to NUMBER HUMAN SERUM ALBUMIN WT-HSA hsa-1 WT - Full Length HSA ± hsa-2 K573Y +++ hsa-3 WT - Domain 3 of HSA± hsa-4 E492G ± hsa-5 V547A ++ hsa-6 E505G + hsa-7 E505G; V547A ++++ hsa-8 V418M ± hsa-9 T420A + hsa-10 V418M; T420A ++ hsa-11 V418M; T420A; E505G +++ hsa-12 V418M; T420A; V547A ++++ hsa-13 V418M; T420A; E505G; V547A +++++ hsa-14 V418M; T420A; E505G; M446V; +++ A449V; T467M; A552T hsa-15 V418M; T420A; V424I; N429D E505R +++++ hsa-16 E505R ± hsa-17 E505K ± hsa-18 V241I ± hsa-19 N429D ± hsa-20 M446V; A449V ± hsa-21 V418M; T420A; E505R ++++ hsa-22 A552T ± hsa-23 PBS [Negative Control] ± - All of the variants described in Table 2, with the exception of HSA-3, are full length HSA (sequence corresponding to SEQ ID NO:2) with the indicated mutations (numbering of the mutations is based on SEQ ID NO:2). As indicated in Table 2, HSA-3 is
Domain 3 only of HSA with the sequence corresponding to SEQ ID NO:22. In subsequent experiments,domain 3 only versions of HSA-5 and HSA-13 were also made; these versions also demonstrated improved affinity. - The experiments described in this example illustrate experimental difficulties that were involved in accurately identifying serum albumin mutants that exhibit improved pharmacokinetics (e.g., increased half-life and reduced clearance) and show how these difficulties were effectively overcome.
- The anti-HSA sandwich ELISA utilized in the mouse PK studies is unable to detect HSA spiked into cynomolgus monkey plasma due to the high homology of human and monkey albumin. Therefore, we developed a novel assay utilizing an epitope tag genetically fused to albumin and an anti-tag capture antibody. HSA variants with a FLAG tag, His tag, HA tag, or c-myc tag were expressed in yeast, purified, and titrated in their respective anti-tag ELISA assays in 10% monkey plasma. Both the FLAG tag and HA tag were detected in their respective assays with high sensitivity (EC50=10 ng/mL for HA, 50 ng/mL for FLAG).
- In a first cynomolgus monkey PK study, FLAG-tagged HSA-wt, HSA-5, HSA-7, HSA-11, and HSA-13 were administered into two monkeys each as a 5 mg/kg iv bolus dose. To control for monkey to monkey variability and directly test for tag-specific effects on PK, a 1 mg/kg dose of HA-tagged HSA-wt was co-dosed into each animal. Bleeds were drawn at 15 minutes, 2 hours, 6 hours, 1 day, 2 days, 5 days, 9 days, 12 days, 16 days, and 21 days, and HSA concentrations were measured by both anti-FLAG and anti-HA ELISAs. A comparison of the PK traces for the FLAG-tagged HSA's (both wild-type and mutant) with the HA-tagged HSA-wt internal control indicated that the FLAG-tagged proteins were cleared at a significantly faster rate, particularly in the alpha phase. To confirm the more rapid clearance of the FLAG-tagged protein, a study was performed in which HA- and FLAG-tagged HSA-wt and HSA-7 were injected into mice. Bleeds were drawn as before and at each time point, the concentration of tagged HSA was measured with both an anti-HSA ELISA and anti-tag ELISA. For HA-HSA-wt and HA-HSA-7, the anti-HSA and anti-HA ELISA's measured HSA concentrations consistent with each other and with previous measurement of untagged HSA in mice suggesting that the HA tag accurately reflected the concentration of plasma HSA. In contrast, the anti-FLAG ELISA measured a significantly lower concentration of FLAG-HSA compared to the anti-HSA ELISA confirming that the tag was cleaved or obscured in a way that distorted the HSA measurement.
- HSA variant binding to mouse FcRn was measured in an ELISA in which recombinant mouse FcRn (R&D Systems, cat#6775-FC-050) was directly immobilized on a Costar Maxisorp® plate. After blocking for 3 hours with PBS+4% fish gelatin, HSA variants at concentrations of 500 nM to 685 μM in PBS+0.1% Tween+0.1% fish gelatin, pH 5.5 were added to each well and incubated for 2.5 hours at RT. Bound HSA was detected with a HRP conjugated goat anti-HSA antibody. The rank order of binding affinity was HSA-13>HSA-7>HSA-11>HSA-5>HSA-wt.
- To test whether the in vitro quality of increased affinity corresponds to improved pharmacokinetics (PK) in vivo, selected examples of VSAs, e.g., HSA-5, HSA-11, and HSA-13 and wild type HSA were injected into wild type mice and the plasma concentration monitored over time (to about 170 hours after administration).
- In wild type mice, increased affinity in a serum albumin extended its pharmacokinetics (see
FIG. 4 ). The VSAs exhibited a longer half-life and a reduced clearance compared with wild type HSA. The observed improvement in pharmacokinetic properties was correlated with the affinities observed in ELISA experiments that tested the affinities of these VSAs for mouse FcRn. In particular, greater affinity for mouse FcRn was associated with longer half-life and reduced clearance. The highest affinity variant HSA-13 had the most extended PK. - The results obtained in the human-FcRn transgenic mice are shown in
FIG. 5 . In these mice, the relationship between affinity for FcRn and PK was more complex; the VSAs with the highest affinity for human FcRn did not show the greatest improvement in pharmacokinetics. - Taken in combination, the data from experiments in mice with VSAs indicate that the optimal FcRn affinity for PK extension is determined by a tradeoff between improved endosomal recycling at pH 5.5 and increased surface binding at pH 7.4. In wild type mice, in which wild type HSA binds FcRn weakly (Kd ˜80 μM), the highest affinity variant HSA-13 had the most extended PK. In human-FcRn transgenic mice, in which wild type HSA binds FcRn with higher affinity (Kd˜21.1M), HSA-13 and HSA-11 bound FcRn too tightly at pH 7.4 (see also
FIG. 1 ), driving rapid clearance and a robust antibody response (seeFIG. 5 ). Medium affinity variants HSA-5 and HSA-7 which have minimal pH 7.4 binding (see alsoFIG. 1 ) have extended PK in the FcRn transgenic mouse, as shown inFIG. 5 . It should be noted that mouse albumin has a high affinity for human FcRn so it is reasonable to expect that a murine model under predicts the improvement that would be observed in humans. Therefore, selection of VSAs suitable for use in humans should not be tested solely in a murine model. - To evaluate the PK of a VSA in a primate model, cynomologus monkeys were injected with an iv bolus dose of 1 mg/kg or 5 mg/kg dose of HSA-7 or wild type HSA (HSA-wt). Two monkeys were analyzed per group by assaying plasma HSA concentration over time using an anti-epitope tag ELISA.
-
FIG. 6 provides the PK parameters of this experiment, demonstrating that the VSA (HSA-7) has a longer plasma half-life and reduced beta phase clearance in a primate model. - When fused to a heterologous polypeptide, protein moieties that extend half-life often do not extend half-life to the same absolute degree as seen with the unfused moiety. This is usually due to active clearance mediated by the heterologous partner. Because it is not clear whether active clearance provides an absolute maximum to the extension seen, or whether the half-life of a fusion is a combination in some way of the half-lives of the two components, we compared wild type HSA fused to IL-2 with a VSA fused to IL-2. Fusion proteins in which human IL-2 is genetically fused to the N- or C-terminus of a selected HSA variant were produced as follows. For N-terminal fusions, cDNA encoding mature human IL-2 was PCR amplified with a 5′ primer that introduces 20-40 by of homology with the app8 yeast leader sequence and a 3′ primer that introduces a (G4S)3 linker (SEQ ID NO: 27) followed by 20-40 by of homology with the N-terminus of mature HSA. For C-terminal fusions, the human IL-2 cDNA was PCR amplified with a 5′ primer that introduces 20-40 by of homology with the C-terminus of HSA followed by a (G4S)3 linker (SEQ ID NO: 27) and a 3′ primer that introduces 20-40 by of homology with the stop codon and downstream sequence of the pYC2/CT vector. In both cases, a Quikchange® mutagenesis reaction (Agilent) was then performed in which a selected HSA variant was used as the template and the IL-2 PCR product was used in place of the primers. DpnI treated reactions were transformed into XL-1 Blue E. coli cells (Agilent) and selected on LB+Amp plates. Selected colonies were miniprepped and sequenced. In place of wild type human IL-2 cDNA, DNA encoding a variant of IL-2, such as those described in U.S. Pat. Nos. 7,569,215 and 7,951,360, can be fused to the selected HSA variant.
- Plasmids encoding the desired fusion sequence were transformed into BJ5α S. cerevisiae cells using the EZ-yeast kit (Zymo Research) and transformants selected on SDCAA+ura plates. Selected colonies were grown in liquid SDCAA+ura media at 30° C. with shaking at 250 RPM to an OD600-5. Cells were then pelleted at 3000 RPM and resuspended in YPG media to induce albumin expression. After 48 hours in YPG at 20° C./250 RPM, the cells were pelleted at 3000 RPM and the cleared supernatant filter sterilized. The secreted fusion protein was purified by affinity chromatography using CaptureSelect® HSA affinity resin (BAC).
- Both mouse and human IL-2 fused to the N-terminus of HSA-wt or HSA-13 through a (G4S)2 linker were also cloned into the pLVX-Puro mammalian expression plasmid. Fusion sequences were amplified by PCR using primers that introduced an N-terminal XhoI site and C-terminal MluI site. The PCR product and pLVX-Puro plasmid were both double digested with XhoI/MluI in
NEBuffer 3+BSA and ligated with the Quick Ligation kit (New England Biolabs) according to manufacturer's instructions. Plasmids were transiently transfected in Hek-293 cells using PEI as a transfection reagent and cultured for 4-7 days at 37° C./8% CO2. - Transient transfections were performed in Hek-293 cells to express HSA, IL-2-GS10-HSA, IL-2-GS25-HSA, hepcidin-GS10-HSA, or factor VII-GS10-HSA. Expressed proteins were evaluated using non-reducing SDS-PAGE. All of the tested proteins were expressed and run on the gel in a manner consistent with their expected molecular weights. Subsequently, products of such transient transfections were purified using an anti-HSA resin. Purified products (murine IL-2-HSA wild type and IL-2-HSA-13) were injected iv into mice at a dose of 0.5 mg/kg. The VSA fusion (i.e., HSA-13 fusion) extended the PK of IL-2 to a greater degree than did the fusion to wild type HSA (shown in
FIG. 7 ). The IL2-HSA-13 fusion protein had increased half-life, greater AUC, and reduced clearance. - These data demonstrate that a VSA as described herein can be used to improve the PK of another agent, e.g., a therapeutic protein, e.g., IL-2.
- The skilled artisan, having read the above disclosure, will recognize that numerous modifications, alterations of the above, and additional optimization of the above, may be conducted while remaining within the scope of the invention. These include but are not limited to the embodiments that are within the scope of the following claims.
Claims (52)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/358,857 US20140315817A1 (en) | 2011-11-18 | 2012-11-18 | Variant serum albumin with improved half-life and other properties |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161561785P | 2011-11-18 | 2011-11-18 | |
US201161576491P | 2011-12-16 | 2011-12-16 | |
US201261710476P | 2012-10-05 | 2012-10-05 | |
US14/358,857 US20140315817A1 (en) | 2011-11-18 | 2012-11-18 | Variant serum albumin with improved half-life and other properties |
PCT/US2012/065733 WO2013075066A2 (en) | 2011-11-18 | 2012-11-18 | Proteins with improved half-life and other properties |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/065733 A-371-Of-International WO2013075066A2 (en) | 2011-11-18 | 2012-11-18 | Proteins with improved half-life and other properties |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/989,985 Continuation US10711050B2 (en) | 2011-11-18 | 2018-05-25 | Variant serum albumin with improved half-life and other properties |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140315817A1 true US20140315817A1 (en) | 2014-10-23 |
Family
ID=47295197
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/358,857 Abandoned US20140315817A1 (en) | 2011-11-18 | 2012-11-18 | Variant serum albumin with improved half-life and other properties |
US15/989,985 Active US10711050B2 (en) | 2011-11-18 | 2018-05-25 | Variant serum albumin with improved half-life and other properties |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/989,985 Active US10711050B2 (en) | 2011-11-18 | 2018-05-25 | Variant serum albumin with improved half-life and other properties |
Country Status (4)
Country | Link |
---|---|
US (2) | US20140315817A1 (en) |
EP (1) | EP2780364A2 (en) |
HK (1) | HK1200842A1 (en) |
WO (1) | WO2013075066A2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9238080B2 (en) | 2010-05-21 | 2016-01-19 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
US20160122713A1 (en) * | 2014-10-14 | 2016-05-05 | Medgenics Medical Israel Ltd. | Genetically-modified micro-organ secreting a therapeutic peptide and methods of use thereof |
US10040840B2 (en) | 2015-10-02 | 2018-08-07 | Silver Creek Pharmaceuticals, Inc. | Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue |
US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
US10329340B2 (en) | 2012-03-16 | 2019-06-25 | Albumedix Ltd | Albumin variants |
US10501524B2 (en) | 2012-11-08 | 2019-12-10 | Albumedix Ltd | Albumin variants |
US10548954B2 (en) | 2010-07-09 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor IX polypeptides and methods of use thereof |
US10633428B2 (en) | 2015-08-20 | 2020-04-28 | Albumedix Ltd | Albumin variants and conjugates |
US10696732B2 (en) | 2009-10-30 | 2020-06-30 | Albumedix, Ltd | Albumin variants |
US10711050B2 (en) | 2011-11-18 | 2020-07-14 | Albumedix Ltd | Variant serum albumin with improved half-life and other properties |
WO2022040375A1 (en) * | 2020-08-19 | 2022-02-24 | Energesis Pharmaceuticals, Inc. | Analogs of human fibroblast growth factors |
US11466073B2 (en) * | 2017-10-18 | 2022-10-11 | Csl Limited | Human serum albumin variants and uses thereof |
US11555061B2 (en) | 2009-02-11 | 2023-01-17 | Albumedix, Ltd | Albumin variants and conjugates |
US11642398B2 (en) | 2013-03-15 | 2023-05-09 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3063171B1 (en) | 2013-11-01 | 2019-07-24 | University Of Oslo | Albumin variants and uses thereof |
AU2015294834B2 (en) | 2014-07-31 | 2021-04-29 | Amgen Research (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody constructs |
WO2016025645A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
EP3180018B1 (en) | 2014-08-12 | 2019-07-24 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein |
DK3283524T3 (en) | 2015-04-17 | 2023-05-30 | Amgen Res Munich Gmbh | BISPECIFIC ANTIBODY CONSTRUCTIONS AGAINST CDH3 and CD3 |
TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for egfrviii and cd3 |
TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for cd70 and cd3 |
TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for flt3 and cd3 |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
TW202346349A (en) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for dll3 and cd3 |
CA3005953A1 (en) | 2015-12-22 | 2017-06-29 | Albumedix Ltd | Improved protein expression strains |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
WO2017214945A1 (en) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | Lentiviral expression vector for improving hepcidin gene expression level and application thereof |
CN110337590A (en) | 2016-11-04 | 2019-10-15 | 奥胡斯大学 | The identification and treatment of tumour characterized by neonatal Fc receptor is overexpressed |
CA3049656A1 (en) | 2017-01-10 | 2018-07-19 | Nodus Therapeutics | Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator |
US10350266B2 (en) | 2017-01-10 | 2019-07-16 | Nodus Therapeutics, Inc. | Method of treating cancer with a multiple integrin binding Fc fusion protein |
US10961310B2 (en) | 2017-03-15 | 2021-03-30 | Pandion Operations, Inc. | Targeted immunotolerance |
WO2018217989A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
ES2906997T3 (en) | 2017-06-20 | 2022-04-21 | Albumedix Ltd | Enhanced protein expression strains |
AU2018311079B2 (en) | 2017-08-03 | 2022-06-23 | Amgen Inc. | Interleukin-21 muteins and methods of treatment |
US11485781B2 (en) | 2017-08-17 | 2022-11-01 | Massachusetts Institute Of Technology | Multiple specificity binders of CXC chemokines |
IL293443A (en) | 2017-09-08 | 2022-07-01 | Amgen Inc | Inhibitors of kras g12c and methods of using the same |
DK3717011T3 (en) | 2017-11-29 | 2023-01-09 | Csl Ltd | METHOD FOR TREATING OR PREVENTING ISCHEMA-REPERFUSION INJURY |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
JP2019122373A (en) | 2018-01-12 | 2019-07-25 | アムジエン・インコーポレーテツド | Anti-pd-1 antibodies and methods of treatment |
BR112020016454A8 (en) | 2018-02-12 | 2022-08-16 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | TREATMENT USING RNA ENCODING CYTOKINE |
CN112118859A (en) | 2018-05-16 | 2020-12-22 | 杰特有限公司 | Type 1 soluble complement receptor variants and uses thereof |
MX2021000801A (en) | 2018-07-24 | 2021-04-12 | BioNTech SE | Il2 agonists. |
MA53330A (en) | 2018-08-03 | 2021-06-09 | Amgen Inc | ANTIBODY CONSTRUCTIONS FOR CLDN18.2 AND CD3 |
WO2020049151A1 (en) | 2018-09-06 | 2020-03-12 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
BR112021004383A2 (en) | 2018-09-28 | 2021-08-03 | Massachusetts Institute Of Technology | immunomodulatory fusion protein, pharmaceutical composition, nucleic acid, expression vector, transformed cell, method for producing an immunomodulatory fusion protein, method for activating, enhancing or promoting a response by an immune cell in a subject, method for inhibiting, reducing or suppressing a response by an immune cell in a subject, method of reducing or inhibiting tumor growth, method of treating cancer in a subject, kit, use of an immunomodulatory fusion protein, and method of reducing or inhibiting tumor growth or treat cancer in a subject |
WO2020154032A1 (en) | 2019-01-23 | 2020-07-30 | Massachusetts Institute Of Technology | Combination immunotherapy dosing regimen for immune checkpoint blockade |
US20220125836A1 (en) | 2019-02-08 | 2022-04-28 | Biontech Cell & Gene Therapies Gmbh | Treatment involving car-engineered t cells and cytokines |
SG11202108857SA (en) | 2019-03-18 | 2021-09-29 | Biontech Cell & Gene Therapies Gmbh | Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells |
WO2020200481A1 (en) | 2019-04-05 | 2020-10-08 | Biontech Rna Pharmaceuticals Gmbh | Treatment involving interleukin-2 (il2) and interferon (ifn) |
JP2022533702A (en) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | MAdCAM-targeted immune tolerance |
TW202115105A (en) | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Rna製藥有限公司 | Il2 agonists |
JP2022538974A (en) | 2019-06-26 | 2022-09-07 | マサチューセッツ インスチテュート オブ テクノロジー | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
WO2021058091A1 (en) | 2019-09-24 | 2021-04-01 | Biontech Rna Pharmaceuticals Gmbh | Treatment involving therapeutic antibody and interleukin-2 (il2) |
EP3819007A1 (en) | 2019-11-11 | 2021-05-12 | Amgen Research (Munich) GmbH | Dosing regimen for anti-bcma agents |
US20230000774A1 (en) | 2019-12-04 | 2023-01-05 | Albumedix Limited | Methods and compositions produced thereby |
WO2021129927A1 (en) | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
WO2021129945A1 (en) | 2019-12-27 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins) |
EP4093771A1 (en) | 2020-01-22 | 2022-11-30 | Amgen Research (Munich) GmbH | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
EP4107187A1 (en) | 2020-02-21 | 2022-12-28 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
TW202200615A (en) | 2020-03-12 | 2022-01-01 | 美商安進公司 | Method for treatment and prophylaxis of crs in patients |
JP2023516201A (en) | 2020-03-12 | 2023-04-18 | バヴァリアン・ノルディック・アクティーゼルスカブ | Compositions that improve the stability of poxviruses |
AU2021238582A1 (en) | 2020-03-16 | 2022-09-22 | Biontech Cell & Gene Therapies Gmbh | Antigen-specific T cell receptors and T cell epitopes |
WO2021197589A1 (en) | 2020-03-31 | 2021-10-07 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination |
US20220017636A1 (en) | 2020-05-19 | 2022-01-20 | Amgen Inc. | Mageb2 binding constructs |
US20230312715A1 (en) | 2020-09-04 | 2023-10-05 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding protein constructs with human serum albumin domains |
CA3194771A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
CN116635421A (en) | 2020-11-06 | 2023-08-22 | 安进公司 | Polypeptide constructs that bind CD3 |
KR20230098335A (en) | 2020-11-06 | 2023-07-03 | 암젠 인크 | Antigen binding domains with reduced clipping ratio |
IL302586A (en) | 2020-11-06 | 2023-07-01 | Amgen Res Munich Gmbh | Polypeptide constructs selectively binding to cldn6 and cd3 |
WO2022103781A1 (en) | 2020-11-10 | 2022-05-19 | Amgen Inc. | Methods for administering a bcma x cd3 binding molecule |
CA3198138A1 (en) * | 2020-11-10 | 2022-05-19 | Craig RAMIREZ | Macropinocytosis selective monobody-drug conjugates |
TW202245808A (en) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | Therapeutic rna for treating cancer |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
CA3215103A1 (en) | 2021-04-12 | 2022-10-20 | Steffen Panzner | Rna compositions comprising a buffer substance and methods for preparing, storing and using the same |
CA3215771A1 (en) | 2021-04-20 | 2022-10-27 | BioNTech SE | Virus vaccine |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
AU2021470029A1 (en) | 2021-10-21 | 2024-05-02 | BioNTech SE | Coronavirus vaccine |
EP4238577A3 (en) | 2021-10-22 | 2023-12-06 | BioNTech SE | Compositions for administration of different doses of rna |
WO2023083434A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection |
WO2023126053A1 (en) | 2021-12-28 | 2023-07-06 | BioNTech SE | Lipid-based formulations for administration of rna |
WO2023165681A1 (en) | 2022-03-01 | 2023-09-07 | BioNTech SE | Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer |
WO2023193892A1 (en) | 2022-04-05 | 2023-10-12 | BioNTech SE | Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same |
WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
WO2024028325A1 (en) | 2022-08-01 | 2024-02-08 | BioNTech SE | Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions |
WO2024028445A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
WO2024027910A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
WO2024077044A1 (en) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
WO2024089258A1 (en) | 2022-10-28 | 2024-05-02 | Aarhus Universitet | Albumin conjugated to cpg oligodeoxynucleotides as super-boosters of immune response |
Family Cites Families (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5625041A (en) | 1990-09-12 | 1997-04-29 | Delta Biotechnology Limited | Purification of proteins |
GB9019919D0 (en) | 1990-09-12 | 1990-10-24 | Delta Biotechnology Ltd | Purification of proteins |
US2714586A (en) | 1951-06-25 | 1955-08-02 | Phillips Petroleum Co | Washing urea and thiourea containing adducts |
US4302386A (en) | 1978-08-25 | 1981-11-24 | The Ohio State University | Antigenic modification of polypeptides |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
JPS60169498A (en) | 1984-02-10 | 1985-09-02 | Kyowa Hakko Kogyo Co Ltd | Adult t cell leukemic viral antigen peptide derivative |
ES8801674A1 (en) | 1985-04-12 | 1988-02-16 | Genetics Inst | Novel procoagulant proteins. |
GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
WO1988008027A1 (en) | 1987-04-09 | 1988-10-20 | Delta Biotechnology Limited | Yeast vector |
EP0305216B1 (en) | 1987-08-28 | 1995-08-02 | Novo Nordisk A/S | Recombinant Humicola lipase and process for the production of recombinant humicola lipases |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
IL88326A (en) | 1987-11-18 | 1993-03-15 | Gist Brocades Nv | Purification of serum albumin |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
GB8909916D0 (en) | 1989-04-29 | 1989-06-14 | Delta Biotechnology Ltd | Polypeptides |
FR2650598B1 (en) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION |
US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
GB8927722D0 (en) | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
DE4000939A1 (en) | 1990-01-15 | 1991-07-18 | Brem Gottfried Prof Dr Dr | METHOD FOR OBTAINING ANTIBODIES |
JP3230091B2 (en) | 1990-06-25 | 2001-11-19 | ウェルファイド株式会社 | Method for suppressing coloration of human serum albumin |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
CA2058820C (en) | 1991-04-25 | 2003-07-15 | Kotikanyad Sreekrishna | Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells |
US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
US5298418A (en) | 1991-09-16 | 1994-03-29 | Boyce Thompson Institute For Plant Research, Inc. | Cell line isolated from larval midgut tissue of Trichoplusia ni |
FR2686899B1 (en) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5663060A (en) | 1992-04-07 | 1997-09-02 | Emory University | Hybrid human/animal factor VIII |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
DE4226971C2 (en) | 1992-08-14 | 1997-01-16 | Widmar Prof Dr Tanner | Modified fungal cells and processes for the production of recombinant products |
US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
JP3095175B2 (en) | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma |
US5824837A (en) | 1993-07-22 | 1998-10-20 | Merck & Co., Inc. | Expression of human interleukin-1β in a transgenic animal |
DE4343591A1 (en) | 1993-12-21 | 1995-06-22 | Evotec Biosystems Gmbh | Process for the evolutionary design and synthesis of functional polymers based on shape elements and shape codes |
US6811773B1 (en) | 1993-12-22 | 2004-11-02 | Human Genome Sciences, Inc. | Human monocyte colony inhibitory factor (M-CIF) polypeptides |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
GB9404270D0 (en) | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US7597886B2 (en) | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5955349A (en) | 1996-08-26 | 1999-09-21 | Zymogenetics, Inc. | Compositions and methods for producing heterologous polypeptides in Pichia methanolica |
US5716808A (en) | 1995-11-09 | 1998-02-10 | Zymogenetics, Inc. | Genetic engineering of pichia methanolica |
GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
US6509313B1 (en) | 1996-02-28 | 2003-01-21 | Cornell Research Foundation, Inc. | Stimulation of immune response with low doses of cytokines |
US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
US5854039A (en) | 1996-07-17 | 1998-12-29 | Zymogenetics, Inc. | Transformation of pichia methanolica |
US6274305B1 (en) | 1996-12-19 | 2001-08-14 | Tufts University | Inhibiting proliferation of cancer cells |
US6605699B1 (en) | 1997-01-21 | 2003-08-12 | Human Genome Sciences, Inc. | Galectin-11 polypeptides |
US7053190B2 (en) | 1997-03-07 | 2006-05-30 | Human Genome Sciences, Inc. | Secreted protein HRGDF73 |
US7196164B2 (en) | 1997-07-08 | 2007-03-27 | Human Genome Sciences, Inc. | Secreted protein HHTLF25 |
US6506569B1 (en) | 1997-05-30 | 2003-01-14 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR10 |
US5875969A (en) | 1997-07-18 | 1999-03-02 | The Toro Company | Sprinkler with self cleaning bowl |
US5948609A (en) | 1997-12-03 | 1999-09-07 | Carter; Daniel C. | Oxygen-transporting albumin-based blood replacement composition and blood volume expander |
AU754237B2 (en) | 1998-08-06 | 2002-11-07 | Syntron Bioresearch, Inc. | Uric acid assay device with stabilized uricase reagent composition |
CA2356542A1 (en) | 1998-12-23 | 2000-07-06 | Human Genome Sciences, Inc. | Peptidoglycan recognition proteins |
GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
JP4216480B2 (en) | 1999-05-17 | 2009-01-28 | コンジュケム バイオテクノロジーズ インコーポレイテッド | Long-lasting fusion peptide inhibitors of viral infection |
MXPA02009221A (en) | 2000-03-22 | 2005-07-25 | Octagene Gmbh | Production of recombinant blood clotting factors in human cell lines. |
CA2405563A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20030091565A1 (en) | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
JP2005500806A (en) | 2000-09-15 | 2005-01-13 | コーリー ファーマシューティカル ゲーエムベーハー | Process for high-throughput screening of immune agonist / immunoantagonists based on CpG |
US7615537B2 (en) | 2000-10-25 | 2009-11-10 | Genzyme Corporation | Methods for treating blood coagulation disorders |
WO2002043658A2 (en) | 2000-11-06 | 2002-06-06 | The Jackson Laboratory | Fcrn-based therapeutics for the treatment of auto-immune disorders |
BR0116024A (en) | 2000-12-07 | 2005-12-13 | Lilly Co Eli | Heterologous Fusion Protein and Use thereof |
US7175988B2 (en) | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
US7507413B2 (en) | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
JP2004536579A (en) | 2001-04-13 | 2004-12-09 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Vascular endothelial growth factor 2 |
AUPR446701A0 (en) | 2001-04-18 | 2001-05-17 | Gene Stream Pty Ltd | Transgenic mammals for pharmacological and toxicological studies |
AU2002321105A1 (en) | 2001-05-25 | 2002-12-16 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis |
WO2002102830A1 (en) | 2001-06-15 | 2002-12-27 | New Century Pharmaceuticals, Inc. | Human albumin animal models for drug evaluation, toxicology and immunogenicity studies |
WO2003012036A2 (en) | 2001-07-27 | 2003-02-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Systems for in vivo site-directed mutagenesis using oligonucleotides |
CN1405182A (en) | 2001-08-10 | 2003-03-26 | 中国人民解放军军事医学科学院生物工程研究所 | Serum albumin and granulocyte colony stimulating factor fusion protein |
AU2002364587A1 (en) | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20080167238A1 (en) | 2001-12-21 | 2008-07-10 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
ES2500918T3 (en) | 2001-12-21 | 2014-10-01 | Human Genome Sciences, Inc. | Albumin and interferon beta fusion proteins |
CN1646154B (en) | 2002-02-07 | 2010-12-01 | 诺维信生物制药英国有限公司 | Albumin-fused anti-angiogenesis peptides |
US20080108560A1 (en) | 2002-03-05 | 2008-05-08 | Eli Lilly And Company | Heterologous G-Csf Fusion Proteins |
WO2003102136A2 (en) | 2002-05-30 | 2003-12-11 | Human Genome Sciences, Inc. | Antibodies that specifically bind to neurokinin b |
CN1241946C (en) | 2002-07-01 | 2006-02-15 | 美国福源集团 | Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells |
GB0217347D0 (en) | 2002-07-26 | 2002-09-04 | Univ Edinburgh | Novel albumins |
AU2003257032A1 (en) | 2002-08-02 | 2004-02-23 | Human Genome Sciences, Inc. | Antibodies against c3a receptor |
RU2359268C2 (en) | 2002-11-19 | 2009-06-20 | ДиАрДжи ИНТЕРНЭШНЛ, ИНК. | Disease diagnostics technique by organism tissues, blood or liquids screening in animal or human for nonphysiological hepsidin levels and its therapeutic application |
EP1594530A4 (en) | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | Albumin fusion proteins |
WO2004071536A1 (en) | 2003-02-17 | 2004-08-26 | Upperton Limited | Conjugates for medical imaging comprising carrier, targeting moiety and a contrast agent |
GB0305989D0 (en) | 2003-03-15 | 2003-04-23 | Delta Biotechnology Ltd | Agent |
WO2004082640A2 (en) | 2003-03-19 | 2004-09-30 | New Century Pharmaceuticals, Inc. | Human serum albumin conjugates with therapeutic compounds |
AU2004231122B2 (en) | 2003-04-15 | 2010-04-08 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof |
WO2004101620A2 (en) | 2003-05-01 | 2004-11-25 | Compound Therapeutics, Inc. | Serum albumin scaffold-based proteins and uses thereof |
US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
US20080308744A1 (en) | 2003-11-18 | 2008-12-18 | Beth Israel Deaconess Medical Center | Serum Albumin Conjugated to Fluorescent Substances for Imaging |
GB0329681D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Gene expression technique |
GB0329722D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Modified plasmid and use thereof |
JP4649954B2 (en) | 2003-12-26 | 2011-03-16 | ニプロ株式会社 | Albumin with enhanced antibacterial activity |
US7166577B2 (en) | 2003-12-26 | 2007-01-23 | Nipro Corporation | Albumin having enhanced antimicrobial activity |
KR100671005B1 (en) | 2004-01-15 | 2007-01-18 | 고려대학교 산학협력단 | Biomarker proteins for diagnosing the exposure to PAH |
RU2369404C2 (en) | 2004-02-09 | 2009-10-10 | Хьюман Дженом Сайенсиз, Инк. | Fused proteins of albumine |
EP1729795B1 (en) | 2004-02-09 | 2016-02-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
JP4492156B2 (en) | 2004-03-03 | 2010-06-30 | ニプロ株式会社 | Protein containing serum albumin domain |
US20060018859A1 (en) | 2004-07-16 | 2006-01-26 | Carter Daniel C | Modified human serum albumin with reduced or eliminated affinity to chemical or biological contaminants at Cys 34 |
US20060051859A1 (en) | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
CA2580141C (en) | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
WO2006066595A2 (en) | 2004-12-22 | 2006-06-29 | Novozymes A/S | Recombinant production of serum albumin |
EP1831375B1 (en) | 2004-12-23 | 2014-07-16 | Novozymes Biopharma DK A/S | Gene expression technique |
JPWO2006073195A1 (en) | 2005-01-07 | 2008-06-12 | 敏一 吉川 | Diabetes prediction / diagnosis method and diabetes prediction / diagnosis kit |
US20060178301A1 (en) | 2005-02-04 | 2006-08-10 | Mathias Jurs | Albumin-fused ciliary neurotrophic factor |
WO2006118772A2 (en) | 2005-04-29 | 2006-11-09 | The Jackson Laboratory | Fcrn antibodies and uses thereof |
GB0512707D0 (en) | 2005-06-22 | 2005-07-27 | Delta Biotechnology Ltd | Gene expression technique |
KR20080071119A (en) | 2005-08-12 | 2008-08-01 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Albumin fusion proteins |
CA2562249A1 (en) | 2005-10-20 | 2007-04-20 | University Of Ottawa Heart Institute | Anf analogue |
US20070269863A1 (en) | 2005-12-22 | 2007-11-22 | Bridon Dominique P | Process for the production of preformed conjugates of albumin and a therapeutic agent |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
WO2007112940A2 (en) | 2006-03-31 | 2007-10-11 | Ablynx N.V. | Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same |
AU2007258609B2 (en) | 2006-06-07 | 2013-01-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
ES2889920T3 (en) | 2006-06-14 | 2022-01-14 | Csl Behring Gmbh | Proteolytically Cleavable Fusion Proteins with High Molar Specific Activity |
AU2007274035A1 (en) | 2006-07-13 | 2008-01-17 | Novozymes Biopharma Dk A/S | Process for preparing particles of proteinaceous material |
JP4983148B2 (en) | 2006-08-18 | 2012-07-25 | ニプロ株式会社 | Glycan-containing albumin, method for producing the same, and use thereof |
MX2009002523A (en) | 2006-09-08 | 2009-03-20 | Ambrx Inc | Modified human plasma polypeptide or fc scaffolds and their uses. |
US20100129846A1 (en) | 2006-12-07 | 2010-05-27 | Power3 Medical Products, Inc. | Isoform specificities of blood serum proteins and their use as differentially expressed protein biomarkers for diagnosis of breast cancer |
EP2594583A1 (en) | 2007-08-08 | 2013-05-22 | Novozymes Biopharma DK A/S | Transferrin variants and conugates |
US8906356B2 (en) | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
CA2611540C (en) | 2007-11-09 | 2017-05-30 | Nipro Corporation | Sugar chain-containing albumin as a drug carrier to the liver |
KR101620539B1 (en) | 2007-12-21 | 2016-05-13 | 메디뮨 리미티드 | -4 -4 -173binding members for interleukin-4 receptor alpha il-4r-173 |
CA2721093A1 (en) | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
WO2009134808A2 (en) | 2008-04-28 | 2009-11-05 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
CN102165075A (en) | 2008-07-18 | 2011-08-24 | 奥洁克公司 | Compositions for the detection and treatment of colorectal cancer |
US8927694B2 (en) | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
CA2867252C (en) | 2008-12-05 | 2015-09-01 | Abraxis Bioscience, Llc | Albumin binding peptide-mediated disease targeting |
US8609383B2 (en) | 2008-12-10 | 2013-12-17 | The Scripps Research Institute | Production of carrier-peptide conjugates using chemically reactive unnatural amino acids |
CN106986933A (en) | 2009-02-11 | 2017-07-28 | 阿尔布梅迪克斯医疗公司 | Albumin variants and conjugate |
EP2419120A4 (en) | 2009-04-08 | 2016-01-06 | Univ California | Human protein scaffold with controlled serum pharmacokinetics |
JP2012525146A (en) | 2009-04-28 | 2012-10-22 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | Overcharged protein for cell penetration |
WO2010138814A2 (en) | 2009-05-29 | 2010-12-02 | The Brigham And Women's Hospital, Inc. | Disrupting fcrn-albumin interactions |
US20120134984A1 (en) | 2009-06-01 | 2012-05-31 | Olga Lubman | Molecules with extended half-lives and uses thereof |
KR101286721B1 (en) | 2009-06-05 | 2013-07-16 | 한국과학기술연구원 | Recombinant albumins fused with poly-cysteine peptide and the methods for preparing the same |
AU2010276453A1 (en) | 2009-07-20 | 2012-02-09 | Dcb-Usa Llc | Polypeptides selective for av beta3 integrin conjugated with a variant of human serum albumin (HSA) and pharmaceutical uses thereof |
US20120269765A1 (en) | 2009-07-24 | 2012-10-25 | Garcia K Christopher | Cytokine compositions and methods of use thereof |
WO2011018611A1 (en) | 2009-08-10 | 2011-02-17 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
US20110172398A1 (en) | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
WO2011044563A2 (en) | 2009-10-10 | 2011-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | Il-17 family cytokine compositions and uses |
US8748380B2 (en) | 2009-10-30 | 2014-06-10 | Novozymes Biopharma Dk A/S | Albumin variants |
EP2515926A4 (en) | 2009-12-23 | 2013-10-09 | Univ Nat Cheng Kung | Compositions and methods for the treatment of angiogenesis-related eye diseases |
CN101875693B (en) | 2010-01-22 | 2012-07-18 | 成都正能生物技术有限责任公司 | Albumin variant having anti-angiogenesis activity and preparation method thereof |
CN102781960B (en) | 2010-02-16 | 2014-12-10 | 米迪缪尼有限公司 | HSA-related compositions and methods of use |
WO2011124718A1 (en) | 2010-04-09 | 2011-10-13 | Novozymes A/S | Albumin derivatives and variants |
US8691771B2 (en) | 2010-05-21 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins for tissue repair |
WO2011161127A1 (en) | 2010-06-21 | 2011-12-29 | Medimmune, Llc | Protease variants of human neprilysin |
EP2603522A1 (en) | 2010-08-13 | 2013-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Improved anti-serum albumin binding variants |
US20130225496A1 (en) | 2010-11-01 | 2013-08-29 | Novozymes Biopharma Dk A/S | Albumin Variants |
US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
JP2014510518A (en) * | 2011-02-15 | 2014-05-01 | メディミューン,エルエルシー | HSA related compositions and methods of use |
CN104011072B (en) | 2011-05-05 | 2018-10-12 | 阿尔布梅迪克斯医疗有限公司 | albumin variants |
AU2012286048A1 (en) | 2011-07-18 | 2014-02-20 | Arts Biologics A/S | Long acting luteinizing hormone (LH) compound |
EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
KR20140136934A (en) | 2012-03-16 | 2014-12-01 | 노보자임스 바이오파마 디케이 에이/에스 | Albumin variants |
WO2014005596A1 (en) | 2012-07-03 | 2014-01-09 | Aarhus Universitet | Modified payload molecules and their interactions and uses |
EP2917233A1 (en) | 2012-11-08 | 2015-09-16 | Novozymes Biopharma DK A/S | Albumin variants |
KR20150118123A (en) | 2013-02-16 | 2015-10-21 | 노보자임스 바이오파마 디케이 에이/에스 | Pharmacokinetic animal model |
WO2014179657A1 (en) | 2013-05-03 | 2014-11-06 | Eleven Biotherapeutics, Inc. | Albumin variants binding to fcrn |
US20160222087A1 (en) | 2013-09-13 | 2016-08-04 | Novozymes Biopharma Dk A/S | Albumin variants |
EP3063171B1 (en) | 2013-11-01 | 2019-07-24 | University Of Oslo | Albumin variants and uses thereof |
US9847012B2 (en) | 2014-07-07 | 2017-12-19 | Google Llc | Meal-based medication reminder system |
EP3337816B1 (en) | 2015-08-20 | 2024-02-14 | Albumedix Ltd | Albumin variants and conjugates |
-
2012
- 2012-11-18 EP EP12795966.6A patent/EP2780364A2/en not_active Withdrawn
- 2012-11-18 US US14/358,857 patent/US20140315817A1/en not_active Abandoned
- 2012-11-18 WO PCT/US2012/065733 patent/WO2013075066A2/en active Application Filing
-
2015
- 2015-02-03 HK HK15101137.5A patent/HK1200842A1/en unknown
-
2018
- 2018-05-25 US US15/989,985 patent/US10711050B2/en active Active
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11555061B2 (en) | 2009-02-11 | 2023-01-17 | Albumedix, Ltd | Albumin variants and conjugates |
US10696732B2 (en) | 2009-10-30 | 2020-06-30 | Albumedix, Ltd | Albumin variants |
US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
US10407512B2 (en) | 2010-05-21 | 2019-09-10 | Silver Creek Pharmaceuticals, Inc. | Bi-specific fusion proteins |
US9718892B2 (en) | 2010-05-21 | 2017-08-01 | Merrimack Pharmaceuticals, Inc. | Method of treating myocardial infarction by administering a bi-specific fusion protein |
US9982060B2 (en) | 2010-05-21 | 2018-05-29 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
US11814443B2 (en) | 2010-05-21 | 2023-11-14 | Silver Creek Pharmaceuticals, Inc. | Bi-specific fusion proteins |
US9238080B2 (en) | 2010-05-21 | 2016-01-19 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
US11673970B2 (en) | 2010-05-21 | 2023-06-13 | Silver Creek Pharmaceuticals, Inc. | Bi-specific fusion proteins |
US10988547B2 (en) | 2010-05-21 | 2021-04-27 | Silver Creek Pharmaceuticals, Inc. | Bi-specific fusion proteins |
US10858450B2 (en) | 2010-05-21 | 2020-12-08 | Silver Creek Pharmaceuticals, Inc. | Bi-specific fusion proteins |
US10561714B2 (en) | 2010-07-09 | 2020-02-18 | Bioverativ Therapeutics Inc. | Factor IX polypeptides and methods of use thereof |
US10568943B2 (en) | 2010-07-09 | 2020-02-25 | Bioverativ Therapeutics Inc. | Factor IX polypeptides and methods of use thereof |
US10898554B1 (en) | 2010-07-09 | 2021-01-26 | Bioverativ Therapeutics Inc. | Factor IX polypeptides and methods of use thereof |
US10548954B2 (en) | 2010-07-09 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor IX polypeptides and methods of use thereof |
US10711050B2 (en) | 2011-11-18 | 2020-07-14 | Albumedix Ltd | Variant serum albumin with improved half-life and other properties |
US10329340B2 (en) | 2012-03-16 | 2019-06-25 | Albumedix Ltd | Albumin variants |
US10934341B2 (en) | 2012-11-08 | 2021-03-02 | Albumedix, Ltd. | Albumin variants |
US10501524B2 (en) | 2012-11-08 | 2019-12-10 | Albumedix Ltd | Albumin variants |
US11642398B2 (en) | 2013-03-15 | 2023-05-09 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
US20160122713A1 (en) * | 2014-10-14 | 2016-05-05 | Medgenics Medical Israel Ltd. | Genetically-modified micro-organ secreting a therapeutic peptide and methods of use thereof |
US10633428B2 (en) | 2015-08-20 | 2020-04-28 | Albumedix Ltd | Albumin variants and conjugates |
US10040840B2 (en) | 2015-10-02 | 2018-08-07 | Silver Creek Pharmaceuticals, Inc. | Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue |
US11155593B2 (en) | 2015-10-02 | 2021-10-26 | Silver Creek Pharmaceuticals, Inc. | Method of inhibiting apoptosis or promoting cell survival by providing a bi-specific protein comprising insulin-like growth factor IGF-1 and Annexin A5 |
US10633425B2 (en) | 2015-10-02 | 2020-04-28 | Silver Creek Pharmaceuticals, Inc. | Method of protecting tissue from damage by administering a bi-specific therapeutic protein comprising insulin-like growth factor 1 (IGF-1) and Annexin A5 |
US11879002B2 (en) | 2015-10-02 | 2024-01-23 | Silver Creek Pharmaceuticals, Inc. | Bi-specific therapeutic proteins, in vivo methods of use thereof and encoding nucleic acids thereof |
US11466073B2 (en) * | 2017-10-18 | 2022-10-11 | Csl Limited | Human serum albumin variants and uses thereof |
WO2022040375A1 (en) * | 2020-08-19 | 2022-02-24 | Energesis Pharmaceuticals, Inc. | Analogs of human fibroblast growth factors |
Also Published As
Publication number | Publication date |
---|---|
HK1200842A1 (en) | 2015-08-14 |
WO2013075066A2 (en) | 2013-05-23 |
US10711050B2 (en) | 2020-07-14 |
EP2780364A2 (en) | 2014-09-24 |
WO2013075066A3 (en) | 2013-07-04 |
US20180334491A1 (en) | 2018-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10711050B2 (en) | Variant serum albumin with improved half-life and other properties | |
ES2610356T3 (en) | Extended recombinant polypeptides and compositions comprising the same | |
JP2021006038A (en) | Molecules selectively activating regulatory t cells for treatment of autoimmune diseases | |
AU2007260185B2 (en) | Proteolytically cleavable fusion protein comprising a blood coagulation factor | |
US20190202881A1 (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
EP2256135B1 (en) | Proteolytically cleavable fusion protein comprising a blood coagulation factor | |
US8927492B2 (en) | Fibroblast growth factor 21 proteins | |
KR101439817B1 (en) | Modified coagulation factor VIIa with extended half-life | |
EP2591006B1 (en) | Processable single chain molecules and polypeptides made using same | |
US9458223B2 (en) | Von willebrand factor variants having improved factor VIII binding affinity | |
JP6474386B2 (en) | Complex | |
EP3231440A1 (en) | Modified coagulation factors with prolonged in vivo half-life | |
WO2007047829A2 (en) | Novel heterodimeric proteins and uses thereof | |
EP3164150B1 (en) | Modified von willebrand factor | |
EP2992329A1 (en) | Albumin variants binding to fcrn | |
EP1935430A1 (en) | Modified coagulation factors with prolonged in vivo half-life | |
AU2013202566B2 (en) | Proteolytically cleavable fusion protein comprising a blood coagulation factor | |
US20210253671A1 (en) | Pharmaceutical Composition Containing Fusion Protein and Use Thereof | |
KR20140101877A (en) | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ELEVEN BIOTHERAPEUTICS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHMIDT, MICHAEL MARCH;FURFINE, ERIC STEVEN;ANDREUCCI, AMY JADA;AND OTHERS;SIGNING DATES FROM 20140114 TO 20140116;REEL/FRAME:033513/0841 |
|
AS | Assignment |
Owner name: NOVOZYMES BIOPHARMA DK A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ELEVEN BIOTHERAPEUTICS, INC.;REEL/FRAME:037679/0640 Effective date: 20151204 |
|
AS | Assignment |
Owner name: ALBUMEDIX A/S, DENMARK Free format text: CHANGE OF NAME;ASSIGNOR:NOVOZYMES BIOPHARMA DK A/S;REEL/FRAME:037862/0029 Effective date: 20151217 |
|
AS | Assignment |
Owner name: ALBUMEDIX A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALBUMEDIX A/S;REEL/FRAME:041638/0344 Effective date: 20161125 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: ALBUMEDIX LTD, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVOZYMES BIOPHARMA DK A/S (BI-NAME ALBUMEDIX A/S);REEL/FRAME:046093/0808 Effective date: 20180412 |